1
Status: Approved ,Date: 11 September 2017Janssen Research & Development *
Clinical Protocol
A Randomized, Double -blind, Double -dummy, Mul ticenter, Adaptive Design, 
Dose -Escalation (Part 1) and Dose -Response (Part 2) Study to Evaluate the Safety and 
Efficacy of Intravenous JNJ- 64179375 Ver sus Oral Apixaban in Subjects Undergoing 
Elective Total Knee Replacement Surgery
TEXT - Targeting EXosite- 1 Thrombin Inhibition, TEXT –TKR
Protocol 64179375THR2001 ; Phase 2
AMENDMENT 1
JNJ-64179375
*Janssen Research & Development is a global organ ization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Jan ssen 
Biologics, BV; Janssen -Cilag International ,NV; Janssen Pharmaceutica, NV; Janssen, Inc; Janssen 
Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout 
the protocol to represent these various legal entities; the sponsor is identified on the Contact Information 
page that accompanies the protocol.
This compound is being investigated in Phase 2 clinical studies.
EudraCT NUMBER: 2016 -004550 -15
Status: Approved
Date: 11 September 2017
Prepar ed by: Janssen Research & Development, LLC 
EDMS number: EDMS- ERI-136897708, 2.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed mus t be informed that the information is privileged or confidential and may not be further disclosed by 
them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as priv ileged or 
confidential.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
2
Approved , Date: 11 September 2017TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
LIST OF A TTACHMENTS ............................................................................................................................ 4
LIST OF IN -TEXT T ABLES A ND FIGU RES ................................................................................................ 5
PROTOCOL A MENDMENTS ....................................................................................................................... 6
SYNOPSIS .................................................................................................................................................... 8
TIME AND EVENTS SCHE DULE FOR PA RT 1 A ND PART 2 ................................................................ .17
ABBREVIA TIONS ...................................................................................................................................... 20
DEFINITIONS OF PHA RMACOKINETIC TERMS ..................................................................................... 21
1. INTRODUCTION ................................................................................................................................ 22
1.1. Background .................................................................................................................................... 23
1.1.1. Nonclinical Studies ..................................................................................................................... 23
1.1.1.1. Nonclinical Pharmacology ....................................................................................................... 23
1.1.1.2. Safety Pharmacology .............................................................................................................. 24
1.1.1.3. Toxicology ................................................................................................................................ 24
1.1.1.4. Pharmacokinetic and Product Metabolism in Animals ............................................................ 25
1.1.2. Clinical Studies ........................................................................................................................... 26
1.1.2.1. Overall Study Design and Status ............................................................................................. 26
1.1.2.2. Part 1 ....................................................................................................................................... 26
1.1.2.2.1. Demographic Characteristics ............................................................................................... 26
1.1.2.2.2. Safety and Tolerability .......................................................................................................... 27
1.1.2.2.3. Pharmacokinetics ................................................................................................................. 31
1.1.2.2.4. Pharmacodynamics .............................................................................................................. 31
1.1.2.2.5. Overall Summary ................................................................................................................. 32
1.1.2.3. Parts 2 and 3 ........................................................................................................................... 33
1.2. Comparator Drug ........................................................................................................................... 33
1.3. Overall Rationale for the Study ...................................................................................................... 36
2. OBJECTIVES, ENDPOINT S, AND HYPOTHESIS ........................................................................... 37
2.1. Objectives and Endpoints .............................................................................................................. 37
2.1.1. Objectives ................................................................................................................................... 37
2.1.2. Endpoints .................................................................................................................................... 38
2.2. Hypothesis ..................................................................................................................................... 40
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .40
3.1. Overview of Study Design .............................................................................................................. 40
3.1.1. Part 1: Single -Asce nding Dose ................................................................................................... 42
3.1.2. Part 2: Dose -Response Evaluation ............................................................................................ 42
3.2. Study Design Rationale .................................................................................................................. 43
4. SUBJECT POPUL ATION.................................................................................................................. 47
4.1. Inclusion Criteria ............................................................................................................................ 47
4.2. Exclusion Criteria ........................................................................................................................... 49
4.3. Prohibitions and Restrictions ......................................................................................................... 50
5. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. 51
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 52
7. TREA TMENT COMPLIA NCE ............................................................................................................ 54
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
3
Approved , Date: 11 September 20178. PRESTUDY A ND CONCOMI TANT THERA PY................................................................................ 54
9. STUDY EVA LUATIONS .................................................................................................................... 56
9.1. Study Procedures ........................................................................................................................... 56
9.1.1. Overview ..................................................................................................................................... 56
9.1.2. Screening Phase ........................................................................................................................ 57
9.1.3. Double -Blind Dosing Phase ........................................................................................................ 58
9.1.4. Follow -Up Phase ........................................................................................................................ 59
9.2. Efficacy  Evaluations ....................................................................................................................... 59
9.2.1. Assessments for DVT ................................................................................................................. 60
9.2.2. Assessments for PE ................................................................................................................... 60
9.2.3. Assessments for Other Thrombotic Events ................................................................................ 61
9.3. Pharmaco kinetics and Immunogenicity ......................................................................................... 62
9.3.1. Evaluations ................................................................................................................................ .62
9.3.2. Analytical Procedures ................................................................................................................. 62
9.3.3. Pharmacokinetic Parameters ..................................................................................................... 63
9.3.4. Immunog enicity Assessments .................................................................................................... 63
9.4. Pharmacodynamic/Biomarker Evaluations .................................................................................... 64
9.5. Pharmacokinetic/Pharmacodynamic Evaluations .......................................................................... 65
9.6. Health Resource Utilization ............................................................................................................ 65
9.7. Safety Evaluations ......................................................................................................................... 66
9.7.1. Adverse Events ........................................................................................................................... 66
9.7.2. Adverse Events of Special Interest ............................................................................................. 67
9.7.2.1. Bleeding Events ....................................................................................................................... 67
9.7.2.1.1. Classification of Bleeding Events ......................................................................................... 67
9.7.2.1.2. Approach to Subjects With a Bleeding Event ...................................................................... 68
9.7.2.2. Infusion or H ypersensitivity Reactions .................................................................................... 69
9.7.2.3. Wound or Joint Complications ................................................................................................ .70
9.7.3. Clinical Laboratory Tests ............................................................................................................ 70
9.7.4. Electrocardiogram ....................................................................................................................... 71
9.7.5. Vital Signs (temperature, heart rate, blood pressure) ................................................................ 71
9.7.6. Physical Examination .................................................................................................................. 72
9.8. Sample Collection and Handling .................................................................................................... 72
10. SUBJECT COMPLETION/D ISCONTINUA TION OF ST UDY DRUG/ WITHDRA WALFROM 
THE STUDY ....................................................................................................................................... 73
10.1. Completion ..................................................................................................................................... 73
10.2. Discontinuation of Study Drug/W ithdrawal from the Study ............................................................ 73
11. STATISTICA L METHODS ................................................................................................................. 75
11.1. Analysis Datasets ........................................................................................................................... 75
11.2. Sample Size Determination ........................................................................................................... 76
11.3. Efficacy  and Bleeding Analyses ..................................................................................................... 78
11.4. Pharmacokinetic Analy ses............................................................................................................. 81
11.5. Immunogenicity Analyses .............................................................................................................. 81
11.6. Pharmacodynamic/Biomarker Analy ses........................................................................................ 82
11.7. Pharmacokinetic/Pharmacodynamic Analyses .............................................................................. 82
11.8. Health Resource Utilization Analy ses............................................................................................ 82
11.9. Safety Analyses ............................................................................................................................. 82
11.10. Interim Analyses ............................................................................................................................. 84
11.11. Committees .................................................................................................................................... 84
11.11.1. Operations Committee ................................................................................................................ 84
11.11.2. Independent Data M onitoring Committee ................................................................................... 85
11.11.3. Steering Committee .................................................................................................................... 85
11.11.4. Clinical Events Committee .......................................................................................................... 85
12. ADVERSE EVENT REPORT ING...................................................................................................... 86
12.1. Definit ions ...................................................................................................................................... 87
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
4
Approved , Date: 11 September 201712.1.1. Adverse Event Definitions and Classifications ........................................................................... 87
12.1.2. Attribution Definitions .................................................................................................................. 88
12.1.3. Severity Criteria .......................................................................................................................... 89
12.2. Special Reporting Situations .......................................................................................................... 89
12.3. Procedures ..................................................................................................................................... 89
12.3.1. All Adverse Events ...................................................................................................................... 89
12.3.2. Serious Adverse Events ............................................................................................................. 90
12.3.3. Pregnancy ................................................................................................................................... 91
12.4. Contacting Sponsor Regarding Safety ........................................................................................... 91
13. PRODUCT QUA LITY COMP LAINT HA NDLING .............................................................................. 92
13.1. Procedures ..................................................................................................................................... 92
13.2. Contacting Sponsor Regarding Product Quality ............................................................................ 92
14. STUDY DRUG INFORM ATION......................................................................................................... 92
14.1. Physical Description of Study Drugs .............................................................................................. 92
14.2. Packaging ...................................................................................................................................... 93
14.3. Labeling .......................................................................................................................................... 93
14.4. Preparation, Handling, and Storage ............................................................................................... 93
14.5. Drug Accountability ........................................................................................................................ 93
15. STUDY -SPECIFIC M ATERIA LS....................................................................................................... 94
16. ETHICA L ASPECTS ......................................................................................................................... 94
16.1. Study-Specific Design Considerations ........................................................................................... 94
16.2. Regulatory Ethics Compliance ....................................................................................................... 96
16.2.1. Investigator Responsibilities ....................................................................................................... 96
16.2.2. Independen t Ethics Committee or Institutional Review Board ................................................... 96
16.2.3. Informed Consent ....................................................................................................................... 98
16.2.4. Privacy of Personal Data ............................................................................................................ 98
16.2.5. Long- Term Retention of Samples for Additio nal Future Research ............................................ 99
16.2.6. Countr y Selection ....................................................................................................................... 99
17. ADM INISTRA TIVE REQUI REM ENTS .............................................................................................. 99
17.1. Protocol Amendments .................................................................................................................... 99
17.2. Regulatory Doc umentation .......................................................................................................... 100
17.2.1. Regulatory Approval/Notification .............................................................................................. 100
17.2.2. Required Prestudy Documentation ........................................................................................... 100
17.3. Subject Identification, Enrollment, and Screening Logs .............................................................. 101
17.4. Source Documentation ................................................................................................................. 101
17.5. Case Report Form Completion .................................................................................................... 102
17.6. Data Quality Assurance/Quality Control ...................................................................................... 102
17.7. Record Reten tion......................................................................................................................... 103
17.8. Monitoring .................................................................................................................................... 103
17.9. Study Com pletion/Termination ..................................................................................................... 104
17.9.1. Study Com pletion/End of Study ................................................................................................ 104
17.9.2. Study Termination ..................................................................................................................... 104
17.10. On-Site Audits .............................................................................................................................. 104
17.11. Use of Information and Publication .............................................................................................. 105
REFERENCES .......................................................................................................................................... 107
INVESTIGA TOR A GREEME NT............................................................................................................... 113
LIST OF A TTACHMENTS
Attachment 1: Sample Bleeding Risk History .................................................................................. 109
Attachment 2: Definitions of Bleeding Events .................................................................................. 111
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
5
Approved , Date: 11 September 2017LIST OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Most Frequent (>5% Incidence) Treatment- Emergent Adverse Events - by Body  
System and Preferred Term: Part 1; Safety Analysis Set (Study 64179375EDI1001) ............. 28
Table 2: Treatment -Emergent Bleedi ng Adverse Events -by Body  System and Preferred Term: 
Part 1; Safety Analy sis Set (Study 64179375EDI1001) ........................................................... 30
Table 3: Mean (±SD) Pharmacokinetic Parameters of JNJ -64179375 Following a Single 30 -
minute IV Infusion (0.03 to 2.5 mg/kg, Part 1) in Healthy Male Subjects ................................ .31
Table 4: ADVANCE -1 and ADVANCE -2 Safety Results ........................................................................ 35
Table 5: ADVANCE -1 and ADVANCE -2 Efficacy Results ...................................................................... 36
Table 6: Volume of Blood to be Collected From Each Subject ............................................................... 57
Table 7: Assumed Efficacy  and Safety Event Rates by Treatment Group in Sample Size 
Determination for Part 2 ............................................................................................................ 78
FIGURES
Figure 1: Thrombin Tim e (s) Mean Ratio to Baseline by Treatment Group Central Specialty 
Laboratory; Safety Analy sis Set (Study 64179375EDI1001) .................................................... 32
Figure 2: Probability to Flag a Higher Event Rate in the JNJ -64179375 Group Than in the 
Apixaban Group at a 1 -Sided, 10% -Level ............................................................................. 77
Figure 3: Candidate Models for Total VTE (Efficacy ).............................................................................. 79
Figure 4: Candidate Models for Any Bleeding (Safety )............................................................................ 80
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
6
Approved , Date: 11 September 2017PROTOCOL A MENDMENTS
Protocol Version Issue Date
Original Protocol 07Jun2017
Amendment 1 11Sep2017
Amendments below are listed beginning with the most recent amendment.
Amendment 1 (11September 2017 )
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union, in that it does not significantly 
impact the safety or physical/mental integrity of subjects, nor the scientific value of t he study.  
The overall reason for the amendment: The overall reason for the amendment is to clarify the distribution of 
norm al saline bags and to remove a laboratory test. Normal saline bags will not be provided by the sponsor to all 
sites because some sites will be providing their own or require local or central distribution. 
Applicable Section(s) Description of Change(s)
Rationale: Removed the text specifying that the sponsor will supply norm al saline bags to clarify that sites will 
provide the norm al saline bags unless regulations require local or central distribution. 
14.2.Packaging Removed the 50 -mL norm al saline bags.
Rationale: Removed the Hemoclot Thrombin Inhibitor as say because additional testing has now shown that the 
assay cannot measur e levels of JNJ -64179375 below  20 ug/mL and most results will likely be less than this low er 
limit of quan titation so testing w ould be of limited value.
Synopsis, Exploratory Objectives, 
Synopsis, Exploratory Endpoint s;
Synopsis, Pharmacodynamic/
Biomarke r Evaluations; 
Synopsis, Statistical Methods; 
Time and Events Schedule; 
2.1.1. Objectives; 2.1.2 .Endpoints; 
3.2.Study Design Rationale; 
9.1.1. Overview (Table 6); 
9.4.Pharmacodynamic/
Biomarker Evaluations; 
11.6.Pharmacodynamic/Biomarker 
Analyses ; 11.7. Pharm acokinetic/
Pharm acody namic AnalysesRemoved references to the Hem oclot Thrombin Inhibitor assay.
Rationale: Corrected discrepancies in the number of laboratory samples collected between the Time and Events 
Schedule and Table 6.
9.1.1. Overview, 9.1.1. Overview  
(Table 6 ); 16.1 Study -Specific 
Design ConsiderationsCorrected the number of sparse and dense pharmacokinetic (PK) and 
pharmacodynamic (PD) samples to match the Time and Events S chedule , 
while separate samples for immunogenicity were removed as the testing can 
be done on the samples collected for PK . Minor adjustments were also made 
to the volume of each sample based on the final laboratory supplies to be 
provided. Total volume was recalculated and updated.
Rationale: Corrected a typograph ical error.
11.2.Sample Size Determination Corrected a typographical error in sample size determination assumptions.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
7
Approved , Date: 11 September 2017Applicable Section(s) Description of Change(s)
Rationale: Included language for an impartial witness in the event a subject cannot read and/or w rite since it had 
been inadvertently omitted and subjects that cannot read and/or w rite are not excluded from the study.
16.2.3 .Informed Consent Included language for an impartial w itness in the event a subject cannot read 
and/or w rite
Rationale: Modifications have been made for consisten cy with the current version of the protocol template.
Throughout the protocol Template changes have been applied, as appropriate.
Rationale: Minor errors w ere noted
Throughout the protocol Minor grammatical, formatting, or editorial changes were made f or clarity.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
8
Approved , Date: 11 September 2017SYNOPSIS
A Randomized, Double -blind, Double -dummy, Multicenter, Adaptive Design, Dose -Escalation 
(Part 1) and Dose -Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous 
JNJ-64179375 Versus Oral Apixaban in Subjects Under going Elective Total Knee Replacement 
Surgery
JNJ-64179375 is a first-in-class, recombinant, fully human immunoglobin (Ig) G4 monoclonal antibody 
that binds reversibly with high affinity and specificity to the exosite -1 region of thrombin. JNJ -64179375 
acts as an anticoagulant by blocking only exosite-1- mediated fibrinogen binding to thrombin (and also 
blocks proteinase -activated receptor -1 binding), but does not inhibit the catalytic activity of the protease. 
The mechanism of action is distinct from curre ntly available direct thrombin inhibitors that block the 
active site only (eg, dabigatran, argatroban) or that block both the active site and exosite 1 
(eg,bivalirudin, hirudin) and from other mechanisms that inhibit thrombin generation (eg,Factor Xa 
[FXa] inhibitors). The primary goal of the clinical program will be to demonstrate noninferior efficacy 
with a reduced bleeding risk versus active comparators. However, the possibility of demonstrating 
superior efficacy may be considered based on better compl iance with a once -monthly dosing regimen 
and/or the ability to achieve more effective drug levels due to a reduced risk of bleeding (ie, doses not 
limited by bleeding risk).
OBJECTIVE S,ENDPOINTS, AND HYPOTHESIS
Objective s
Part 1
In men and women undergoin g primary unilateral total knee replacement (TKR )surgery, after 
single -ascending intravenous ( IV)doses of JNJ -64179375 or 10 to 14 days of oral apixaban:
Primary Objective
The primary objective is to assess the safety and tolerability of JNJ -64179375 for each dose level for dose 
escalation within Part 1 and any bleeding events (thecomposite of major, clinically relevant nonmajor, 
and minimal bleeding events) for the selection of doses for Part 2.
Secondary Objectives
 To assess the dose response of JNJ-64179375 for the occurrence of the composite endpoint of any 
bleeding events, the composite endpoint of major or clinically relevant nonmajor bleeding events, 
and the individual components of the composite endpoint of any bleeding event
 To assess the dose response of JNJ-64179375 for the prevention of total venous thromboembolism 
(VTE )(proximal and/or distal deep vein thrombosis [DVT , asymptomatic confirmed by venography 
assessment of the operated leg or objectively confirmed symptomatic], nonfatal pulmonary
embolism [ PE], or any death) and the individual components of total VTE
Part 2
In men and women undergoing primary unilateral TKR surgery, after a single IV dose of JNJ-64179375 
or 10 to 14 days of oral apixaban:
Primary Objective
The primary objective isto assess the efficacy dose response of JNJ -64179375 for the prevention of total 
VTE (proximal and/or distal DVT [asymptomatic confirmed by venography assessment of the operated 
leg or objectively confirmed symptomatic], nonfatal PE, or any death).
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
9
Approved , Date: 11 September 2017Key Se condary Objectives
 To assess the dose response of JNJ-64179375 for the occurrence of the composite endpoint of any 
bleeding events, the composite endpoint of major or clinically relevant nonmajor bleeding events, 
and the individual components of the compos ite endpoint of any bleeding event
 To assess the dose response of JNJ-64179375 for the prevention of major VTE (asymptomatic 
confirmed by venography assessment of the operated leg or objectively confirmed symptomatic 
proximal DVT, nonfatal PE, or any death ) and the individ ual components of the total VTE endpoint
Common Objectives in Parts 1 and 2
Other Secondary Objectives
 To assess the effect of individual doses of JNJ-64179375 compared with apixaban for both efficacy 
and safety endpoints, with the goal toidentify a studied or model -predicted dose with the most 
promising benefit -risk profile for a more extensive evaluation in Phase 3
 To assess the effect of JNJ-64179375 compared with apixaban on wound or joint complications in 
the operated leg
Exploratory Objectives
 To assess the effect of JNJ-64179375 compared with apixaban on other thrombotic events 
(ie,myocardial infarction [MI], ischemic stroke, peripheral arterial embolism)
 To evaluate the cost effectiveness of JNJ-64179375 compared with apixaban based on health 
resource utilization
 To assess the pharmacokinetics (PK), pharmacodynamics (PD),and PK/PD relationships of 
JNJ-64179375 in men and women undergoing primary unilateral TKR surgery and the relation of 
these measures to efficacy and safety endpoi nts (eg, exposure -response analyses)
 To evaluate the PD assays (thrombin time [TT], ecarin clotting time [ECT], prothrombin time [PT], 
activated partial thromboplastin time [aPTT ], and D-dimer) to determine the most appropriate tests 
to measure the effect of JNJ -64179375
Endpoint s
The endpoints of the study will be the same for Parts 1 and 2 although the focus of Part 1 will be 
primarily dose escalation based on safety while the focus of Part 2 will primarily be the assessment of 
dose response in both safet y and efficacy.
Common Endpoints in Parts 1 and 2
Primary Safety Endpoint
The primary safety endpoint is any bleeding event defined as the composite of major, clinically relevant 
nonmajor, and minimal bleeding events assessed through the Day 10- 14 visit .
Primary Efficacy Endpoint
The primary efficacy endpoint is total VTE, defined as the composite of proximal and/or distal DVT 
(asymptomatic confirmed by venography assessment of the operated legor objectively confirmed 
symptomatic), nonfatal PE, or any deat hassessed through the Day 10 -14 visit .
Key Secondary Endpoints
The key secondary endpoints are the assessment of the primary endpoints through the Week 18 visit ,and:
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
10
Approved , Date: 11 September 2017 All individual components of the primary safety endpoint (major bleeding, clinically relevant 
nonmajor bleeding, and minimal bleeding)
 Composite of major and clinically relevant nonmajor bleeding
 Major VTE, a composite of proximal DVT (asymptomatic confirmed by venography assessment of 
the operated leg or objectively confirmed symptomatic), n onfatal PE, or any death
 All individual components of the primary efficacy endpoint (ie, proximal and/or distal DVT 
[asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed 
symptomatic], nonfatal PE, any death)
Other Se condary Endpoints
 Any wound or joint complication in the operated leg
Exploratory Endpoints
 Other thrombotic events ( ie, MI, ischemic stroke, peripheral arterial embolism)
 The total length of the initial hospitalization, including the level of care and dis charge destination
 The incidence of rehospitalization for any reason
 The number of scheduled and unscheduled visits, including the associated cost to healthcare 
providers for study outcomes, any other medical reasons, and the diagnostic procedures used in 
relation to study endpoints
 Calculation of PK parameters, eg, total clearance of the drug after IV administration ( CL), volume of 
distribution (Vd), terminal half- life ( t1/2),area under the plasma concentration versus time curve from 
time 0toinfinity (A UC inf), and maximum concentration during a dosing interval ( Cmax)
 Changes in PD by dose: TT ,ECT, PT, aPTT, and D -dimer
 Changes in PD assays as listed above by concentration metrics (AUC inf, C max, or time-matched 
concentrations)
Refer to Section 9, Study E valuations for related evaluations.
Hypothesis
In Part 1,a range of doses of JNJ-64179375 will be assessed to determine if it is sufficiently safe to 
proceed with Part 2of the study. No formal hypothesis testing will be conducted for Part 1. In Part 2, the 
clinical hypothesis is to demonstrate proof -of-efficacy based on the total VTE endpoint. This can be 
achieved by either showing that JNJ-64179375 hasa statistically significant dose-response trend with 
respect tothe total VTE endpoint, or the combined dose groups of JNJ-64179375 have a total VTE event 
rate of less than 30% .
OVERVIEW OF STUDY DESIGN
This is a randomized, double -blind, double -dummy, active -controlled, multicenter, dose-escalation and 
dose-response study of JNJ-64179375. The study has 2 parts, dose-escalation and dose-response 
evaluation , and will be conducted in subjects undergoing primary unilateral elective TKR surgery. Part1 
will assess the safety of single-ascending IV doses of JNJ-64179375 while Part 2 will confirm the safety 
of thedoses selected from Part 1 and will assess the efficacy dose-response relationship with respect to 
the selected doses in the parallel groups. Subjects will participate in either Part 1 or Part 2 of the study 
only.
For each subject in each part, the study will be conducted in 3 phases: an up to 30-day screening phase 
before surgery, a 14-day double -blind dosing phase, and a 16-week follow -up phase. Unscheduled visits 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
11
Approved , Date: 11 September 2017may be performed at the discretion of the investigator for the assessment of any potential bleeding or 
efficacy endpoint events. The total duration of the subject’s participation in Part 1 or Part 2 after 
randomization will be approximately 18 weeks.
Screening for eligible subjects in Parts 1 and 2 may be done up to 30 days before randomization, pre-or 
postoperatively. Following primary unilateral elective TKR  surgery, eligible subjects will be randomly 
assigned to treatment with either JNJ -64179375 or apixaban. All subjects will receive a single IV infusion 
of JNJ -64179375 or JNJ -64179375 placebo and oral apixaban or matching apixaban placebo the day after
TKR surgery (Day 1, 0 hours), while the subject is still hospitalized and within a minimum of 12hours 
and a maximum of 24 hours after the end of the TKR surgery, defined as the time of wound closure .
Following discharge or transfer to an alternate facility, subjects in both parts will continue to take 
apixaban or matching apixaban placebo twice daily  to complete a total of 10 to 14 days of dosing. 
Unilateral venography assessment of the operat ed leg will be performed after the last dose of apixaban or 
matching apixaban placebo is taken.
Subjects in both Parts 1 and 2 will return to the site for study -related procedures 5, 10, and 18 weeks after 
TKR surgery. Safety evaluations will include the m onitoring of all nonserious and serious adverse events, 
(including adverse events of special interest: bleeding events, infusion reactions, hypersensitivity 
reactions , and wound or joint complications ), clinical laboratory tests (ie,hematology, clinical chemistry, 
urinalysis), vital signs measurements (blood pressure, pulse/heart rate [HR], temperature) , and physical 
examinations. Pharmacokinetic s(dense and sparse), PD, and immunogenicity samples will be collected 
and health resource utilization will alsobe assessed.
An Operations Committee (OC), Independent Data Monitoring Committee (IDMC), Steering Committee 
(SC), and independent Clinical Events Committee (CEC) will be commissioned for this study.
The number of cohorts and the size of each cohort in Part 1 may be adjusted based on the ongoing 
unblinded data review by the OC. Additionally, anunblinded data review is planned forPart 1 after all 
subjects are expected tohave completed the Day 10-14 visit to determine the dose range and doses of 
JNJ-64179375 for Part 2. An adaptive approach will be used to guide decisions to drop and/or add the 
doses of JNJ-64179375 and adjust the randomization ratio based on available efficacy, safety, PK, and 
PDdata at 2planned, unblinded interim analyses in Part 2. The sponsor will also be responsible for 
conducting anunblinded administrative interim analysis after all subjectsare expected tohave completed 
the Day 10-14- visit in Part 2 to facilitate additional study planning .
SUBJECT POPULATION
Subjects will be m en and women of non -childbearing potential, at least 50 years of age or older who have 
undergone an elective primary unilateral TKR and are considered to be medically appropriate for 
postoperative anticoagulant prophylaxis as determined by the investigator on the basis of thephysical 
examination, medical history, vital signs measurements , and clinical laboratory tests performed as part of 
screening for elective TKR surgery and any examinations performed as part of standard postoperative 
care following surgery. It is estimated that approximately 1,500 subjects will be randomly assigned to 
treatment in this study. Part 1 will include up to approximately 300 subjects and Part 2 is estimated to be
1,200 subjects. Subjects who are withdrawn early from the study will not be replaced.
DOSAGE AND ADMINISTRATION
In both Parts 1 and 2, subjects will be randomly assigned to receive an active single IV dose of 
JNJ-64179375 or apixaban 2.5 mg given orally twice daily for 10 to 14 days. The administration of the 
study drugs will begin the day after theTKR surgery (Day 1, 0 hours), while the subject is still 
hospitalized and within a minimum of 12hours and a maximum of 24 hours after the end of the 
TKR surgery, defined as the time of wound closure. Within that timeframe, both the single IVinfusion 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
12
Approved , Date: 11 September 2017and the oral study drug should be administered as close as possible to each other, with up to a maximum 
of 60 minutes between the start of the IV infusion and the first dose of the oral study drug. 
All study drug administrations ofJNJ-64179375 must be calculated based on the subject’s weight on 
Day -1 or prior to dosing on Day 1. The single infusion of JNJ-64179375 or JNJ-64179375 placebo 
(saline) will be administered under the supervision of the investigator or his/her designee ov er a period of 
approximately 30minutes by infusion pump or by gravity flow using a flow regulator. A physician must 
be immediately available at the study site at all times during the administration of the study drug infusion.
The first dose of apixaban ormatching apixaban placebo will be administered as previously described. 
Subjects will receive apixaban or matching apixaban placebo twice a day while hospitalized and will be 
given a supply of apixaban or matching apixaban placebo at the time of discharge or transfer to an 
alternate facility, with instructions to take the study drug orally, twice a day at approximately the same 
times each day to complete a total of 10 to 14 days of dosing. Apixaban or matching apixaban placebo 
should be swallowed with wate r, with or without food. 
Part 1 Dosing
Eligible subjects in Part 1 will be randomly assigned to a single -ascending IV dose of JNJ-64179375 or 
apixaban 2.5mg given orally twice daily for 10to 14 days. Sixcohorts of up to approximately 50unique 
subjects per cohort (total of up to approximately 300 unique subjects) are planned but the number of 
cohorts and the size of each cohort may be adjusted based on the ongoing unblinded data review by the 
OC. Within each cohort ,subjects will be randomized in a 4:1 ratio to JNJ-64179375 or apixaban, 
respectively (ie,approximately 40 subjects to JNJ-64179375: approximately 10subjects to apixaban). 
JNJ-64179375 will be administered in a dose-escalation manner, with planned doses of 0.3, 0.6, and 
1.2mg/kg in Cohorts 1, 2, and 3, respectively. 
 Cohort 1: JNJ-64179375 0.3 mg/kg IV/JNJ-64179375 placebo (saline) IV infusion and matching 
apixaban placebo/apixaban, orally twice a day for 10 to 14 days
 Cohort 2: JNJ-64179375 0.6 mg/kg IV/JNJ-64179375 placebo (saline) IV infusion and matching 
apixaban placebo/apixaban, orally twice a day for 10 to14 days
 Cohort 3: JNJ-64179375 1.2 mg/kg IV/JNJ-64179375 placebo (saline) IV infusion and matching 
apixaban placebo/apixaban, orally twice a day for 10 to14 days
The doses of JNJ-64179375 to be used in the optional cohorts will be dependent on the available 
preliminary safety, tolerability, efficacy, PK, and PD data obtained from the preceding cohorts. Doses 
within the optional cohorts will either be new doses within the range of 0.1to 1.8 mg/kg not previously  
administered in the preceding cohorts, or doses from the preceding cohorts, which may be repeated, as 
needed. 
After all of the subjects in Part1are expected tohave completed the Day 10-14 visit, an unblinded data 
review will be conducted by the OC, SC, IDMC, and sponsor to determine the dose range and doses for 
Part2.
Part 2 Dosing
Part 2 of this study has an adaptive design, with the intent to optimize data collection for the 
dose-response evaluation using multiple compari son procedure and modeling (MCP -Mod) . Eligible 
subjects prior to the first interim analysis in Part 2 will be randomly assigned equally to 1 of up to 
5parallel treatment groups, including up to 4dose levels of JNJ-64179375, given as a single, active 
IVinfusion, or oral apixaban 2.5mg twice daily  for 10to14days. The number of doses and 
randomization ratio after the 2interim analyses will depend on the interim analysis results. However, the 
number of ongoing doses of JNJ -64179375 in the study is not expected to exceed 4doses.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
13
Approved , Date: 11 September 2017 Group A: JNJ-64179375 Dose A mg/kg IV and apixaban placebo orally  twice a day for 
10to14days
 Group B: JNJ -64179375 Dose B mg/kg IV and apixaban placebo orally twice a day for 10 to14 days
 Group C: JNJ -64179375 Dose C mg/kg IV and apixaban placebo orally twice a day for 10 to14 days
 Group D: JNJ-64179375 Dose D mg/kg IV and apixaban placebo orally  twice a day for 
10to14days
 Group E: JNJ-64179375 placebo (saline) IV and apixaban 2.5 mg orally twice a day for 
10to14days
EFFICACY EVALUATIONS
Efficacy evaluations will include unilateral venography assessment of the operated leg and assessments of 
symptomatic DVT, PE, death, or other thrombotic events (ie, MI, ischemic stroke, and peripheral arterial 
embolism) to assess the pr imary ,secondary , and exploratory efficacy outcomes.
Venography assessments of the operated leg will be performed by injecting contrast agent into a foot vein 
and obtaining x-ray images of the proximal and distal leg veins. Evaluable venography assessments
require the visualization of all of the deep veins except for the muscular, anterior tibial, and deep femoral 
veins. An ultrasound will be performed in those subjects with suspected symp tomatic DVT prior to the 
Day 10-14 visit. In these cases, if the ultrasound confirms symptomatic proximal DVT, a subsequent 
venography assessment is not required. If the ultrasound is negative or confirms a distal DVT, the 
venography assessment shoul d be conducted on the Day 10-14 visit.
For all subjects with symptoms of PE, spiral computed tomography (CT), pulmonary angiography, or 
perfusion/ventilation lung scintigraphy combined with chest radiography will be performed. If a subject is 
diagnosed with a PE meeting the specified definitions, a subsequent venography assessment of the 
operated leg is not required.
Other thrombotic events will include MI, ischemic stroke, and peripheral arterial embolism. In addition, 
events that appear suggestive of study endpoints (eg, transient ischemic attack [TIA], unstable angina) 
will be reported by the investigator and reviewed by the CEC to ascertain if a thrombotic event has 
occurred.
PHARMACOKINETIC EVALUATIONS
Samples for analysis of JNJ -64179375 plasma concentration will be collected for all subjects over time as 
specified in the Time and Events Schedule but will only be analyzed for subjects randomly assigned to 
JNJ-64179375. Dense PK sampling will be conducted at all sites for subjects at all visits in Part 1 until 
approximately up tothe first 200 subjects have been randomized. Thereafter, the remaining subjects in 
Part1 and all subjects in Part 2will have PK blood samples collected at a limited number of visits 
(ie,sparse PK sampling). The exact date and time of each PK blood sample collection will be recorded
even if the time deviates slightly from the scheduled time of collection. Subjects who experience a 
bleeding event or symptomatic thrombotic event should have PK sam ples collected as soon as practically 
possible after the event occurs. 
The PK parameters to be calculated following the single IV dose of JNJ-64179375 will include, but are 
not limited to, the following: Cmax, AUC inf, t1/2, CL, and apparent volume of distribution in the terminal 
phase (V Z). Additional PK parameters may be determined, as appropriate.
A separate population PK modeling plan will be developed before the first subject is consented and the
population PK modeling results will be reported separately, in a document other than the clinical study 
report (CSR) .
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
14
Approved , Date: 11 September 2017IMMUNOGENICITY EVALUATIONS
Blood samples for antibodies to JNJ-64179375 will be collected from all subjects according to the Time 
and Events Schedule but will only be analyzed in plasma samples for subjects randomized to 
JNJ-64179375. The exact date and time of each blood sample collection will be reco rded. Plasma samples 
will be screened for antibodies binding to JNJ-64179375 and the titer of confirmed positive samples will 
be reported. Other analyses (eg, neutralization capacity) may be performed to further characterize the 
immunogenicity of JNJ-64179375.
PHARMACODYNAMIC /BIOMARKER EVALUATIONS
All subjects will have plasma samples collected to assess PD markers as specified in the Time and Events 
Schedule. The assay plan is designed to assess target engagement and the mechanism of action with a 
battery of PD assessments. Pharmacodynamic evaluations will include the coagulation assays 
(ie,TT,ECT, PT, aPTT) and a D-dimer assessment. Subjects who experience a bleeding event or 
symptomatic thrombotic event should have PD samples (except D-dimer) collected as soon as practically 
possible after the event occurs. 
SAFETY EVALUATIONS
The safety and tolerability of JN J-64179375 will be evaluated throughout the study according to the tim e 
points provided in the Time and Events Schedule by the assessment ofadvers e events, including serious 
adverse events, adverse events of special interest (ie, bleeding events, infusion reactions, hypersensitivity 
reactions , and wound or joint complications ), clinical laboratory tests (ie,hematology, clinical chemistry, 
urinalysi s), vital signs measurements (blood pressure, pulse/ HR, temperature), and physical examinations. 
Safety evaluations may also be performed at unscheduled time points, if deemed by the investigator or 
appropriate designee as necessary to ensure the safety ofthe subject. All suspected symptomatic efficacy
(thrombotic) events will alsobe captured as adverse events of special interest.
STATISTICAL METHODS
A total of 1,500 subjects are planned for this study, of which up to 300 subjects will be enrolled in Part 1 
and the remainder for the entire study will be enrolled in Part 2. In Part 1, the sample size is not based on 
hypothesis testing but rather on making a preliminary assessment of the bleeding risk for the doses of 
JNJ-64179375. 
In Part 1, the intent is to escalate across the planned doses (0.3 to 0.6 to 1.2 mg/kg) of JNJ-64179375 
based on the OC review of the totality of the data but with a focus on bleeding events. Specific analyses 
to be reviewed (eg, continual reassessment or escalation with overdose control methods) and dose-
escalation decision guidelines will be included in the OC charter. After all subject sin Part 1 are expected 
to have completed the Day 10-14 visit,an unblinded data review is planned and the selection of the dose 
range and doses for Part 2 will be based on the evaluation of the totality of the data but with a focus on 
the any bleeding and total VTE endpoints. Analyses to aid in dose selection will be prespecified in the 
OCcharter and the Part 1 statistical analysis plan (SAP). Noformal hypothesis testing is planned for 
Part1 due to the limited sample size. Historical apixaban bleeding and VTE event rates may also be 
considered in making decisions. 
In Part 2, this study will use an adaptive design intended to optimize data colle ction for dose-response 
modeling. In Part 2, the primary goal is to assess the efficacy (total VTE endpoint) dose-response 
relationship of JNJ-64179375. A hybrid methodology that combines aspects of multiple testing with 
modeling techniques (MCP -Mod) will be used for evaluating dose-response trends and estimating the 
dose-response relationships for the efficacy and bleeding endpoints for JNJ-64179375. The sample size 
for Part 2 may be adjusted based on the observed bleeding and total VTE event rates in Part 1.
Assuming that 80% of the venography assessments are evaluable and the true underlying total VTE event 
rates are 15%, 10%, 8%, and 6% at potential doses of JNJ-64179375 of0.3, 0.6, 0.9, and 1.2mg/kg, 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
15
Approved , Date: 11 September 2017respectively, with a total sample size of 1,200 subjects, the study is expected to have over 90% power to 
declare proof -of-efficacy , which is defined as either a statistically significant dose-response trend or a
total VTE event rate lower than 30% in the pooled doses of JNJ -64179375 at a 1- sided, 2.5% -level. The 
exact power will vary because of the nature of the adaptive study design .
For comparison with apixaban in Part 2, i f the true underlying total VTE and any bleeding event rates are 
as specified in the table below, asimulation study  demonstrates that there will be approximately 
90% probability to identify a dose within the dose range of 0.3to1.2mg/kg, of which both the 
model -predicted total VTE and any bleeding event rates met the prespecified noninferiority (NI) criterion 
(the upper bound of the 1-sided 90% confidence interval [CI]for the odds ratio 
[JNJ-64179375 toapixaban] is equal to or lower than 1.5 for total VTE and any bleeding events).
Assu med Efficacy and Safety Event Rates by Treatment Group in Sample Size Determination for Part 2
JNJ-64179375 Apixaban
0.3 m g/kg 0.6 m g/kg 0.9 m g/kg 1.2 m g/kg 2.5 mg bid
Total VTE
(Efficacy) 15% 10% 8% 6% 15%
Any Bleeding
(Safety) 5% 6% 7% 8% 8%
bid=tw ice daily; VTE=venous thromboembolism
Two planned, unblinded interim analyses will be conducted in Part 2 by the IDMC as part of the adaptive 
approach that will be used to guide decisions to drop and/oradd doses of JNJ-64179375 and adjust the 
randomization ratio based on available efficacy, safety, PK, and PD data. A futility analysis will also be 
included as part of both interim analyses. Further details related to the interim analyses and decision 
guidelines will be specified in the IDMC charter and Part 2 SAP. In addition, an unblinded administrative 
interim analysis is planned to be conducted by the sponsor after all subjects are expected tohave 
completed the Day 10 -14 visit in Part 2 to facilitate additional study planning.
Plasma concentrations of JNJ -64179375 will be listed for all subjects by time of collection and dose level. 
For each dose, descriptive statistics, including mean, median, standard deviation (SD), and coefficient of 
variation will be calculated for the plasma concentrations at each nominal sampling time. In addition, a 
population PK model will be developed and dependence of PK of JNJ -64179375 on population covariates 
(eg, demographics, laboratory variables) will be evaluated. 
The incidence of antibodies to JNJ-64179375 will be summarized for all subjects who receive a dose of 
JNJ-64179375 and have at least 1 appropriate sample obtained after study drug administration for the 
detection of antibodies to JNJ-64179375. A listing of subjects who are positive for antibodies to 
JNJ-64179375 will be provided. The maximum titers of antibodies to JNJ-64179375 will be summarized 
for subjec ts who are positive for antibodies toJNJ-64179375. Analyses of the impact of immunogenicity 
on PK, PD, PK/PD, efficacy, and safety endpoints will be performed to further characterize the immune 
responses that are generated.
Descriptive statistics including mean, median, SD, minimum, and maximum will be provided for the 
PDparameters of TT, ECT, PT, aPTT, and D-dimer. The parameters of TT, PT, and aPTT may be 
statistically analyzed using mixed models. Other PD parameters may be analyzed similarly.
The PK/PD relationships will be investigated graphically and, if appropriate, may be further analyzed 
using suitable statistical methods. Preliminary assessments of these relationships will be made available 
to the IDMC at both interim analyses to support their evaluations.
Health resource utilization will be descriptively summarized by treatment group.
All safety data will be fully listed. The reporting of the safety data of all subjects receiving at least 
1active dose of JNJ-64179375 or apixaban will include the incidence and type of adverse events, plus 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
16
Approved , Date: 11 September 2017absolute values and changes in blood pressure (systolic and diastolic), HR, clinical laboratory data, and 
physical examinations from predose to the final postdose time point.
Based on the mechanism of action of JNJ-64179375 and given that it is a monoclonal antibody, adverse 
events of special interest will include bleeding events, infusion reactions, hypersensitivity reactions , and 
wound or joint complications . Subjects with adverse events of special interest may be counted or listed 
using standardized Medical Dictionary for Regulatory Activities (MedDRA) queries (SMQs )
(eg,hemorrhage excluding laboratory terms SMQ). All suspected symptomatic efficacy (thrombotic) 
events will also be captured as adverse events of s pecial interest.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
17
Approved , Date: 11 September 2017TIME A ND EVENTS SCHE DULE FOR PA RT 1 A ND P ART 2
Phase ScreeningaDouble -Blind Dosing Follow -upb
Unsche duled 
VisitfUp to
Day -30Day 1
Day 
2Day 
3dDay 
7dDay
10-14
(EOD /
EW)eWeek 5
(±1 wk)Week 10
(±2 wk)Week 18
(±2 wk) Study Proced ures 0 h 1 hc4 h
Screening/ Baseline/ Administrative
Informed consentgX
Inclusion/exclusion criteriahX X
Medical history and demographics X
Bleeding risk history X
Relevant p restudy therapy X
ECG X
Total knee replacement surgeryjX
Study Drug Administration
Randomization X
Dispense/administer study drugkX X X X X
Drug accountability X
Safety Assessments
Physical examinationlX X X
Vital signsmX XiX X X X X X X
Efficacy Assessments
Venography of the operated leg Xn
Symptomatic thrombotic eventsoX X X X X X X X X X X
Clinical Laboratory Assessments
Hematology XiX X X X
Serum chemistry XiX X X X
Urinalysis XiX X X
Pharm acokinetics /Immunogenicity
Dense PK sample collectionpX X X X X X X X X X
Sparse PK sample collectionqX X X X X XrX
ADA sample collection XiX X X X
Pharm acody namics
PD coagulation sample collectionsXiX X X X
D-dimer XiX X
Ongoing Subject Review
Health resource utilization X X X X X X X X X X X
Concomitant therapy X X X X X X X X X X X X
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
18
Approved , Date: 11 September 2017Phase ScreeningaDouble -Blind Dosing Follow -upb
Unsche duled 
VisitfUp to
Day -30Day 1
Day 
2Day 
3dDay 
7dDay
10-14
(EOD /
EW)eWeek 5
(±1 wk)Week 10
(±2 wk)Week 18
(±2 wk) Study Proced ures 0 h 1 hc4 h
Adverse events monitoring, including 
adverse events of special interest (ie, 
bleeding events, infusion reactions, 
hypersensitivity reactions , wound or joint 
complications )tX X X X X X X X X X X X
Key: ADA=antidrug antibody; ECG=electr ocardiogram; EOD =end of dosing ; EW=early withdrawal; h=hour ; PD=pharmacodynamic(s); PK=pharmacokinetic(s) ; 
wk=week
aScreening for eligible subjects in Parts 1 and 2 may be done up to 30 days before randomization , pre-or postoperatively .Final eligibility must be confirmed after 
surgery , prior to randomization .
bReasonable attempts should be made to conduct the follow -up visit (s)at the scheduled time points . If a subject w ithdraws from the study before the end of the
follow -up phase and is unwilling or unable to return for follow -up visits in person or have follow -up contacts , the study site should collect as much follow -up visit 
information as possible , including contacting the subject or subject’s representative or health care professional by  telephone or mail .
cOne hour (10 minutes) from the start of the 30 -minute infusion .
dStudy procedures will be conducted on Days 3 and 7 only for those subjects who are still hospitalized .
eSubjects who do not receive the full infusion of JNJ -64179375 or prematur ely discontinue dosing (ie, EW) with apixaban or matching apixaban placebo before the 
end of the double -blind dosing phase will be instructed to return to the study site at the originally sch eduled Day 10 -14 visit to conduct assessments, including the 
veno graphy assessment of the operated leg (unless a pulm onary  embolism [PE] or symptomatic proximal deep vein thrombosis [ DVT ]has been diagnosed ), and to 
complete the remaining visits through the Week 18assessments .
fAt the discretion of the investigator, s ubjects may return to the study site betw een scheduled visits. Subjects sho uld return to the study site for the assessment of 
any potential bleeding or efficacy endpoint events. Unscheduled PKand PD samples (except D -dimer) should be collected as soon as practical ly possible for any 
subject who experiences symptomatic thrombotic or bleeding events.
gAt the time of informed consent , 2 alternative means of contact for the each subject w ill be collected (eg, contact information of the subject’s children, spouse,
significant other, caretaker, legal representative, or health care professional ).
hThe investigator will need to determine if the subject is medically appropriate for postoperative anticoagulant prophylaxis on the basis of physical examination, 
medic al history , vital signs measurement s, and clinical laboratory tests performed as part of screening for elective TKR surgery and any examination performed as 
part of standard postoperative care follow ing surgery .
iProcedures should be conducted prior to th e first dose of the study drug.
jDetails regarding the total knee replacement (TKR) surgery and the post -surgery management (eg, type of anesthesia, procedure duration, cement use, tourniquet 
use and duration, drain use and volume, us eof all mechanical v enous thromboembolism [ VTE ] prophylaxis methods) will be collected in the electronic case report 
form (eCRF) .
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
19
Approved , Date: 11 September 2017kThe dayafter TKR surgery (Day  1, 0 hours) , while the subject is still hospitalized and within a minimum of 12 hours and a maximum of 24 hours a fter the end of 
the TKR surgery, defined as the time of wound closure, all subjects will receive a single IV infusion of JNJ -64179375 or JNJ -64179375 placebo and oral apixaban 
or matching apixaban placebo . The first dose of apixaban or matching apixaban pl acebo w ill be administered while the subject is hospitalized, w ith up to a 
maximum of 60 minutes between the start of the IV infusion and the first dose of oral study drug. Subjects will receive apixa ban or matching apixaban placebo 
twice a day while hospi talized and w ill be given a supply of apixaban or matching apixaban placebo at the time of discharge or transfer to an alternate facility , with 
instructions to take the study drug orally, twice a day at approximately the same times each day to complete a t otal of 10 to 14 days of dosing .
lHeight and weight should be obtained at the screening visit, with weight only on Day -1 or prior to dosing on Day 1 and the final visit. A n assessment of the wound 
will be made at all visits as p art of the adverse event a ssess ment and the final physical examination will assess the range of motion of the operated joint.
mBlood pressure and pulse/ heart rate (HR) measurements will be assessed with subjects in the supine position with a completely automated device andshould be 
preceded by at least 5 minutes of rest . The subject’s temperature should also be obtained.
nSubjects who complete dosing w ith apixaban or matching apixaban placebo w ill return to the study site for final EOD assessments ( at the Day 10 -14visit, EOD ), 
at which time a unilateral venography assessment of the operated leg will be performed within 24 hours of the last dose of apixaban or matching apixaban placebo. 
If dosing with apixaban or matching apixaban placebo is prematurely discontinued, the venograph y assessment should be completed on the originally scheduled 
Day 10-14(EOD ) visit, not earlier. If a subject has suspected symptomatic DVT prior to the Day 10-14 visit , an ultrasound will be performed. If the ultrasound 
confirms symptomatic proximal DVT, a subsequent venography assessment is not required. If the ultrasound is negative or confirms a distal DVT , the venography 
assessment should be conducted on the Day 10 -14 visit .In addition, if the subject is diagnosed w ith a PE, a venography assessment ofthe operated leg is not 
required.
oSuspected s ymptom aticefficacy (thrombotic ) events ( DVT, PE, death, myocardial infarction, ischemic stroke, peripheral arterial embolism) will be reported by the 
investigator and reviewed by the Clinical Events Committe e to ascertain if a thrombotic event has occurred.
pAllsites in Part 1 will collect PK blood samples for subjects at all visits (hereafter referred to as dense PK sample collection )until approximately up to the first 
200subjects have been randomized . The Day 1 samples will be drawn at 1 hour and 4 hours from the start of the IV infusion . The Day 2 blood sample will be 
draw n 24 hours after the start of the IV infusion and may be done w ith the subject as an inpatient or outpatient . The Day 3 (48hours) an d Day 7 (144 hours) blood 
samples are only required for those subjec ts who are still hospitalized. 
qAfter approximately up to the first 200 randomized subjects in Part 1 have initiated dense PK sampling , the remaining subjects in Part 1 and all subjects in Part 2
will have PK blood samples collected at a limited number of visits (hereafter referred to as sparse PK sample collection). The Day 2 sample will be drawn 24 hours 
after the start of the IV infusion and may be done with the subject as an inpatient or outpatient .
rThe PK sample will only be collected at this visit if it was not collected at the Week 10 visit.
sPharm acody namic evaluations w ill include the coagulation assays (ie, thrombin time [TT], ecarin clotting time [ECT], prothrom bin time [PT], and activated partial 
thromboplastin time [aPTT]). Samples on Day 1 will be obtained before the study drug is administered and at 1 hour after the start of the study drug infusion. 
tAll adverse events, whether serious or nonserious, will be reported fro m the time a signed and dated informed consent form (ICF) is obtained until the completion 
of the subject’s last study -related procedure. Adverse events of special interest are bleeding events, infusion reactions, hypersensitivity reactions, and wound or 
joint complications). All suspected symptomatic efficacy (thrombotic) events will also be captured as adverse events of special interest. 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
20
Approved , Date: 11 September 2017ABBREVIA TIONS
ADA antidrug antibody
aPTT activated partial thromboplastin time
AV arteriovenous
CEC Clinical Eve nts Committee
CI confidence interval
CSR clinical study report
CT computed tomography
CYP cytochrome P450
DOAC direct-acting oral anticoagulants
DVT deep vein thrombosis
ECG electrocardiogram
eCRF electronic case report form
ECT ecarin clotting ti me
eDC electronic data capture
EOD end of dosing
FeCl 3 ferric chloride
FSH follicle stimulating hormone
FXa Factor Xa
GCP Good Clinical Practice
GLP Good Laboratory Practice
HaNDL Headache and Neurological Deficits with ce rebrospinal fluid Lymphocy tosis
HR heart rate
IB Investigator’s Brochure
ICF informed consent form
ICH International Conference on Harmonisation
IDMC Independent Data Monitoring Committee
IEC Independent Ethics Committee
Ig immunoglobin
IPPI Investigational Product Preparat ion Instructions
IRB Institutional Review Board
ITT intent to treat
IV intravenous
IWRS interactive web response system
LMWH low molecular -weight heparin
MCP -Mod multiple comparison procedure and modeling
MedDRA Medical Dictionary for Regulatory Act ivities
MI myocardial infarction
NI noninferiority
NSAID nonsteroidal anti -inflammatory drug
OC Operations Committee
PCC prothrombin complex concentrate
PD pharmacodynamic(s)
PE pulmonary embolism
P-gp P-glycoprotein
PK pharmacokinetic (s)
PQC product quality complaint
PT prothrombin time
QTcF QT corrected according to Friderica’s formula
RBC red blood cell
SAD single -ascending dose
SAP statistical analysis plan
SC Steering Committee
SD standard deviation
SMQ standardized MedDRA queries
SQ subcutaneous
SUSAR suspected unexpected serious adverse reaction
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
21
Approved , Date: 11 September 2017TEAE treatment -emergent adverse event
TIA transient ischemic attack
TK toxicokinetic
TKR total knee replacement
TT thrombin time
TXA tranexamic acid
VTE venous thromboembolism
WBC white blood cell
wk week
DEFINITIONS OF PHARM ACOKINETIC TERMS
AUC area under the plasma concentration curve
AUC inf area under the plasma concentration versus time curve from time 0 to infinity
AUC Day22 -29 area under the concentration -time curve during the dosing interval betw een Days 22 and 29
CL total clearance of drug after IV administration
Cmax maximum concentration during a dosing interval
t1/2 terminal half -life
Tmax time to reach the maximum observed plasma concentration
Vd volume of distrib ution
VZ apparent volume of distribution in the terminal phase
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
22
Approved , Date: 11 September 20171. INTRODUCTION
JNJ-64179375 is a first-in-class, recombinant, fully  human immunoglobin (Ig) G4 monoclonal 
antibody  that binds reversibly  with high affinity  and specificity  to the exosite -1 region of 
thrombin. JNJ-64179375 was engineered to mimic the pharmacologic effects of an IgA antibody  
that was found in a patient with markedly  abnormal clotting times but with a lack of spontaneous 
bleeding episodes over a prolonged follow -up period, repres enting the profile of an anticoagulant 
that might have a beneficial therapeutic index in terms of anticoagulation efficacy  with low 
bleeding risk.1JNJ-64179375 acts as an anticoagulant by blocking only exosite -1-mediated 
fibrinogen binding to thrombin (and also blocks proteinase -activated receptor -1 binding) , but 
does not inhibit the catalytic activity  of the protease. The mechanism of action is distinct from 
currentl y available direct thrombin inhibitors that block the active site only (eg, dabigatran, 
argatroban) or that block both the active site and exosite 1 (eg,bivalirudin, hirudin) and from 
other mechanisms that inhibit thrombin generation (eg, Factor Xa [FXa] inhibitors). The primary  
goal of the clinical program will be to demonstrate noninferior efficacy  with a reduced bleeding 
risk versus active comparators. However, the possibility  of demonstrating superior efficacy  may 
be considered based on better compliance with a once -monthly  dosing regimen and/or the ability 
to achieve more effective drug levels due to a reduced risk of bleeding (ie, dosesnot limited by 
bleeding risk).
An estimated 920,000 patients in Japan and Europe experience venous thromboembolism (VTE) 
annually , which includes deep vein throm bosis (DVT) and pulmonary  embolism (PE).6,19Joint 
replacement surgery  of the lower extremities carries a high risk of VTE due toprothrombotic 
processes such as softtissue and bone injury during surgery ,which causes coagulation activation
from thromboplastin release , venous stasis from peri-and postoperative immobilization , and 
inflammation from the healing process.32This has led to recommendations in the guideline sthat 
all patients undergoing total knee replacement (TKR )should receive pharmacologic and/or 
mechanical VTE prophy laxis .10,19Low molecular -weight heparin (LMWH) and several 
direct -acting oral anticoagulants (DOAC s), including apixaban ,have been used in the prevention 
of VTE in patients undergoing TKR surgery . However, limitations of these drugs include once -
or twice -daily dosing regimens and the possibility  of an increased bleeding risk at their 
recommended dosages.
JNJ-64179375 is being developed for multiple thrombosis -mediated conditions, including the 
prevention of VTE after TKR surgery ,andmay offer the potential for equivalent (orsuperior) 
efficacy  to currentl y available anticoagulant drugs with a reduced risk of bleeding and a simpler
dosing regimen .A novel antithrombotic agent requires the demonstration of both efficacy  and 
safet y in relevant populations. Phase 2studies are frequentl y performed in subject s undergoing 
TKR surgery  because of the well-documented high incidence of DVT in the absence of adequate 
thromboprophy laxis, as well as the increased risk of bleeding after recent surgery .7An 
assessment of the effect on efficacy  and safet y of JNJ-64179375 compared with apixaban in this 
study  will be used to identify  an appropriate dose for evaluation in the Phase 3 clinical 
development program.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
23
Approved , Date: 11 September 2017For the most comprehensive nonclinical and clinical information regarding JNJ-64179375 , refer 
to the latest version of the Investigator's Brochure (IB) 17and the Addendum to the IB18for
JNJ-64179375 .
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
Information page(s), which will be provided as a separate document.
1.1. Background
1.1.1. Nonclinical Studies
1.1.1.1. Nonclinical Pharmacology
JNJ-64179375 binds tohuman, mouse, rat, and monkey  thrombin with high affinity 
(ie,equilibrium dissociation constant s<2 nM) and does not bind to prothrombin or other serine 
proteases. Spiking of JNJ-64179375 in human plasma in vitro resulted in 
concentration -dependent prolongation of clotting in various coagulation assay s (thrombin time 
[TT] [dilute and normal], ecarin clotting time [ECT ], prothrombin time [PT], and activated 
partial thromboplastin time [aPTT] ), with TT being the most sensitive for this compound. 
JNJ-6417937 5 inhibited thrombin- induced platelet aggregation in human platelet -rich plasma 
invitro but did not affect platelet aggregation induced by other platelet agonists. 
The antithrombotic efficacy  of JNJ-64179375 was evaluated in several different thrombosis 
models in rats andcynomolgus monkey s, andin a human translational ex-vivo flow-chamber
model (Badimon chamber) . JNJ -64179375 inhibited thrombosis in rat ferric chloride (FeCl 3) and 
arteriovenous (AV) -shunt model sof venous thrombosis in a dose-dependent manner 
(0.1to1mg/kg, intravenous [IV]). At0.3 and1 mg/kg, JNJ-64179375 produced antithrombo tic 
efficacy  accompanied by approximately  1.5- and2-fold increase sin TT ex vivo, respectively
(serum level approximately  7 and 23 μg/mL , respectivel y). JNJ-64179375 (0.3 and 1mg/kg, IV) 
also inhibited thrombosis in a dose-dependent manner in a FeCl 3model of venous thrombosis in 
cynomolgus monkey s. At the 1 -mg/kg dose, serum l evels were approximately 40 μg/mL .
The Badimon chambe r is a clinical ex-vivo model of thrombosis that mimics the arterial flow 
conditions within the coronar y circulation. Under these conditions, higher concentrations of 
JNJ-64179375 added extracorporeall y to the blood (approximately  250 g/mL ) were required to 
demonstrate efficacy . Overall, the pharmacology  data suggests that the therapeutic range of 
JNJ-64179375 for the prevention of venous thrombosis may be between approximately  7 μg/mL
and 40 μ g/mL (ie, the concentration sin rats at the 0.3-mg/kg dose and in monkey s at the
1-mg/kg dose, respectively ).
The ability  of 4 marketed nonspecific reversal agents (Beriplex®, FEIBA, NovoSeven®, and 
tranexamic acid [TXA ]) to reverse the bleed ing induced by JNJ-64179375 was evaluated in the 
rat-tail transection model. JNJ-64179375 at a dose of 10 mg/kgIV,(ie, a 10-fold higher dose 
than the effective dose in the FeCl 3 and AV-shunt models ofvenous thrombosis), resulted in 
increases in bleeding time and blood loss in this model ;however, these increases in bleeding 
parameters were significantly  attenuated by pretreatment with either Beriplex (a 4-factor 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
24
Approved , Date: 11 September 2017prothrombin complex concentrate [PCC]) or FEIBA (an activated PCC). In contrast, TXA and 
Novo Seven did not shorten the bleeding times after dosing with JNJ-64179375 at the doses 
studied.
1.1.1.2. Safety  Pharmacology
Safety  pharmacology  evaluations were incor porated into the 1-month repeat -dose Good 
Laboratory  Practice (GLP) toxicology  studies in rats (T-2016-006) and cynomolgus monkey s 
(T-2016 -005). The results of the 1-month GLP toxicity  study in monk eys with JNJ-64179375 
(3,15, 50 mg/kg/week [wk]) IV and 30 mg/kg/wk subcutaneous [SQ]) indicated no 
treatment -related abnormalities in rhythm or waveform morphology  at any dose level based on 
comparison of predose and postdose electrocardiogram (ECG) recordings, and the ECGs
evaluated in this study  were qualitatively  considered normal for cynomolgus monkey s. In the 
monkey  study, there were no treatment -related changes in blood pressure, heart rate (HR), 
respiratory  rate,or body  temperature. Clinical observati ons from both the rat (up to 
30mg/kg/wk) and monkey  studies did not reveal any  treatment -related neurobehavioral effects.
1.1.1.3. Toxicology
A series of in-vitro and in-vivo nonclinical studies were conducted as part of the JNJ-64179375 
safet y assessment in support of clinical studies with a treatment period up to 1 month. Both the 
rat and cynomolgus monkey  are pharmacologically  relevant species for toxicology  testing. The 
maximum dose tested in the non -GLP studies in rats and monkey s was 100 mg/kg/wk IV, and in 
GLP studies, 30 mg/kg/wk and 50 mg/kg/wk in rats and monkey s, respectively . In these 1 -month 
repeat -dose studies, animals did not demonstrate any overt or target organ toxicities upon 
administration of JNJ-64179375 other than those related to an extension of the intended 
pharmacology , including dose -dependent prolongation in PT, aPTT, and TT, bruises and 
hemorrhage at the site of administration (rats only), increased hold -off times (bleeding stop time) 
after venipuncture (monkey s),and mortalit y (rat only).
Five of 8 mortalities observed in the non-GLP and GLP rat studies occurred in the toxicokinetic 
(TK) animals that had blood sample s collected from the jugular vein repeatedly  throughout the 
in-life phases. The 2 main study  rats in the non-GLP study  died either on the day of or the 
morning after blood sampling. In the GLP study  (no blood sampling in main study  animals), the 
death of 1main study  rat in the 10-mg/kg dose group represented 1 in 90 rats at the same or 
higher doses (10-mg/kg IV, 30-mg/kg IV, and SQ groups). However, there were no 
histopathologic alfindings in anyof the tissues and organs examined. In addition, there were no 
histopathologic alfindings in any rats examined at the end-of-dosing phase. Therefore , it can be 
concluded that the mortalities in rats are most likely  related to study  procedures in anticoagulated 
animals and not directl y due to treatment with JNJ -64179375.
Excluding the pharmacologic aleffects, the no-observable -adverse- effect -level was defined at the 
highest doses tested in the 1-month GLP studies; 30 mg/kg/wk IV for the rat and 
50mg/kg/wk IV for the monkey , respectivel y. The corresponding exposures were: rat maximum 
concen tration during a dosing interval (Cmax) at 1,241 µg/mL and area under the 
concentration -time curve during the dosing interval between Day 22 andDay 29 (AUC Day22 -29) at 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
25
Approved , Date: 11 September 20174,607 µg•day/mL; monkey  Cmaxat 2,853 µg/mL and AUC Day22 -29 at 11,962 µg•day/mL (both a rea 
under the plasma concentration curve [AUC] values were from the last dose interval, 
Days 22-29).
1.1.1.4. Pharmacokinetic and Product Metabolism in A nimals
Single -dose pharmacokinetic (PK) studies were conducted in rats and cynomolgus monkey s and 
multiple -dose TKswere assessed in the 1 -month non -GLP and GLP rat and cy nomolgus monkey 
toxicology  studies. In the single -dose PK studies in rats, the drug exposure increased with dose 
in an approximately  dose -proportional manner following a single IV dose in the dose range from 
0.1to 10 mg/kg. In cynomolgus monkey s, the Cmaxincreased with dose in an approximately  
dose-proportional manner, but the dose -normaliz ed area under the concentration -time curve from 
time zero to infinity  (AUC inf) increased with dose in a more than dose-proportional manner 
following a single IV dose ranging from 0.3 to 10 mg/kg. The maximum concentration occurred 
at 3 to 5days postdose and the estimated absolute bioavailability  was 61.40% to 70.40% 
following administra tion of a single SQdose of JNJ-64179375 of 1 mg/kg and 3 mg/kg, 
respectivel y, in rats. Following administration of a single SQdose of JNJ -64179375 (3 mg/kg) in 
monkey s, the maximum concentration occurred at 3 days postdose, and the absolute 
bioavailability  was nearly  complete.
Inthe single -dose PK studies in rats, the mean total clearance of drug after IV administration 
(CL) of JNJ-64179375 from the 0.1- to 10-mg/kg IV-dose groups ranged from 3.95 to 
6.44 mL/day/kg, and the mean terminal half-life (t1/2) ranged from 9.64 to 13.44 days across all 
dose groups. The mean CL of JNJ-64179375 from the IV-dose groups ranged from 1.81 to 
4.82 mL/day/kg, and the mean values of t1/2 ranged from 7.2 to 17.3 days across all dose groups 
in monkey s. The mean apparent volume of distribution in th e terminal phase (Vz) of 
JNJ-64179375 ranged from 53.07 to 94.46 mL/kg across the 0.1-to 10-mg/kg single IVdose 
groups in rats. The mean Vzof JNJ-64179375 following a single IV dose ranged from 26.32 to 
62.26 mL/kg across all dose groups in monkey s. The Vzof JNJ-64179375 in rats and 
cynomolgus monkey s was similar to the blood volume in each species , suggesting that 
JNJ-64179375 was mainly distributed in the intravascular space in rats and monkey s.
In the1-month non-GLP and GLP repeat -dose studies in rats and monkey s, the drug exposure 
increased with dose in an approximately  dose-proporti onal manner following weekl y 
IVadministration of JNJ -64179375 (3 to 100 mg/kg). The mean drug accumulation ratios ranged 
from approximately  1.5-to 3-fold in the system ic circul ation following weekl y IV or 
SQadministration of JNJ-64179375 in rats and monkey s,indicating moderate drug 
accumulation.
Some rats and cynomolgus monkey s exhibited faster decreases in serum concentrations of 
JNJ-64179375 during the terminal phase following single or repeated administration of 
JNJ-64179375 . It is likely  that the relativel y rapid clearance and short half-life in some rats and 
cynomolgus monkey  was due to the impact of antidrug antibodies (ADAs) on PK but the formal 
analysis has notyet been completed. No apparent differences in drug exposure were observed 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
26
Approved , Date: 11 September 2017between female and male rats following weekly  IV or SQdoses of JNJ-64179375 in both non-
GLP and GL P toxicology  studies.
1.1.2. Clinical Studies
The safet y, tolerability , PK, immunogenici ty,and pharmacod ynamics (PD)of single -ascending
IV and SQdoses of JNJ-64179375 arecurre ntly being evaluated in a first-in-human study  
(Protocol 64179375EDI1001) .Interim data from this study  are included in the Addendum to the 
IB.18The study  was initiated in November 2016 and is being conducted at a single study  sitein 
Belgium.
1.1.2.1. Overall Study Design and Status
The study  is ongoing, has 3 parts ,and is being conducted in health y male subjects: Part 1 
assess esthe safet y, tolerability , PK, immunogenicity ,and PD of single -ascending IV doses of 
JNJ-64179375; Part 2 assess esthe reversibility  ofthe PD effects of JNJ-64179375 following a 
single IV dose of a 4-factor PCC, as well as safety , tolerability , PK, and immunogenicity ; and 
Part3 assess esthe safety , tolerability , PK, immunogenicity ,and PD of a single SQdose of 
JNJ-64179375.
In Part 1, up to6 cohorts of 8 subjects each were to be enrolled to evaluate successivel y 
increasing doses of JNJ-64179375 over a dose range of 0.03 to5.0 mg/kg(planned doses of 
0.03, 0.1, 0.3, 1.0, 2.5, and 5.0 mg/kg) .Up to 2 additional optional cohorts could be enrolled to 
repeat a dose or examine other doses. In Parts 2 and 3, 1 cohort of 8 subjects wasto be enrolled
in each.
In Parts 1 and 3 of the study , 6 of the 8 subjects to be enrolled in each cohort were to be 
randomly  assigned to treatment with JNJ -64179375 and 2 subjects were to be randomly  assigned 
to treatment with placebo. In Part 2, all 8 subjects were to receive JNJ-64179375 followed by 
either 4-factor PCC (n=6) or placebo (n=2) .For each subject in each part, the study  consist sof a 
screening period (up to 28 days), an in-house period (15 days/14 nights), and an outpatient 
period (approximately  99 days), with the total study  duration up to approximately  22 weeks for 
each subject .
1.1.2.2. Part 1
The preliminary  results presented below are based on unblinded data from a planned interim 
analysis that was conducted after all Part 1 subjects completed the in-house perio d (data cutoff 
5April 2017).
1.1.2.2.1. Demographic Characteristics
In Part 1, the mean age of the subjects was 32.7 years (range 19 to 45 y ears) and the mean weight 
was 81.24kg (range 60 .2to 100 .3kg). Over 90% of the subjects were Caucasian. There were no 
meaningful dif ferences between the cohorts for any  demographic parameter.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
27
Approved , Date: 11 September 20171.1.2.2.2. Safety  and Tolerability
The actual dose sequence in Part 1 (8 cohorts) was 0.03, 0.1, 0.3, 1.0, 2.5, repeat 2.5, 1.75, and 
2.125 mg/kg (total n=63 subjects: JNJ-64179375=48 subjects, placebo =15 subjects). After the 
dose was escalated to 2.5 mg/kg of JNJ -64179375 or placebo as planned, an increased frequency  
and severity  of bleeding -related adverse events were observed, which suggested a potential 
bleeding -risk signal. To further characterize the safety/tolerabili ty of the 2.5-mg/kg dose of 
JNJ-64179375, an additional 8 subjects were enrolled to repeat the JNJ-64179375 2.5 -mg/kg or 
placebo dose cohort. Based on the safet y and tolerability  data pooled from the two 2.5 -mg/kg 
cohorts (Cohorts 5 and 6), 2.5 mg/kg of JNJ-64179375 was assessed as a dose with a bleeding 
signal and therefore the planned 5-mg/kg dose of JNJ-64179375 was not studied. Instead, the 
2.5-mg/kg dose was de-escalated to 1.75 mg/kg (Cohort 7) and then a dose of 2.125 mg/kg 
(Cohort 8) was completed as the last dose cohort studied in Part 1.
Singl e-ascending IVdoses of JNJ-64179375 have been generall y well tolerated in healthy  male 
subjects over the dose range of 0.03 to 2.5 mg/kg. No subject has withdrawn from the study  due 
to an adver se event. A summary  of the most frequent treatment -emergent adverse event (TEAE) 
preferred terms (> 5%incidence for placebo and the JNJ -64179375 groups combined) is provided 
in Table 1. Overall, most subjects experienced at least 1 TEAE (placebo, 80%;
JNJ-64179375 dose groups combined, approximately  90%), with no clear dose relationship for 
nonbleeding adverse events. The most frequent nonbleeding TEAEs were headache 
(placebo 33.3%, JNJ-64179375 22.9%), laceration (placebo 6.7%, JNJ-64179375 20.8 %), and 
diarrhoea (placebo 13.3%, JNJ-64179375 12.5%). Most TEAEs were assessed by the 
investigator as mild in intensity . Three events were assessed as severe in intensity 
(meningitis viral, subsequently  diagnosed as Headache and Neurologica l Deficits with 
cerebrospinal fluid Lym phocy tosis [HaNDL] syndrome , metabolic acidosis, and pneumonia 
aspiration) in the 2 subjects with serious adverse events as described below. 
Three serious adverse events considered doubtfully related to the study  drug were reported for 
2subjects. Metabolic acidosis and panic attack were reported for 1 subject who had personal 
problems related to a relationship. The subject hada prior history  of anxiety  and alcohol abuse
that were not disclosed at the screening visit. The subject was hospitalized on Study  Day  18 after 
drinking a liter of vodka. He was admitted to the intensive care unit for the treatment of 
metabolic acidosis and aspiration pneumonia. After transferring to the psychiatric unit for 
alcohol treatment, he signed himself out against medical advice. The second subject was 
hospitalized on Study Day 82, with a headache, fever, neurological sy mptoms, and a preliminary 
diagnosis of viral meningitis. The majority  of the workup was negative (clinical laboratory 
reports, polymerase chain reaction for herpes virus , magnetic resonance imaging , and 
electroencephalogram) except for the lumbar puncture, which revealed white blood cells (WBCs) 
(330 perµl) and protei n. The subject received symptomatic treatment and was discharged. 
Five days later (Study  Day 91), the subject was readmitted and a diagnosis of HaNDL syndrome 
was made (after the interim analy sis data cutoff date). The symptoms improved and the subject 
was discharged.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
28
Approved , Date: 11 September 2017Table 1: Most Fr equent (>5% Incidence) Treatm ent-Emergent Adverse Events -by Body System  and Preferred Term: Par t 1; Safety Analysis Set 
(Study 64179375EDI1001 )
JNJ-64179375
Plc 0.03mg /kg 0.1mg /kg 0.3mg /kg 1.0mg /kg 1.75 mg /kg 2.125 mg /kg 2.5mg /kg Active Total
Subjec ts treated 15 6 6 6 6 6 6 12 48
Subjects with 1 or more AEs 12 (80%) 5 (83.3%) 6 (100%) 6 (100%) 5 (83.3%) 4 (66.7%) 6 (100%) 11 (91.7%) 43 (89.6%)
Body System or Organ Class/
Dictionary -Derived Term
General disorders and administration site conditions 8 (53.3%) 2 (33.3%) 3 (50%) 2 (33.3%) 2 (33.3%) 4 (66.7%) 6 (100%) 9 (75%) 28 (58.3%)
Vessel puncture -site bruise 2 (13.3%) 0 2 (33.3%) 2 (33.3%) 2 (33.3%) 4 (66.7%) 6 (100%) 7 (58.3%) 23 (47.9%)
Fatigue 2 (13.3%) 1 (16.7% ) 1 (16.7%) 0 0 0 0 0 2 (4.2%)
Influenza like illness 3 (20%) 0 1 (16.7%) 0 0 0 0 0 1 (2.1%)
Gastrointestinal disorders 5 (33.3%) 4 (66.7%) 3 (50%) 2 (33.3%) 0 0 3 (50%) 7 (58.3%) 19 (39.6%)
Gingival bleeding 2 (13.3%) 2 (33.3%) 1 (16.7%) 2 (33.3%) 0 0 2 (33.3%) 3 (25%) 10 (20.8%)
Diarrhoea 2 (13.3%) 2 (33.3%) 2 (33.3%) 0 0 0 0 2 (16.7%) 6 (12.5%)
Abdominal pain 0 2 (33.3%) 1 (16.7%) 0 0 0 1 (16.7%) 1 (8.3%) 5 (10.4%)
Nausea 1 (6.7%) 1 (16.7%) 0 0 0 0 2 (33.3%) 0 3 (6.3%)
Injury , poisoning and procedural complications 2 (13.3%) 1 (16.7%) 4 (66.7%) 2 (33.3%) 3 (50%) 1 (16.7%) 1 (16.7%) 6 (50%) 18 (37.5%)
Laceration 1 (6.7%) 0 2 (33.3%) 0 3 (50%) 1 (16.7%) 1 (16.7%) 3 (25%) 10 (20.8%)
Contusion 2 (13.3%) 0 1 (16.7%) 2 (33.3%) 0 0 0 1 (8.3%) 4 (8.3%)
Nervous system disorders 5 (33.3%) 1 (16.7%) 3 (50%) 2 (33.3%) 1 (16.7%) 3 (50%) 2 (33.3%) 3 (25%) 15 (31.3%)
Headache 5 (33.3%) 1 (16.7%) 1 (16.7%) 2 (33.3%) 0 2 (33.3%) 2 (33.3%) 3 (25%) 11 (22.9%)
Respiratory, thoracic and mediastinal disorders 6 (40%) 4 (66.7%) 0 1 (16.7%) 1 (16.7%) 1 (16.7%) 1 (16.7%) 4 (33.3%) 12 (25%)
Epistaxis 3 (20%) 1 (16.7%) 0 1 (16.7%) 1 (16.7%) 0 0 2 (16.7%) 5 (10.4%)
Cough 2 (13.3%) 2 (33.3%) 0 0 0 0 0 0 2 (4.2%)
Infections and infestations 5 (33.3%) 2 (33.3%) 5 (83.3%) 0 1 (16.7%) 0 1 (16.7%) 0 9 (18.8%)
Nasopharyngitis 2 (13.3%) 0 2 (33.3%) 0 1 (16.7%) 0 1 (16.7%) 0 4 (8.3%)`
Investigations 1 (6.7%) 2 (33.3%) 2 (33.3%) 1 (16.7%) 1 (16.7%) 0 0 3 (25%) 9 (18.8%)
Blood creatine phosphokinase increased 1 (6.7%) 1 (16.7%) 0 0 1 (16.7%) 0 0 1 (8.3%) 3 (6.3%)
AEs= adverse events; Plc=placebo
Note: Percentages calculated with the number of subjects in each group as denominator.
Note: Incidence is based on the n umber of subjects, not the number of events.
Reported dictionary version: MedDRA 19.1.
[TSFAE01P1.RTF] [JNJ- 64179375 \EDI1001\ DBR_IA_SEQUESTERED \RE_IA_SEQUESTERED \PREPROD \TSFAE01P1.SAS] 25APR2017, 15:30
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
29
Approved , Date: 11 September 2017Table 2shows alltreatme nt-emergent bleeding adverse events selected using theMedical 
Dictionary  for Regulatory  Activities (MedDRA) standardized MedDRA queries (SMQ )term 
hemorrhage (excluding laboratory  terms). In the placebo group, 46.7% of the subjects had 1 or 
more events compared with 72.9% for the combined JNJ-64179375 groups. This difference was 
mostly  due to the increased incidence of treatment -emergent bleeding adverse events observed i n 
the 2.125 -(100%) and 2.5- (91.7 %) mg/kg groups.
The most common bleeding adverse events observed were vessel puncture -site bruises 
(placebo ,13.3%; JNJ-64179375 ,47.9%), gingival bleedi ng (placebo, 13.3%; 
JNJ-64179375, 20.8%), and epistaxis (placebo , 20%; JNJ-64179375, 10.4%). Most 
treatment -emergent bleeding adverse events were associat ed with mild trauma (ie,venipuncture, 
brushing teeth/gums, blowing nose) and all resolved. All were considered mild in intensity  
except for 6 events considered to be of moderate intensity (1event of epistaxis at 1mg/kg, 
1event of ecchymosis at 2.125 mg/kg, and 4 skin-bruising or hematoma events at 2.5mg/kg). 
The criteria for moderate intensity  were defined as an episode of epistaxis lasting more than 
5 minutes or a skin bruise event with a maximum dimension of 10 cm or larger.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
30
Approved , Date: 11 September 2017Table 2: Treatm ent-Emergent Bleeding Adverse Events -by Body System  and Preferred Term: Part 1; Safety Analysis Set (Study 64179375EDI1001)
JNJ-64179375
Plc 0.03 mg/kg 0.1 mg/kg 0.3 mg/kg 1.0 mg/kg 1.75 mg/kg 2.125 mg/kg 2.5 mg/kg Active Total
Subje cts treated 15 6 6 6 6 6 6 12 48
Subjects with 1 or more Bleeding AEs 7 (46.7%) 3 (50%) 5 (83.3%) 4 (66.7%) 2 (33.3%) 4 (66.7%) 6 (100%) 11 (91.7%) 35 (72.9%)
Body System or Organ Class
Dictionary- Derived Term
General disorders and administration site conditions 3 (20%) 0 2 (33.3%) 2 (33.3%) 2 (33.3%) 4 (66.7%) 6 (100%) 8 (66.7%) 24 (50%)
Vessel puncture site bruise 2 (13.3%) 0 2 (33.3%) 2 (33.3%) 2 (33.3%) 4 (66.7%) 6 (100%) 7 (58.3%) 23 (47.9%)
Infusion si te bruising 1 (6.7%) 0 0 0 0 0 0 2 (16.7%) 2 (4.2%)
Catheter site haemorrhage 0 0 0 0 0 0 0 1 (8.3%) 1 (2.1%)
Infusion site haematoma 0 0 0 0 0 0 0 1 (8.3%) 1 (2.1%)
Injection site bruising 0 0 0 0 0 0 0 1 (8.3%) 1 (2.1%)
Vessel puncture site haema toma 0 0 0 0 0 0 1 (16.7%) 0 1 (2.1%)
Gastrointestinal disorders 2 (13.3%) 3 (50%) 1 (16.7%) 2 (33.3%) 0 0 2 (33.3%) 4 (33.3%) 12 (25%)
Gingival bleeding 2 (13.3%) 2 (33.3%) 1 (16.7%) 2 (33.3%) 0 0 2 (33.3%) 3 (25%) 10 (20.8%)
Haematochezia 0 0 0 0 0 0 0 1 (8.3%) 1 (2.1%)
Mouth haemorrhage 0 1 (16.7%) 0 0 0 0 0 0 1 (2.1%)
Injury, poisoning and procedural complications 2 (13.3%) 1 (16.7%) 1 (16.7%) 2 (33.3%) 0 0 0 2 (16.7%) 6 (12.5%)
Contusion 2 (13.3%) 0 1 (16.7%) 2 (33.3%) 0 0 0 1 (8.3%) 4 (8.3%)
Procedural haemorrhage 0 1 (16.7%) 0 0 0 0 0 0 1 (2.1%)
Traumatic haemorrhage 0 0 0 0 0 0 0 1 (8.3%) 1 (2.1%)
Respiratory, thoracic and mediastinal disorders 3 (20%) 1 (16.7%) 0 1 (16.7%) 1 (16.7%) 0 0 2 (16.7%) 5 (10 .4%)
Epistaxis 3 (20%) 1 (16.7%) 0 1 (16.7%) 1 (16.7%) 0 0 2 (16.7%) 5 (10.4%)
Skin and subcutaneous tissue disorders 2 (13.3%) 0 0 0 0 0 1 (16.7%) 1 (8.3%) 2 (4.2%)
Ecchymosis 1 (6.7%) 0 0 0 0 0 1 (16.7%) 0 1 (2.1%)
Blood blister 1 (6.7% ) 0 0 0 0 0 0 0 0
Skin haemorrhage 0 0 0 0 0 0 0 1 (8.3%) 1 (2.1%)
Investigations 0 1 (16.7%) 1 (16.7%) 0 0 0 0 1 (8.3%) 3 (6.3%)
Blood urine present 0 1 (16.7%) 1 (16.7%) 0 0 0 0 1 (8.3%) 3 (6.3%)
Ear and labyrinth disorders 0 0 0 0 0 0 1 (16.7%) 0 1 (2.1%)
Ear haemorrhage 0 0 0 0 0 0 1 (16.7%) 0 1 (2.1%)
AE=adverse event; Plc=placebo
Note: Percentages calculated with the number of subjects in each group as denominator.
Note: I ncidence is based on the number of subjects, not the number of events.
Reported dictionary version: SMQ19 .1, HAEMORRHAGE TERMS (EXCL LABORATORY TERMS) (SMQ)
[TSFAE02P1.RTF] [JNJ- 64179375 \EDI1001\ DBR_IA_SEQUESTERED \RE_IA_SEQUESTERED \PREPROD \TSFAE02P1.SAS] 25APR2017, 15:30
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
31
Approved , Date: 11 September 2017Clinical Laboratory, Vital Si gns, and ECG Assessments
Clinical safet y laboratory tests (clinical chemistry , hematology , coagulation ,and urinal ysis), vital 
signs, and ECGs were collected at specified times before and after stud y drug dosing .
There were no apparent group -mean trends ordose-related effects in these assessments with 
JNJ-64179375, with the exception of dose-related increases in PT, aPTT, and TT levels 
consistent with the mechanism of action of JNJ-64179375 (see Section 1.1.2.2.4 , 
Pharmacod ynamics ). Individual ECGs did not show any clinically  significant changes from 
baseline; no subject had a QT corrected according to Fridericia’s formula (QTcF) >450 msec or 
an increase from baseline in QTcF >30 msec .
1.1.2.2.3. Pharmacokinetics
The result s presented below are based on preliminary  bioanal ytical data and nominal sampling 
times from the subjects who received at least 1 dose of JNJ-64179375 in Part 1. Plasma samples 
were analyzed to determine concentrations of JNJ-64179375 using a validated, selective ,and 
sensitive immunoassay  method (lower limit of quantification 0.01 µg/mL ). Interim preliminary  
PK results were determined using noncompartmental methods and are summarized in Table 3 .
Table 3: M ean (±SD) Pharm acokinetic Param eters of JNJ -64179375 Following a Single 30 -minute 
IVInfusion (0.03 to 2.5 m g/kg, Part 1 )in Healthy Male Subjects
CohortJNJ-64179375 
mg/kg IVCmax
μg/mLTmaxa
hAUC inf
day*μg/mLCL
mL/day/kgVz
mL/kgt1/2
day
1 0.03 0.707 (0.196) 1 (0.5 -1) 15.4 (3.87) 2.07 (0.628) 73.3 (21.8) 24.7 (3.6)
2 0.1 2.15 (0.183) 1 (0.5 -8) 47.2 (6.74) 2.16 (0.361) 76.3 (5.67) 24.8 (3.2)
3 0.3 6.86 (1.30) 1 (0.5 -4) 145 (22 .3) 2.11 (0.286) 78.8 (19.1) 26.0 (5.3)
4 1 28.4 (3.90) 1 (0.5 -4) 514 (71.3) 1.98 (0.285) 83.0 (11.5) 29.2 (3.1)
5+6 2.5 58.0 (12.7) 2.5 (0.5 -8)1266 (266) 2.06 (0.487) 80.5 (12.4) 27.8 (5.2)
7 1.75 44.3 (8.90) 2.5 (0.5 -4) 813 (124) 2.20 (0.328) 68.7 (9 .64) 21.8 (2.1)
8 2.125 42.9 (3.62) 1 (0.5 -4) 970 (209) 2.28 (0.499) 73.5 (15.3) 23.2 (6.9)
AUC inf=area under the concent ration curve from zero to infini ty; CL= total clearance of drug after IV administration ; 
Cmax=maximum concentration during a dosing interval ;h=hour; IV=intravenous; SD=standard deviation; 
t1/2=terminal half -life; Tmax=time to reach the maximum observed plasma concentration ; Vz= apparent volume of 
distribution in the terminal phase
aData presented as Median (Minimum -Maximum)
The median time to reach the maximum observed plasma concentration (T max) was 1 to 2.5 hours 
postdose. The mean Cmaxand AUC infincreased in an approximately  dose-proportional manner. 
The mean t 1/2ranged from approximately  21.8 to 29 .2days.
1.1.2.2.4. Pharmacody namics
Prothr ombin time, aPTT, and TT demonstrated dose-dependent increases whether measured 
locally  or at a central specialty  laboratory ,with TT being the most sensitive test and PT the least 
sensitive test. A plot of mean ratio to baseline for TT from the central specialt y laboratory  is 
provided in Figure 1. For TT, the 2 highest dose groups show edsimilar prolongations for the 
early timepoints (an approximately  7-fold increase) as some subjects in both groups exceeded the 
laboratory  upper reporting limit of 120 seconds. At 14 days, the prolongation in TT was about 
5-fold for the highest dose group. At the 0.3-mg/kg dose level, the peak prolongation in TT was 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
32
Approved , Date: 11 September 2017approximately  2.7-fold and it was approximately  1.7-fold at 14 days. For aPTT, the assay upper 
reporting limit was not approached for any subject but the maximum prolongation appears to be 
an approximately  1.6-fold increase from baseline for each of the 3 highest dose groups. For PT, 
the maximum -fold increase was approximately  1.3-fold atthe highest dose. These data are 
consistent with the in-vitro data and with the mechanism of action of JNJ-64179375. Local
laboratory  results demonstrated a similar pattern .
Figure 1: Thrombin Time (s) Mean Ratio to Baseline by Tr eatm ent Group Central Specialty Laboratory; 
Safety Analysis Set (Study 64179375EDI1001)
Baselineisdefinedasthelastvalidmeasurementpriortodosing.
[GSFEPDC1 .RTF] [JNJ-64179375\EDI1001\DBR_IA_SEQUE STERED\RE_IA_SEQUES TER ED\PREPROD \GSFEPDC1.S AS] 30MA Y2017, 12:09
1.1.2.2.5. Overall Summary
In this single -ascending dose (SAD) , randomized, double -blind, placebo -controlled study  in 
healthy  male subjects (Part 1), JNJ-64179375 was generally  well tolerated at all doses. All 
observed bleeding events were of mild or moderate intensity , most ly related to local trauma 
(eg,venipuncture, brushing teeth, blowing nose), and none were severe or serious. At the 
2highest doses (2.125 and 2.5 mg/kg), anincreased frequency  (and severity  at 2.5 mg/kg) of 
bleeding events was observed compared with placebo.
With the exception of the bleeding adverse events, there was no evidence of dose-dependent 
adverse events over the studied dose range. As hypersensitivi ty reactions have been observed 
with the administration of monoclonal antibodies, infusion or allergic reactions were closel y 
monitored for this study . One subject in the 2.5-mg/kg cohort developed mild urticaria that 
started prior to receiving the study  drug. The urticaria spread and was assessed as moderate in 
severit y at approximately  4 hours postdose. The urticaria resolved spontaneously  24 hours later 
and was considered doubtfully  related to the study drug.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
33
Approved , Date: 11 September 2017JNJ-64179375 administered as an IV infusion exhibited a favorable PK profile in healthy  
subjects, and the observed PK parameters were close to those predicted based on the animal 
PKdata. Mean Cmaxand AUC infvalues increased in an approximately  dose-proportional manner 
in the studied dose range. Mean t 1/2 ranging from 21.8 to 29.2 days is consistent with the 
expected t1/2 of human IgG4. Importantly , variations of the PK concentration and parameters 
(Cmaxand AUC inf) of JNJ -64179375 were low, indicating PK predictability .
Consistent with the nonclinic al findings, JNJ-64179375 produced a dose-dependent prolongation 
of the coagulation parameters (PT, aPTT, and TT) over the studied dose range. Based on 
fold- changes from baseline observed in this study , TT was the most sensitive assay  for 
JNJ-64179375, which is consistent with its mechanism of action and direct effect on 
thrombin- mediated clot formation. The effect -time curves for all coagulation parameters seemed
parallel to the plasma drug concentration -time curves of JNJ-64179375 with no apparent lag 
time.
1.1.2.3. Parts 2 and 3
Parts 2 and 3 of the study  (1 single cohort in each part) had also completed dosing asof
21April 2017 . A blinded data review as of 02 May 2017 is briefl y summarized below; however, 
thisdata was not included in the unblinded interim analysis as it was not available until after the 
cutoff date. Eight subjects were dosed intravenously  with 1.0 mg/kg of JNJ-64179375 in Part 2 
followed by  either placebo (n=2) or 50 IU/kg of the 4 -factor PCC Confidex(n=6). Confidex did 
not appea r to reverse the effects of JNJ-64179375 on either aPTT or TT. In Part 3, 8 subjects 
were dosed subcutaneously  with either 1.0 mg/kg of JNJ-64179375 (n=6) or placebo (n=2). The 
PKdata showed the expected delay  to peak drug levels. For both cohorts, the bleeding advers e 
events were mostl y mild skin-site events as observed in Part 1. One moderate intensit y epistaxis
bleed ing event was reported in Part 2.
In the nonclinical studies, 4-factor PCC and activated PCC were able to normalize rat-tail 
bleeding times after the administration of JNJ-64179375 but did not revers e TT or aPTT 
prolongation (data on file). Therefore, the lack of reversal of TT and aPTT with 4-factor PCC in 
Part 2 of the Phase 1 study  was not unexpected and likely reflects the insensitivity  of these 
coagu lation assay s for measuring the potential hemostatic effects of PCC administration.
1.2. Comparator Drug
Eliquis(apixaban)
The following information, taken from the European Union Summary  of Product Characteristics, 
is intended to provide a brief, representat ive overview of apixaban .8
Eliquis(apixaban) is a potent, oral, reversible, direct and highl y selective active -site inhibitor of 
FXa. Apixaban does not require antithrombin III for antithrombotic activity . Itinhibits free and 
clot-bound FXa and prothrombinase activity . Apixaban has no direct effects on platelet 
aggregation but indirectly  inhibits platelet aggregation induced by thrombin. By inhibiting FXa, 
apixaban prevents thrombin generation and thrombus development. Apixaban does not have any 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
34
Approved , Date: 11 September 2017effects on TT but does prolong PT and aPTT although the changes in these assay s are small and 
variable at therapeutic doses.
Apixaban is indicated in the European Union for the prevention of VTE in adult patients who 
have undergone elective hip or knee replacement surgery .For the prevention of VTE after 
TKR surgery , the recommended dose of apixaban is 2.5 mg taken orally twice daily ,with the 
initial dose taken 12to 24 hours after surgery. The recommended duration of treatment is 
10to14days.
The ADVANCE-1 and ADVANCE -2 studies included subjects who had undergone a TKR for 
one or both knees .
In the ADVANCE- 1 study , which included 3,195 randomized subjects and 3,184 subjects in the 
safet y population , apixaban 2.5 mg twice dailyfollowing TKR was compared with enoxaparin 
30mg twice daily.Both medications were started 12to 24 hours after surgery  and continued for 
10to 14 days. The primary  efficacy  endpoint was total VTE defined as the composite of 
adjudicated asympto matic and symptomatic DVT, nonfatal PE, or all-cause death. The primary  
safet y outcome was major bleeding during the treatment period or within 2 days after the last 
dose of the study  drug. The total VTE rates were similar for apixaban and enoxaparin although 
statistically  apixaban did not meet 1 of the 2 prespecified criteria for noninferior efficacy . 
Bleeding events were lower in the apixaban group.23(Table 4 and Table 5 )
In the ADVANCE- 2 study , which included 3,057 randomized subjects and 3,009 subjects in the 
safet y population undergoing elective TKR surgery , subjects received either apixaban 2.5 mg 
given orally  twice daily  or enoxaparin 40mgSQonce daily .Apixaban was started 12 to 
24hours after surgery , while enoxaparin was started 9 to 15 hours before surgery , with both 
drugs given for 10 to 14 days. The primary  efficacy  endpoint was total VTE and the primary  
safet y outcome was major bleeding reported during the treatment period. Apixaban demonstrated 
a statistically  superior reduction in total VTE and in the major VTE endpoint, a composite of 
proximal DVT, nonfatal PE, and VTE-related death, compared with enoxaparin. The safet y 
endpoints of major bleed ing, the composite of major and clinicall y relevant nonmajor bleeding, 
and all bleeding were not statistically  different but were numerically  lower for subjects treated 
with apixaban 2.5 mg twice daily compared with enoxaparin 40 mg SQonce daily .24(Table 
4and Table 5 )
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
35
Approved , Date: 11 September 2017Table 4: ADVANCE -1 and ADVANCE -2 Safety Results
Oral Apixaban 
2.5mg BIDSQEnoxaparin
30 mg BIDDifference in Risk 
(95%CI) p- value
ADVANCE -1 N=1,596 95% CI N=1,588 95% CI
Major Bleeding 11 (0.7) 0.4-1.3 22 (1.4) 0.9-2.1 -0.81 (- 1.5 to 0.1) 0.05
CRNM 35 (2.2) 1.6-3.1 47 (3.0) 2.2-3.4 -0.77 (- 1.8 to 0.3)
Surgical site†22 (1.4) 35 (2.2)
Major or CRNM bleeding 46 (2.9) 2.2-3.8 68 (4.3) 3.4-5.4 -1.46 (- 2.8 to 0.2) 0.03
All bleeding events 85 (5.3) 4.3-6.6 108 (6.8) 5.7-8.2 -1.52 (- 3.2 to 0.1) 0.08
Minor bleeding events 39 (2.4) 40 (2.5)
Oral Apixaban 
2.5mg BIDSQ Enoxaparin
40 mg QD
ADVANCE -2 N=1,5 01 N=1,508Absolute Risk 
Difference p- value
Major Bleeding 9 (0.6) 14 (0.9) -0.3 (- 1.0 to 0.3) 0.3
CRNM 44 (2.9) 58 (3.8) -0.9 (- 2.2 to 0.4) 0.17
Surgical site†32 (2.1) 44 (2.9 )
Major + CRNM bleeding 53 (3.5) 72 (4.8) -1.2 (- 2.7 to 0.2) 0.09
All bl eeding events 104 (6.9) 126 (8.4) -1.4 (- 3.3 to 0.5) 0.14
Minor bleeding events 51 (3.4) 54 (3.6)
BID=tw ice daily; CI=confidence interval; CRNM=clinically relevant nonmajor ; N=number; QD=once daily; 
SQ=subcutaneous
†Numbers are from investigator reports
Source: Lassen 200923; Lassen 201024
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
36
Approved , Date: 11 September 2017Table 5: ADVANCE -1 and ADVANCE -2 Efficacy Results
Intended 
Treatment Period Oral Apixaban 2.5mg BID SQ Enoxaparin 30 mg BIDRelative Risk 
(95% CI)Difference in 
Risk (95% CI)
ADVANCE -1 n/N 95% CI n/N 95% CI
Total VTE 104/11579.0
(7.47 -10.79) 100/11308.8
(7.33 -10.66)1.02
(0.78 -1.32)0.11
(-2.22-2.44)
Major VTE 26/12692.0
(1.39 -3.01) 20/12161.6
(1.06 -2.55)1.25
(0.70 -2.23)0.36 
(-0.68-1.40)
Symptomatic VTE 
and VTE- related 
death 19/15991.2
(0.75 -2.95) 13/15960.8
(0.46 -1.41)1.46
(0.72 -2.95)0.38
(-0.30-1.06)
All DVT 89/11427.8
(6.37 -9.51) 92/11228.2
(6.73 -9.97) --- ---
All PE 16/15991.0
0.61-1.64 7/15960.4
(0.20 -0.93) --- ---
ADVANCE -2 n/N RateSQ Enoxaparin 40 mg QDRelative Risk 
(95% CI)/
p-valueAbsolute risk 
difference (%) n/N Rate
Total VTE 147/97615.0
(12.95-17.46 ) 243/99724.37
(21.81 -27.14 )0.62
(0.51 -0.74) /
0.0001-9.27%
(-12.74 -[-5.79])
Major VTE 13/11951.09
(0.62 -1.88) 26/11992.17
(1.47 -3.18)0.5
(0.26 -0.97)/
0.0186-1.04%
(-2.03-[-0.05])
Symptomatic VTE 
and VTE- related 
death 7/15280.46%
(0.20 -0.97) 7/15290.46
(0.20 -0.97)1.00
(0.35 -2.85)/
---0.00%
(-0.48-0.48)
All DVT 142/97114.6%
(12.5 -17.0) 243/99724.4
(21.8 -27.1) ---/--- ---
All PE 4/15280.26%
(0.08 –0.70) 0/15290.00
(0.00 -0.31) ---/--- ---
BID=tw ice daily; CI=confidence interval; DVT=deep vein throm bosis; n/N=number; PE=pulmonary embolism; 
QD=once daily; SQ=subcutaneous ;VTE=venous thromboembolism
Source: Lassen 200923; Lassen 201024
1.3. Overall Rationale for the Study
Low molecular -weight heparins have a long and well-established role in the prevention of VTE 
in subjects undergoing TKR surgery , and while very effective with an acceptable bleeding risk, 
SQdosing once or twice a day is required. More recently , several DOACs (eg, apixaban, 
rivaroxaban, dabigat ran, edoxaban ) have been approved for use in TKR, based on comparisons 
with the LMWH,enoxaparin, and their use has become more widespread in this patient 
population. Apixaban starting 12 to 24 hours after TKR surgery  demonstrated superior efficacy 
compare d with enoxaparin 40 mg once daily  and similar efficacy  to enoxaparin 30 mg twice 
daily , with numerically  less bleeding than both enoxaparin regimens.23,24Apixaban was chosen 
as the active comparator for this study  because it is orally  administered and compares favorabl y 
with enoxaparin for both efficacy  and bleeding endpoints.
JNJ-64179375 is a first -in-class, recombinant, fully human IgG4 monoclonal antibody  that binds 
reversibl y with high affinity and specificity  to the exosite -1 region on thrombin. By only 
blocking exosite -1, the catal ytic activity  of the protease is maintained. Therefore, this unique 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
37
Approved , Date: 11 September 2017mechanism of action of JNJ-64179375 may offer the potential for noninferior (or superior) 
efficacy  compared with currentl y available anticoagulant drugs (eg, vitamin K antagonists , 
enoxaparin, and DOACs) with a reduced risk of bleeding.
Given that TKR surgery  carries a high risk of VTE combined with the hemostatic challenges of 
surgery , it provides a good setting to evaluate the relative efficacy  and safet y (bleeding) 
characteristics of novel anticoagulants.7As a monoclonal antibody , JNJ-64179375 has an 
expected duration of action of approximately 4 weeks, thereby  allowing for the postoperative 
administration of a single IV dose to be used for VTE prophy laxis after TKR surgery . Based on 
the preclinical and Phase 1 studies conducted to date, JNJ-64179375 is anticipated to have a 
favorable safet y profile with respect to bleeding risk. Therefore, JNJ-64179375 offers the 
potential for an efficacious treatment that has limited bleeding, with a simpler dosing regimen 
compared with currentl y available oral or parenteral treatments.
2. OBJECTIVE S, ENDPOINTS, AND HYPOTHESIS
2.1. Objectives and Endpoints
2.1.1. Objectives
Part 1
In men and women undergoing primary  unilateral TKR surgery , after single -ascending IV doses 
of JNJ -64179375 or 10 to 14 day s of oral apixaban:
Primary Objective
The primary  objective is to assess the safety  and tolerability  of JNJ -64179375 for each dose level 
for dose escalation within Part 1 and any bleeding events (the composite of major, clinicall y 
relevant nonmajor, and minimal bleeding events) for the selection of doses for Part 2.
Secondary Objectives
To assess the dose response of JNJ-64179375 for the occurrence of the composite endpoint 
of any bleeding event s, the composite endpoint of major orclinicall y relevant nonmajor 
bleeding event s, and the individual components ofthecomposite endpoint ofanybleeding 
event
To assess the dose response of JNJ-64179375 for the prevention of total VTE 
(proximal and/or distal DVT [asymptomatic confirmed by venograph yassessment of the 
operated leg or objectively  confirmed symptomatic] , nonfatal PE, or any death) and the 
individual components of total VTE
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
38
Approved , Date: 11 September 2017Part 2
In men and women undergoing primary  unilateral TKR surgery , after a single IV dose of 
JNJ-64179375 or 10 to 14 day s of oral apixaban:
Primary Objective
The primary  objective is to assess the efficacy dose response of JNJ-64179375 for the prevention 
of total VTE (proximal and/or distal DVT [asymptomatic confirmed by venograph y assessment 
of the operated leg or objectivel y confirmed symptomatic], nonfatal PE, or any death) .
Key Secondary Objectives
To assess the dose response of JNJ-64179375 for the occurrence of the composite endpoint 
of any bleeding events, the composite endpoint of major or clinicall y relevant nonmajor 
bleeding events, and the individual components of the composi te endpoint of any bleeding 
event
To assess the dose response of JNJ-64179375 for the prevention of major VTE 
(asymptomatic confirmed by venograph y assessment of the operated leg or objectivel y 
confirmed symptomatic proximal DVT, nonfatal PE, or any death) and the individ ual 
components of the total VTE endpoint
Common Objectives in Parts 1 and 2
Other Secondary Objectives
To assess the effect of individual doses of JNJ-64179375 compared with apixaban for both 
efficacy  and safet y endpoints, with the goal to identify  a studied or model-predicted dose 
with the most promising benefit- risk profile for a more extensive evaluation in Phase 3
To assess the effect of JNJ-64179375 compared with apixaban on wound or joint 
complications in the operated leg
Exploratory O bjective s
To assess the effect of JNJ-64179375 compared with apixaban on other thrombotic events 
(ie,myocardial infarction [ MI], ischemic stroke, peripheral arterial embolism )
To evaluate the cost effectiveness of JNJ-64179375 compared with apixaban based on 
health resource utilization
To assess the PK, PD, and PK/PD relationships of JNJ-64179375 in men and women 
undergoing primary  unilateral TKR surgery  and the relation of these measures to efficacy  
and safet y endpoints (eg, exposure -response analyses)
Toevaluate the PD assay s(TT, ECT, PT, aPTT, and D-dimer) to determine the most 
appropriate tests to measure the effect of JNJ- 64179375
2.1.2. Endpoints
The endpoints of the study  will be the same for Parts 1 and 2 although the focus of Part 1 will be 
primarily  doseescalation based on safet y while the focus of Part 2 will primarily  be the 
assessment of dose response in both safet y and efficacy .
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
39
Approved , Date: 11 September 2017Common Endpoints in Part s 1and 2
Primary Safety Endpoint
The primary  safety  endpoint is any bleeding event defined as the composite of major, clinically 
relevant nonmajor, and minimal bleeding events assessed through the Day 10 -14 visit .
Primary Efficacy Endpoint
The primary  efficacy  endpoint is total VTE, defined as the composite of proximal and/or distal 
DVT (asymptomatic confirmed by venograph y assessment of the operated leg or objectivel y 
confirmed s ymptomatic), nonfatal PE, or anydeath assessed through the Day  10-14 visit .
Key Secondary Endpoints
The key secondary  endpoints arethe assessment of the primary  endpoints through the 
Week 18visit,and:
All individual components of the primary  safety  endpoint (major bleeding , clinically 
relevant nonmajor bleeding, and minimal bleeding)
Composite of major and clinically  relevant nonmajor bleeding
Major VTE, a composite of proximal DVT (asymptomatic confirmed by venograph y 
assessment of the operated leg or objectivel y confirmed symptomatic), nonfatal PE,or any
death
All individual components of the primary  efficacy  endpoint (ie, proximal and/or distal DVT
[asymptomatic confirm ed by venograph y assessment of the operated leg or objectivel y 
confirmed s ymptomatic] , nonfatal PE, anydeath)
Other Secondary Endpoints
Any wound or joint complication in the operated leg
Exploratory Endpoints
Other thrombotic events (ie, MI, ischemic str oke, peripheral arterial embolism)
The total length of the initial hospitalization, including the level of care and discharge 
destination
The incidence of rehospitalization for any  reason
The number of scheduled and unscheduled visits, including the associ ated cost to healthcare 
providers for study  outcomes, any  other medical reasons, and the diagnostic procedures used 
in relation to study  endpoints
Calculation of PK parameters, eg, CL, volume of distribution (Vd), t 1/2,AUC inf, and C max
Changes in PD by dose: TT, ECT, PT, aPTT, and D -dimer
Changes in PD assay s as listed above by concentration metrics (AUC inf, C max,or 
time-matched concentrations)
Refer to Section 9, Study Evaluations for evaluations related to endpoints.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
40
Approved , Date: 11 September 20172.2. Hypothe sis
In Part 1, a range of doses of JNJ -64179375 will be assessed to determine if it is sufficiently  safe 
to proceed with Part 2 of the study . No formal hypothesis testing will be conducted for Part 1. In 
Part 2, the clinical hypothesis is to demonstrate proof-of- efficacy based on the total 
VTE endpoint. This can be achieved by either showing that JNJ-64179375 has a statisticall y 
significant dose-response trend with respect tothe total VTE endpoint , orthe combined dose 
groups of JNJ -64179375 have a total V TE event rate of less than 30%. 
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This is a randomized, double -blind, double -dummy ,active -controlled ,multicenter,
dose-escalation and dose-response study of JNJ-64179375 . The study  has2parts, 
dose-escalation and dose-response evaluation ,and will be conducted in subjects undergoing 
primary  unilateral elective TKR surgery .Part1 will assess the safet y of single-ascending 
IVdoses of JNJ-64179375 while Part 2 will confirm the safety  of the doses selected from Part 1 
and will assess the efficac y dose-response relationship with respect to the selected doses in the 
parallel groups. Subjects will be men or women of non-childbearing potential 50 years of age, 
considered medically  appropriate for postoperative anticoagulant prophy laxis based on the 
study -and local standard-of- care-required assessments for pre-and postoperative evaluation . 
Subjects will participate in either Part 1 or Part 2 of the study  only.A total of approximately 
1,500 subjects combined for Parts 1 and 2 are planned to be enrolled .Part 1 will include 
approximately  300subjects and Part2 will include appro ximately  1,200 subjects as described in 
Section 3.1.1 , Part 1: Single -Ascending Dose and Section 3.1.2 , Part 2: Dose -Response 
Confirmation, respectively .
For each subject in each part, thestudy  will be conducted in3 phases: an up to 30-day screening 
phase before surgery , a 14-day double -blind dosin gphase, and a 16-week follow -up phase. 
Unscheduled visits may be performed at the discretion of the investigator for the assessment of 
any potential bleeding or efficacy endpoint event s. The total duration of the subject’s 
participation in Part 1 or Part 2 after randomization will be approximately  18weeks.
Screening for eligible subjects in Parts 1 and 2 may be done up to 30 day s before randomization,
pre-or postoperativel y. Following primary  unilateral elective TKR surgery , eligible subjects will 
be randomly  assigned to treatment with either JNJ-64179375 or apixaban. All subjects will 
receive a single IV infusion of JNJ-64179375 or JNJ-64179375 placebo and oral apixaban or 
matching apixaban place bo the dayafter TKR surgery (Day  1, 0 hours) , while the subject is still 
hospitalized and within a minimum of 12hours and a maximum of 24 hours after the end of the 
TKR surgery , defined as the time of wound closure . Details regarding the timing of oral dosing 
in relation to the start of the IV infusion are provi ded in Section 6, Dosage and Administration. 
Following discharge or transfer to an alternate facility , subjects in both parts will be reminded to 
continue to take apixaban or matching apixaban placebo twice daily to complete a total of 
10to14days of dosing as described in Section 6, Dosage and Administration . Unilateral 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
41
Approved , Date: 11 September 2017venograph y assessment of the operated leg will be performed after the last dose of apixaban or 
matching apixaban placebo is taken as described in Section 9.2.1 , Assessments for DVT.
Subjects in both Parts1 and 2will return to the site for study -related procedures 5, 10 , and 
18weeks after TKR surgery  as described in the Time and Events Schedule that follows the 
Synopsis. Safet y evaluations will include the monitoring of all nonserious and serious adverse 
events, (including adverse events of special interest :bleeding events , infusion reactions,
hypersensi tivity  reactions , and wound or joint complications ),clinical laboratory  tests
(ie,hematology , clinical chemistry , urinal ysis), vital signs measurements (blood pressure, 
pulse/ HR, temperature) , and physical examinations. Pharmacokinetic s (dense and sparse ), PD, 
and immunogenicit y samples will be collected and health resource utilization will also be 
assessed at the time points indicated in the Time and Event Schedule.
An Operations Committee (OC), Independent Data Monitoring Committee (IDMC), 
Steering Committee (SC) ,and independent Clinical Events Committee (CEC) will be 
commissioned for this study . Refer to Section 11.11,Committee s.
An unblinded data review is planned forPart 1 after all subjects are expected tohave completed 
the Day 10-14 visit to determine the dose range and doses of JNJ-64179375 forPart 2. Two 
planned, unblinded interim analy sis will be conducted in Part 2 by the IDMC as part of the
adaptive approach that will be used to guide decisions t o drop and/or add doses of JNJ -64179375 
and adjust the randomization ratio based on the available efficacy, safety , PK, and PDdata. 
Additional details are provided in Section 11.10, Interim Anal yses. An unblind ed administrative 
interim analy sis is planned after all subjects are expected tohave completed the Day 10-14 visit
in Part 2 to facilitate additional study  planning as described in Section 11.10, Interim Anal yses.
A diagram of the stud y design is provided below.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
42
Approved , Date: 11 September 2017Schematic Overview of the Study
3.1.1. Part 1: Single -Ascending Dose
Eligible subjects in Part 1 will be randoml y assigned to a single -ascending IV dose of 
JNJ-64179375 or apixaban 2.5 mg given orall ytwice d ailyfor 10 to 14 day s. Sixcohorts of up to 
approx imately  50unique subjects per cohort (total of up to approximately  300 unique subjects) 
are planned but the number of cohorts and the size of each cohort may be adjusted based on the 
ongoing unblinded data review by the OC. Within each cohort ,subjects will be randomized in a 
4:1 ratio to JNJ-64179375 or apixaban, respectivel y (ie, approximately  40 subjects to 
JNJ-64179375 : approximately 10subjects to apixaban). JNJ-64179375 will be administe red in a 
dose-escalation manner, with planned doses of 0.3, 0.6, and 1.2 mg/kg in Cohorts 1, 2, and 3, 
respectivel y. In Part 1, the OC will be responsible for reviewing ongoing safety  and efficacy  data 
by unblinded subject treatment assignments approximately  every  1 to 3 weeks. Subjects enrolled 
in the 3optional cohorts will receive doses ofJNJ-64179375 in the range of 0.1 to 1.8 mg/kg, 
which will be dependent on theavailable preliminary safety, tolerability , efficacy , PK, and PD 
data obtained from the preceding coho rts(refer to Section 6, Dosage and Administration for 
additional details). After all of the subjects in Part 1 are expected to have completed the 
Day 10-14visit, an unblinded data review will be conducted by the OC, SC, IDMC, and sponsor 
to determine the dose range and doses for Part 2.
3.1.2. Part 2: Dose -Response Evaluation
Part 2 of this study  has an adaptive design, with the intent to optimize data collection for the 
dose-response evaluation using multiple compar ison procedure and modeling (MCP -Mod). 
Eligible subjects prior to the first interim analy sisin Part 2 will be randomly  assigned equall yto 
1of up to 5parallel treatment groups, including up to 4dose levels of JNJ-64179375 ,given as a 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
43
Approved , Date: 11 September 2017single, active IV infusion ,or oral apixaban 2.5 mg twice daily for 10 to 14 days.The number of 
doses and randomization ratio after the 2 interim analy ses will depend on the interim analy sis 
results. However, the number of ongoing doses of JNJ-64179375 in the study  is not expected to 
exceed 4doses. The Part 2 sample size is estimated to be 1,200 subjects. In Part 2, the IDMC 
will be responsible for monitoring ongoing safety and efficacy and for conducting the 2 planned 
interim analyses to apply  the adaptive design rules. Subjects will be randomized to 1 of the 
treatment groups with a balanced randomization ratio until the first interim analy sis. After the 
review of each planned interim analy sis, the IDMC will make a recommendation to declare 
futility , adjust the study drug doses, or modify the randomization ratio (see Section 11.10 , 
Interim Anal yses for details) .The SC and sponsor will make a decision whether to implement 
the IDMC’s recommendation. The interim analy seswill be performed after approximately 
400and800subjects are enrolled andare expected tohave completed the Day 10-14 visit. The 
final number of subjects in each dose group will depend on the results of the interim anal yses.
3.2. Study Design Rationale
Blinding, Contr ol, Study Phase/Periods, Treatment Groups
Randomization will be used to minimize bias in the assignment of subjects to treatment groups, 
to increase the likelihood that known and unknown subject attributes (eg,demographic and 
baseline characteristics) areevenly  balanced across treatment groups, and to enhance the validity 
of statistical comparisons across treatment groups. Blinded treatment will be used to reduce 
potential bias during data collection and evaluation of clinical endpoints.
The treatment phase duration of up to 14 days is the approved duration of therap y with apixaban 
after TKR surgery . JNJ-64179375 hasan estimated human plasma t½of approximately  25days 
based onpreliminary  datain healthy  subjects. The 16-week follow -up duration (18week s from 
dosing) in this study  is approximately  5times the calculated t1/2of JNJ-64179375, and is 
therefore adequate for PK anal ysis and is consistent with the safet y reporting period.
Thedose-escalation design in Part 1 will allow for a careful stepwise approach to assess bleeding 
risk in subjects undergoing TKR surgery  to determine the dose range for the parallel design in 
Part2, which will confirm the safet y and efficacy dose response of JNJ -64179375.
Study Population
The risk of VTE following major orthopedic surgery , specificall y joint replacement surgery , has 
been well documented and the use of postoperative proph ylactic anticoagulant therap y is widel y 
accepted as standard of care.10,19Over the past 20years, Phase 2 studies of injectable 
anticoagulants (LMWH, fondaparinux) and all of the newer oral anticoagulant s
(apixaban, rivaroxaban, dabigatran, and edoxaban) were conducted in this population using 
venograph y to detect asymptomatic DVT .Subsequently , all of these oral medications were
evaluated in large, similarly  designed Phase 3 studies and have been approved by regulatory  
agencies for the prevention of VTE in TKR surger y because they were found to be at least as 
effective as LMWH, have a similar or improved bleeding profile, and have the convenience of 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
44
Approved , Date: 11 September 2017easy administration.9,13,15,23,24,30Therefore, the TKR study  population is appropriate to evaluate 
the efficacy  and safety  of JNJ -64179375.
Total knee replacement surgery  is most commonly  performed due to arthritic disease of the joint, 
which occurs primaril y in older men and women. The risks of VTE and bleeding also increase 
with age. Therefore, the intended population, which includes both men and women who are at 
least 50 years of age, is also appropriate. Women of childbearing potential are excluded from this 
study  because reproductive toxicology  testing of JNJ -64179375 has notbeen conducted. 
Dose Selection
The Part 1planned doses of JNJ-64179375 (0.3, 0.6, or 1.2mg/kg) were chosen based on 
preclinical data and data from the Phase 1study in health y subjects
(Protocol 64179375EDI1001). In preclinical venous thrombosis models in both rats and 
monkey s, JNJ-64179375 at adose of 0.3mg/kg demonstrated good efficacy , which increased 
even further at 1 mg/kg . In healthy  subjects , the 0.3-mg/kg dose was associated with a maximum 
mean blood level ofapproximately 7 g/mL  and TT prolongation of approximately  3-fold from 
baseline while the 1-mg/kg dose had maximum mean blood levels of about 30 g/mL , with 
TTprolongations of greater than approximately  5-fold from baseline. Both doses demonstrated 
an acceptable safety  profile. Therefore, the starting dose of 0.3 mg/kg was selected as it should 
be effect ive for VTE prevention after TKR surgery  and provides a wide safet y margin from the 
Phase 1 doses that showed a bleeding signal (2.125 and 2.5 mg/kg). Dose escalation will then be 
guided by the OC based on accumulating data for both safety  and efficacy. The highest planned 
dose in Part 1 of 1.2mg/kg has been selected because it issimilar to the 1 -mg/kg dose studied in 
the Phase 1study and is approximately  50% of the lowest dose with a bleeding signal 
(ie,2.125 mg/kg) in healthy  subjects. If the 0.3-mg/k g dose appear s to be fully effective in 
Part1, there isthe option to study  a lower dose (as low as 0.1 mg/kg); likewise, if the 1.2-mg/kg 
dose appears well tolerated and incremental benefit is expected from a higher dose, there isthe 
option to study  a higher dose (up to 1.8 mg/kg). The dose selection in Part 2 will be based on the 
safet y and efficacy  results/comprehensive analysesfrom Part 1, with the goal being to study  the 
widest possible dose range supported b y the data.
Choice of Comparator
An activ e control (apixaban) will be used because pharmacologic VTE prophy laxis is considered 
standard -of-care in subjects undergo ingTKR surgery . Given thatVTE and bleeding event rates 
vary across studies, the active control will also provide an internal referen ce for comparison with 
JNJ-64179375 in this study.
Apixaban waschosen as the comparator in this study  because it is an approved oral drug for this 
indication , has a start time after surgery  that is preferred by many surgeons, and has 
demonstrated favorabl e efficacy  and safet y (ie, bleeding) results compared with enoxaparin.
Refer to Section 1.2, Comparator Drug for additional details regarding apixaban.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
45
Approved , Date: 11 September 2017The 2.5-mg dose of apixaban, taken twice daily  for 10 to 14days beginning 12 to 24 hours after 
the end ofTKR surgery  will be used inthis study  as it is the approved dosage regimen 
(inapproved countries ) for the indication being studied.8
Choice of Efficacy Measures
Total VTE is a standard efficacy  measure for Phase 2 TKR VTE proph ylaxis studies. The use of 
venograph y to detect asymptomatic DVT and standardized definitions to assess bleeding events 
are specifically  recommended as the best approach for the Phase 2 orthopedic surgery  setting.7
The assessment time between Days 10-14 isappropriate given that it is the approved duration of 
therap y for apixaban.
Ultrasound is a noninvasive, widely  available technique ,with a high sensitivity  and specificity 
for symptomatic DVT that has replaced venography  in clinical practice for the diagnosis of 
DVT events (all DVT sensitivity  88%, specificity  96%).20However, ultrasound has repeatedl y
been shown to have very lowsensitivity  compared with venograph y for detecting asymptomatic 
DVT in the postoperative setting.20,27In a  m eta-analysis of 15 studies, the sensitivity  of 
ultrasound compared with venography  for detecting asymptomatic DVT was 47%.20More recent 
data are from the Phase 2studies of rivaroxaban in DVT prophy laxis following hip and knee 
replacement surgeries, where a substudy  (VENUS study ) was conducted comparing venograph y 
to ultrasound. Despite rigorous methodology , including separate adjudication sites for each 
technique and a large number of matching pairs of evaluable venography  assessments and
ultrasounds, the authors concluded that ultrasound cannot replace venography  for DVT diagnosis 
in this setting . The observed frequency  of any  DVT was 18.9% with venography  and 11.5% with 
ultrasound. The sensitivity  o f ultrasound compared with venograph y was 
31.1% (95% confidence interval [CI]: 23.4, 38.9) for any DVT, 21.0% (95% CI: 2.7, 39.4) for 
proximal DVT, and 30.8% (95% CI: 23.1, 38.6) for distal DVT. The result s for specificity  were 
93.0% (95% CI: 91.0, 95.1), 98.7% (95% CI: 98.0, 99.5), and 93.3% (95% CI: 91.5, 95.3), 
respectivel y.27
Therefore, venograph y is still considered the gold standard and the only reliable method for 
diagnosing asymptomatic DVT after TKR surgery . The most likely  explanation sfor the poor 
performance of ultrasound compared with venography  in this setting arethe nature of the clots 
that form early after surgery  (small and compressible) compared with symptomatic clots 
(larger and noncompressible) and the distortion of the veins produced by the postoperative 
swelling .
Although research into new anticoagulants has slowed in recent years, all proof -of-concept 
studies using the postoperative orthopedic model have continued to use venography  to assess the 
primary  endpoint.5,22,31Venograph y produces plausible and reliable results in clinical 
studies7,14,29and no anticoagulant has been approved by a  health authority  for postoperative 
orthopedic DVT proph ylaxis without venograph y data. Despite the challenges with performing
venograph y,it remains the standard fordetecting DVT after TKR surgery  and is the most 
appropriate method for use in this study . 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
46
Approved , Date: 11 September 2017Bilateral venography  has been used in most but not all previous Phase 3 studies.11,13However, as 
unilateral venograph y of the operated leg detects over 90% of DVTs after TKR surgery12and 
exposes subjects to less risk (radiation, contrast dye,venipuncture) and less discomfort , only 
venograph y of the operated leg will be performed in this study .
Suspected symptomatic efficacy  (thrombotic )events (ie, DVT, PE, death, MI, stroke, peripheral 
arterial embolism) will also be specificall y assessed in this study  as these are clinically  important 
events from the perspective of both the subject and the surgeon.
Choice of Safety Measures /Assessments
Bleeding events are the standard primary  safety endpoint in studies of anticoagulant 
VTE proph ylaxis after TKR surgery . Because the occurrence of major bleeding events is 
infrequent and previous dose-ranging studies have demonstrated that all categories of bleeding 
events increase with dose in a similar manner, the any bleeding event composite will be the 
primary  safety  endpoint in this study .21Published guidelines that describe how to define major 
bleeding events after major orthopedic surgery  will be followed .28For nonmajor bleeding events,
standardized definitions, as utilized in the Phase 3 studies of apixaban, will be followed.23,24All
wound or joint complications will also be speci ficall y assessed in this study  as these are 
important from the perspective of both the subject and the surgeon.
Choice of PK and Immunogenicity Measures
Pharmacokinetic blood samples will be collected from all subjects and analy zed for subjects who 
are randoml y assigned to treatment with JNJ-64179375 to further understand the 
PKcharacteristics and variability  of JNJ-64179375 in the TKR patient population. The 
combination of dense and sparse PK samples in this patient population will be sufficient forthe
development of a population PKmodel and predicted concentrations from such a model will 
allow for the development of exposure -response models for various endpoints related to safet y 
and efficacy .Immunogenicity  blood samples will be collected from all subj ects and analyzed for 
subjects randomly  assigned to JNJ -64179375 to assess for the development of an y ADAs .
Choice of Pharmacodynamic/Biomarker and PK/PD
The PD assay s(TT, ECT, PT, aPTT, and D-dimer) will be used to evaluate the mechanism of 
action and pharmacologic activity  of JNJ-64179375. A battery  of coagulation assay s with 
different inhibition profiles for JNJ-64179375 has been chosen to evaluate those assay sthat 
might be most appropriate for assessing both pharmacologic activity  and any relationship s with 
PK and/or efficacy  and/or safet y endpoints. The goal of the PDanalyses is toevaluate the PD 
effects of JNJ-64179375 ,the PK/PD relationship , and PD outcome relationships. Additional 
details regarding the collection of the PD assessment blood sampl es and the test procedures will 
be included in the laboratory  manuals. It is expected that apixaban willhave no effect or minimal 
effects on all of the coagulation assay s and therefore, analysis of the apixaban samples is not 
planned.
Biomarker samples may be used to help address emerging issues and enable the development of 
safer, more effective, and ultimately  individualized therapies. An exploratory  objective will be to 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
47
Approved , Date: 11 September 2017evaluate and compare the performance of the various PD assay s. A central specialt y laboratory 
will be used toprovide more robust qualit y control for these assay s by performing them in 
batches and to maintain the study  blind. No local PD sample collection is planned. Detailed 
descriptions of each of the assay s areprovided in Section 9.4, Pharmacody namic/Biomarker 
Evaluations.
Choice of Health Resource Utilization Data Collection
With the growing demand on limited healthcare resources and concern about healthcare 
expenditures, the collection of health resource utilization data will be integrated into the study . 
Health resource utilization endpoints collected from this study  will bekey inputs for conducting 
exploratory  cost-effectiveness analyses.
4. SUBJECT POPULA TION
It is estimated that approxima tely 1,500 subjects will be randomly  assigned to treatment in this 
study as described in Section 3.1.1 , Part 1: Single -Ascending Dose and Section 3.1.2 , Part 2: 
Dose -Response Evaluation . Subjects who are withdrawn early from the study  will not be 
replaced. For a discussion of the statistical considerations of subject selection, refer to 
Section 11.2, Sample Size Determinatio n.
The inclusion and exclusion criteria for enrolling subjects in this study  are described in the 
following 2 subsections. If there is a question about the inclusion or exclusion criteria below, the 
investigator must consult with the appropriate sponsor representative and resolve any issues 
before enrolling a subject in the study . Waivers are not allowed .
Screening for eligible subjects in Parts 1 and 2 may be done up to 30 day s before randomization, 
pre-or postoperatively .Subjects will be eligible for rescreening only in those cases when 
TKR surgery  is rescheduled outside of the 30-day window. Subje cts may only be rescreened on 
1occasion.
4.1. Inclusion Criteria
Each potential subject must satisfy all of the following criteria to be enrolled in the study :
1. M aleor female of non-childbearing potential
2. A t least 50 years of age or older
3. Weight 40 kg to 150 kg
4. M edically  appropriate for postoperative anticoagulant proph ylaxis as determined by the 
investigator on the basis of the physical examinati on, medical history , andvital signs
measurements performed as part of screening for elective TKR surger y and any 
examinations performed as part of standard postoperative care following surgery
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
48
Approved , Date: 11 September 20175. M edically  appropriate for postoperative anticoagulant prophylaxis on the basis of 
clinical laboratory  tests performed as part of screening for elective TKR surgery and any 
examinations performed as part of standard postoperative care following surger y. If the 
results of the laboratory  testsareoutside the norma l reference ranges, the subject may 
be included only if the investigator judges the abnormalities or deviations from normal 
to be not clinically  significant or to be appropriate and reasonable for the population 
under study . This determination must be reco rded in the subject's source documents.
6. H as undergone an elective primary  unilateral TKR
7. M ust sign an informed consent form (ICF) indicating that he or she understands the 
purpose of,and procedures required for,the study  and iswilling to partici pate in the 
study .
8. B efore randomization, a woman must not be of childbearing potential defined as:
oPostmenopausal
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level 
(>40 IU/L or mIU/mL )in the postmenopausal range may be used to 
confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy, however in the absence 
of 12 months of amenorrhea, a single FSH measurement is insufficient .
oPermanently  sterile
Permanent sterilization methods include hysterectomy, bilateral 
salpingectomy, bilateral tubal occlusion/ligation procedures, and bilateral 
oophorectomy.
If reproductive status is questionable, additional evaluation should be considered in 
consultation with the sponsor . 
9. A woman must agree not to donate eggs (ova, oocy tes) for the purposes of assisted 
reproduction during the study
10. Contraceptive use by men should be consistent with local regulations regarding the use 
of contraceptive methods for subject participating in clinical studies.
During the study  from Day  1 through the Week 18visit, aman
Who issexually  active with a woman of childbearing potential must agree to use a 
barrier method of contraception (eg, condom with spermicidal 
foam/gel/film/cream/suppository )
Who issexually  active with a woman who is pregnant must use a condom
Must agree not to donate sperm
Must agree not to father a child
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
49
Approved , Date: 11 September 201711. W illing and able to adhere to the prohibitions and restric tions specified in this protocol .
4.2. Exclusion Criteria
Any potential subject who meets any  of the following criteria will be excluded from participating 
in the study :
1. A ny condition forwhich the use of apixaban is not recommended in the opinion of the 
investigator (eg, spinal anesthesia procedure with bleeding or significant trauma, 
postoperative epidural analgesia with an epidural catheter within 5 hours of oral or 
IVstudy  drug administration, previous allergic reaction, creatinine clearance 
<15mL/minute or on dialy sis)
2. Bilateral, revision or unicompartmental procedure
3. K nown or suspected hypersensitivity  or intolerance toany biologic medication or 
known allergies or clinically  significant reactions to murine, chimeric, or human 
proteins, monoc lonal antibodies or antibody  fragments, orany of theexcipients of 
JNJ-64179375 (refer to Investigator's Brochure)17
4. U nable to undergo venography  (eg, due to contrast agent allergy , poor venous access ,or 
impaired renal function that would increase the risk of contrast -induced nephropathy )
5. Known previous DVT  in either lower extremity
6. C hronic anticoagulation therap y for any condition (eg, atrial fibrillation ,mechanical
heart valve )is required
7. A ny preplanned invasive procedure (eg, surgery , colonoscopy ) up to Week 18 for which 
anticoagulant or antiplatelet therap y would be interrupted
8. Planned use of intermittent pneumatic compression after randomization
9. R eceived an investigational drug (including investigational vaccines, experimental 
antibody  or biologic therapy )within the previous 6 months or 5 half-lives , whichever is 
longer, or received any other experimental therapy ,or used an invasive investigational 
medical device within 60 day s before the planned first dose of study  drug or is currently  
enrolled in an investigational stud y
10. P revious randomized subject in this study  or participated inprevious studies with 
JNJ-64179375
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
50
Approved , Date: 11 September 201711. A ny condition for which , in the opinion of the investi gator, participation would not be 
in the best interest of the subject (eg, compromise the well-being) or that could prevent, 
limit, or confound the protocol- specified assessments
12. E mploy ee of the investigator or study  site, with direct involvement in the proposed 
study  or other studies under the direction of that investigator or study  site, as well as 
family  members of the employ ees or the investigator
13. A t the time of informed consent , the subject does not agree tofollowing up with 
scheduled study  visits or allowing a telephone contact to the subject ’s alternative means 
of contact (eg,subject’s children, spouse, significant other, caretaker, legal 
representative, or healthcare professional), as necessary ,until the end of the study ,
should he or sh ediscontinue prematurel y
NOTE: Investigators should ensure that all study enrollment criteria have been met at screening. 
If a subject's clinical status changes (including any available laboratory  results or receipt of 
additional medical records) after screening but before the first dose of study  drug is given such 
that he or shenolonger meet sall eligibility  criteri a, then the subject should be excluded from 
participation in the study . Section 9.1.2 , Screening Phase , describes options for retesting. 
Section 17.4, Source Documentation, describes the required documentation to support meeting 
the enrollment criteria.
4.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the study  to be eligible for participation .Additionally , for 
apixaban, i nvestigators should follow the prohibitions and restrictions in the Summary  of 
Product C haracteristics.
1. Refer to Section 8, Prestudy  and Concomitant Therap yfor details regarding prohibited 
and restricted therap y during the stud y.
2. Agree to follow all requirements that must be met during the study  as noted in the 
Section 4.1, Inclusion Criteria and Section 4.2, Exclusion Criteria .
3. A man who is sexually active must agree to use a barrier method of contraception 
method as described in Section 4.1, Inclusion Criteria. All men must also not donate 
sperm through the Week 18visit.
4. Subjects who are given permission by the treating physician to resume normal activity  
following TKR surgery  should avoid activities that could produce significant trauma, 
and when participating in low-risk sports (eg,biking), proper safet y gear 
(eg,helmet, gloves) should be worn through the Week 18visit. In addition, subjects 
should be more cautious when using sharp objects (eg, razors, scissors, and knives) 
through the Week 18visit.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
51
Approved , Date: 11 September 20175. Subjects should not donate blood or blood products for the duration of the study  and for 
at least 4 weeks after the Week 18visit.
5. TREA TMENT ALLOCA TION AND BLINDING
Treatment Allocation
Procedures for Randomization and Stratification
Central randomization will be implemented in this study . In Part 1, within each of the up to 
6planned cohort s, subjects will be randoml y assigned to 1 of 2treatment groups based on a 
computer -generated randomization schedule prepared by  or under the supervision of the sponsor. 
The randomization will be balanced by using randomly  permuted blocks and in Part 2 will also
be stratified by region . The interactive web response system (IWRS) will assign a unique 
treatment code, which will dictate the treatment assignment for the subject. The requestor must 
use his or her own user identification and personal identification number when contacting the 
IWRS , and will then give the relevan t subject details to uniquely  identify  the subject.
In Part 2, subjects will be randomly  assigned to 1 of thetreatment groups based on a 
computer -generated randomization schedule as previously  described for Part 1.Separate 
randomization schedules will be used for Part 1 and Part 2 of the study .
Blinding
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality  to allow the investigator to break the blind for an 
individual subj ect.
Data that may potentially  unblind the treatment assignment (ie, coagulation testing, study  drug 
concentrations, antibodies to JNJ-64179375, study  drug preparation/accountability  data, 
treatment allocation, and biomarker laboratory  data) will be handle d with special care to ensure 
that the integrit y of the blind is maintained and the potential for bias is minimized. This can 
include making special provisions, such as segregating the data in question from view by the 
investigators, clinical team, or others as appropriate until the time of database lock and 
unblinding. To maintain the blind of the study , the investigator should not measure coagulation 
assay s locall y unless considered necessary  for subject clinical care. In addition, the investigator 
will not receive the results of the PD parameters from the central specialt y laboratory  during the 
conduct of the stud y.
Under normal circumstances, the blind should not be broken until all subjects have completed 
the study  and the database is finalized. Otherwi se, the blind should be broken only if specific 
emergency  treatment/course of action would be dictated by knowing the treatment status of the 
subject. In such cases, the investigator may in an emergency  determine the identity  of the 
treatment by contacting the IWRS. While the responsibility  to break the blind in emergency  
situations resides solely  with the investigator, it is recommended that the investigator contact the 
sponsor or its designee if possible to discuss the particular situation, before breaking the blind.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
52
Approved , Date: 11 September 2017Telephone contact with the sponsor or its designee will be available 24hours per day , 7days per 
week. In the event the blind is broken, the sponsor must be informed as soon as possible. The 
date and time for the unblinding must be documented by the IWRS and the reason for the 
unblinding must be documented in the source document. The documentation received from the 
IWRS indicating the code break must be retained with the subject's source documents in a secure 
manner.
Subjects who have had their treatment assignment unblinded may continue on study  drug unless 
the subject meets a study  drug discontinuation criterion. Investigators should not disclose the 
treatment assignment to the subject whenever possible, even in a special situation where the 
treatment assignment has been unblinded to the investigator. Subjects who have had their 
treatment assignment unblinded should continue to return for scheduled evaluations .
In general, randomization codes will be disclosed fully  only if the study is comple ted and the 
clinical database is closed. However, the randomization codes and the translation of 
randomization codes into treatment and control groups will be disclosed to those authorized
individuals of the OC for theongoing data reviews in Part 1 and ofthe IDMC for data reviews 
and interim analy ses in Part 2. Refer to Section 11.10 , Interim Analysis , Section 11.11.1 ,
Operations Committee ,and Section 11.11.2 , Independent Data Monitoring Committee for 
additional details.
JNJ-64179375 (Parts 1 and 2)
Using the randomization code, an unblinded pharmacist or other appropriately  licensed and 
authorized health professional at each study  sitewill prepare an individual study  drug dose of 
JNJ-64179375 or JNJ-64179375 placebo (0.9% normal saline) for each subject in a 
50-mL normal saline IV bag as per the directions in the Investigational Product Preparation 
Instructions (IPPI). Subjects randomized to apixaban will receive a0.9% normal saline IV bag 
with no active study  drug. All study  drug swill have a blinded label applied prior to dispensing.
Apixaban (Parts 1 and 2)
Using the randomization code, the pharmacist or other appropr iately licensed and authorized 
health professional will dispense a bottle of blinded oral study  drug (over -encapsulated apixaban 
tablets or matching apixaban placebo capsules) to each subject at the time of randomization. The 
subject will be administered the capsules from the bottle while hospitalized and will be given the 
bottle for outpatient useat the time ofdischarge from the hospital .Refer to Section 6, Dosage 
and Administration for additional details reg arding subject dosing.
6. DOSA GE A ND A DMINISTR ATION
In both Parts 1 and 2, subjects will be randoml y assigned to receive an active single IV dose of 
JNJ-64179375 or apixaban 2.5 mg given orally twice daily  for 10 to 14 day s. The administration 
of the study  drugswill begin the day after the TKR surgery  (Day 1, 0 hours), while the subject is 
still hospitalized and within a minimum of 12hours and a maximum of 24 hours after the end of 
the TKR surgery , defined as the time of wound closure . Within that timeframe , both the single 
IVinfusion and the oral study  drug should be administered as close as possible to each other, 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
53
Approved , Date: 11 September 2017with up to a maximum of 60 minutes between the start of the I V infusion and the first dose of the 
oral study  drug. Subjects will be randomly  assigned to thetreatment groups as follows:
Part 1
Cohort 1: JNJ-64179375 0.3mg/kg IV/JNJ-64179375 placebo (saline) IV infusion and 
matching apixaban placebo /apixaban , orally twice a day  for 10 to 14 day s
Cohort 2: JNJ-64179375 0.6mg/kg IV/JNJ-64179375 placebo (saline) IV infusion and
matching apixaban placebo /apixaban, orally twice a day  for 10 to14 day s
Cohort 3: JNJ-64179375 1.2mg/kg IV/JNJ-64179375 placebo (saline) IV infusion and 
matc hing apixaban placebo /apixaban , orally twice a day  for 10 to14 da ys
Optional Cohorts (JNJ- 64179375 in the R ange of 0.1 to 1.8 m g/kg)
The doses of JNJ-641793 75 to be used in the optional cohorts will be dependent on the available 
preliminary  safety , tolerability , efficacy , PK, and PD data obtained from the preceding coho rtsas 
described in Section 3.1.1 , Part 1, Single -Ascending Dose . Doses within the optional cohorts will 
either be new doses within the range of 0.1 to 1.8 mg/kg not previously  administered in the 
preceding cohorts , ordoses from the preceding cohorts , which may be repeated, as needed.
Cohort 4: JNJ-64179375 Dose to be determined (TBD) mg/kg IV/JNJ -64179375 placebo 
(saline) IV infusion and matching apixaban placebo /apixaban, orally twice a day for 
10to14days
Cohort 5: JNJ-64179375 Dose TBD mg/kg IV/JNJ -64179375 placebo (saline) IV infusion 
andmatching apixaban placebo /apixaban, orallytwice a day  for 10 to 14 day s
Cohort 6: JNJ-64179375 Dose TBD mg/kg IV/JNJ -64179375 placebo (saline) IV infusion 
andmatching apixaban placebo /apixaban, orallytwice a day  for 10 to 14 day s
Part 2
Group A: JNJ-64179375 Dose Amg/kg IVand apixaban placebo orally twice a dayfor 
10to14 day s
Group B: JNJ-64179375 Dose Bmg/kg IV and apixaban placebo orally twice a day for 
10to14days
Group C: JNJ-64179375 Dose Cmg/kg IV and apixaban placebo orally twice a day for 
10to14 day s
Group D: JNJ-64179375 Dose D mg/kg IV and apixaban place bo orally  twice a day for 
10to14 day s
Group E: JNJ-64179375 placebo (saline) IV and apixaban 2.5 mg orally twice a day for
10to14 day s
Doses of JNJ-64179375 may change after the interim analy ses in Part2as described in 
Section 11.10 , Interim Analy ses.
For both parts , JNJ-64179375 will be prepared according to the subject’s weight and treatment 
assignment by the pharmacist or other appropriately  licensed and authorized health professional 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
54
Approved , Date: 11 September 2017who is not blinded to the treatment assignment. All study  drug administrations of JNJ-64179375
must be calculated based on the subject ’s weight onDay -1or prior to dosing on Day 1.The 
single infusion of JNJ-64179375 or JNJ-64179375 placebo (saline) will be administered under 
the supervision of the investigator or his/her designee over a period of approximately  30minutes 
by infusion pump or by gravity  flow using a flow regulator .A physician must be immediately 
available at the study  site at all timesduring the administration of the study  druginfusion. 
Detailed instructions for dose preparation, dosing procedures, a nd storage conditions of the study 
drug will be provided to the study  site in the IPPI. These documents may be revised as needed 
and should be maintained in the study  files.
The first dose of apixaban or matching apixaban placebo will be administered as previousl y 
described . Subjects will receive apixaban or matching apixaban placebo twice a day while 
hospitalized and will be given a suppl y of apixaban or matching apixaban placebo at the time of 
discharge or transfer to an alternate facility , with instructi ons to take the study  drug orally , twice 
a day at approximately  the same times each dayto complete a total of 10 to 14 days of dosing . 
Apixaban or matching apixaban placebo should be swallowed with water, with or without food. 
If a dose of apixaban or matching apixaban placebo is missed, the missed dose should be taken 
as soon as possible and then the subject should continue with the twice -daily  intake as previously 
instructed. The dose should not be doubled to make up for a missed dose and more than 2 doses 
should not be taken on the same day .
Refer to Section 14, Study  Drug Information for details regarding a physical description of the 
study  drugs, packaging, labeling, and preparation, handling, and storage.
7. TREA TMENT COMPLIA NCE
Drug supplies will be inventoried and accounted for throughout the study . The IWRS will track 
the study  drug dispensed to(JNJ-64179375 or apixaban /matching apixaban placebo) and 
returned b y(apixaban or matching apixaban placebo only )subjects.
JNJ-64179375 or JNJ-64179375 placebo will be administered as a single IV infusion by 
qualified study  site personnel and the details of the administration will be recorded .For apixaban 
or matching apixaban placebo, subjects will be required to return empt y study  drug containers 
and unused study  drug at their Day 10-14visit, at which time study  drug accountability  will be 
performed.
8. PRESTUDY AND CONCOMI TANTTHERAPY
Modification of an effective preexisting therap y should not be made for the explicit purpose of 
entering a subject into the study .
The use of the following medications/therapies is not permitted from randomization through 
Week 18:
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
55
Approved , Date: 11 September 2017Additional anticoagulant(s) (eg, vitamin K antagonists, Factor IIa or FXa inhibitors). The 
blinded study  drug (apixaban) will be discontinued in subjects who develop any condition 
that requires long-term anticoagulation (eg, DVT, atrial fibrillation). Refer to Section 9.2, 
Efficacy  Evaluations for details regarding the management approach for subjects who 
develop a symptomatic VTE event or who have asymptomatic DVT detected by 
venograph y.
Antiplatelet therapies (eg, platelet adenosine diphosphate P2Y 12receptor antagonist
[eg,clopidogrel, ticagrelor] ) during the stu dy except for aspirin 100mg/day
Nonsteroidal anti-inflammatory  drugs (NSAIDs) should be avoided, if possible, during the 
study  because their use can increase the risk of bleeding and may interfere with collagen 
formation. If NSAID use is necessary , it is recommended that the minimum dose is used for 
the shortest possible duration.
Intermittent pneumatic compression after randomization (all other mechanical 
VTE prevention methods such as foot pumps, graduated compression stockings and 
continuous passive motion devices are permitted)
In addition, the use of the following medications is not permitted concomitantly  with apixaban or 
matching apixaban placebo:
Concomitant sy stemic treatment with strong inhibitors of both cy tochrome P450 (CYP) 3A4 
and P-glycoprotein (P-gp), such as azole -antimy cotics (eg,ketoconazole, itraconazole, 
voriconazole, and posaconazole) and human immunodeficiency  virus protease inhibitors 
(eg, ritonavir). These medicinal products may increase apixaban exposure by 2-fold or 
greater in the presence of additional factors that increase apixaban exposure (eg, severe 
renal impairment).8
Strong CYP3A4 and P-gp inducers (eg, rifampicin, pheny toin, carbamazepine, 
phenobarbital, or St. John’s Wort). The concomitant use with apixaban may lead to an 
approximately  50% reduction in apixaban exposure.8
Only  selected medications administered up to 7days before randomization will be recorded in 
the electronic case report form (eCRF )as prestudy  therapies (eg, TXA, antiplatelet therapies, 
anticoagulant therapies , and NSAIDs) .
All concomitant pharmacologic therapies ,including prescription or over-the-counter 
medications, products to manage bleeding, vaccines, vitamins, and herbal supplements different 
from the study  drug must be recorded throughout the study  from the time of randomization 
through the last follow -up visit on Week 18.
All non -pharmacologic therapies such as intermittent pneumatic compression devices , foot pump 
devices, continuous passive motion devices , compression stockings, electrical stimulation, 
acupuncture, special diets, exercise regimens , including physical and occupational therap ymust 
also be recorded in the eCRF.
Recorded information will include a description of thetype of therapy , duration of use, dosing 
regimen, route of administration, and its indication.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
56
Approved , Date: 11 September 2017The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered.
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule summarizes the frequency  and timing of efficacy , PK, 
immunogenicit y, PD/biomarker, health resource utilization, and safet y measurements applicable 
to this study .The Time and Events Schedule ,and the description of the study  phases that 
follows, are applicable to subjects participating in either Part 1 or Part 2 of the study , unless 
otherwise noted.
If multiple assessments are scheduled for the same time point, it is recommen ded that procedures 
be performed in the following order :ECG (as applicable) , vital signs, and blood draw. 
Blood collections for PK and PD assessments should be kept as close to the specified time as 
possible. Other measurements may be done earlier than specified time points, if needed. Actual 
dates and times of assessments will be recorded in the source documentation .Blood samples for 
PK and PD assessments on Day 1  p ostdose should be collected in the opposite arm as the 
infusion of JNJ-64179375 or placeb o. Blood samples will be collected in thefollowing order: 
safet y (serum chemistry , hematology ), PK, immunogenicity , and PD.
Venous blood will be collected for all blood -based analy sis. Blood will be drawn using a cannula 
or by venipuncture. Only  saline (not heparin) canbe used for flushing the cannula. If blood 
samples are collected via an indwelling cannula, an appropriate amount (ie, 1 mL) of fluid 
slightly  greater than the dead space volume of the lock will be removed from the cannula and 
discarded bef ore blood sample saretaken.
The total blood volume to be collected from each subject will be approximately  95.4 mLfor 
subjects with dense PK sampling and approximately  80.4 mL for subjects with sparse 
PKsampling as described in Table 6.It is important to record the exact date and time for 
PKsample collection even if the time deviates slightly  from the scheduled time of collection.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
57
Approved , Date: 11 September 2017Table 6: Volume of Blood to be Collected From  Each Subjec t
Type of SampleVolume per 
Sample (mL)aNo. of Samples 
per SubjectApproximate 
Total Volume of 
Blood (mL)b,c
Safety (including follow -up assessments)
Hem atology 2.0 5 10.0
Serum chemistry 2.5 5 12.5
PK samples , including ADA, where required
Dense 5.0 9 45.0
Sparse 5.0 6 30.0
PD/Biomarker samples
TT, PT , aPTT 4.5 4 18.0
ECT (alone) 1.8 1 1.8
ECT including D -dimer 2.7 3 8.1
Approximate Totalcfor Dense PK subjects 95.4
Approximate Totalcfor Sparse PK subjects 80.4
ADA=antidru g antibody; aPTT=activated partial thromboplastin time; ECT=ecarin clotting time; No.=number; 
PD = pharmacodynamics; PK=pharmacokinetic, PT = prothrombin time; TT = thrombin time
aSome sample volumes will vary slightly for subjects in Japan (due to custom s requirements for laboratory 
tubes) .
bCalculated as number of samples per subject multiplied by volume of blood per sample.
cRepeat or unscheduled samples may be taken for safety reasons or technical issues with the samples.
Note: An indw elling IV cannu la may be used for blood sample collection.
Additional blood samples may be collected, if necessary , for additional safet y, PK, or 
PDassessments based on emerging data, but the total bl ood volume collected from an individual 
subject during this study will not exceed 200 mLwithout prior Independent Ethics Committee 
(IEC) or Institutional Review Board (IRB) and health authority  approvals. Repeat or 
unscheduled samples may be taken for safety  reasons or for technical issues with the samples
and do not req uire prior IEC/I RB and health authority  approvals.
Health resource utilization data will be collected. Refer to Section 9.6, Health Resource 
Utilization for details.
9.1.2. Screening Phase
The screening phase will occu r up to 30 days before randomization, pre-or postoperativel y. 
Potential subjects may be evaluated for eligibility  before or afte r their unilateral elective 
TKR surgery .Final eligibility  must be confirmed after surgery , prior to randomization.
Prior to conducting any study -related procedure, the investigator (or designated study  personnel) 
will review and explain the written ICFto each subject. No study  procedures can be performed 
until the subject signs the ICF. At the time of informed consent , 2 alterna tive means of contact 
for the each subject will be collected (eg, contact information of the subject’s children, spouse,
significant other, caretaker, legal representative, or health care professional). Details regarding 
the TKR surgery and the post-surger ymanagement (eg, type of anesthesia, procedure duration, 
cement use, tourniquet use and duration, drain use and volume, and useof all mechanical 
VTE proph ylaxis methods) will be collected in the eCRF .In addition, the subject will respond to 
questions (s eeAttachment 1) regarding his or her family  and personal bleeding history, including 
any bleeding from previous surgical procedures .
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
58
Approved , Date: 11 September 2017Subjects will be eligible for rescreening only in those cases when TKR surgery  isrescheduled
outside of the 30 -day window .Subjects may  only be rescreened on 1 occasion.
9.1.3. Double -Blind Dosing Phase
Day 1/Day of Randomization
On Day 1, subjects who meet all of the eligibility  criteria will be randomly  assigned to study  
drug, either JNJ-64179375 or apixaban as described in Section 6, Dosage and Administration.
JNJ-64179375 or JNJ-64179375 placebo will be administered under the supervision of the 
investigator or his/her designee .Subjects will also begin to take oral apixaban or matching 
apixaban placebo twice daily . All procedures specified forthe 0-hour time point should be 
conducted prior to the first dose of the study  drug . The postdose samples will be drawn at 1 hour 
(10 minutes) and 4 hours from the star t of the IV infusion .
Dosing Visits
Subjects will be discharged from the hospital or transferred to an alternate facilit y at an 
appropriate time as determined by the managing physician. The Day 2 blood sample will be 
drawn 24 hours after the start of the I V infusion and may  be done with the subject as an inpatient 
or outpatient . Study  procedures will be conducted on Days 3 (48 hours) and 7 (144 hours) only 
for those subjects who are still hospitalized. At the time ofhospital discharge or transfer to an 
alternate facility , the subject will be reminded to continue totake theoral apixaban or matching 
apixaban placebo twice daily  to complete a total of 10 to 14 daysof dosing , the duration of 
which will be determined by the managing physician .Subjects who complete dosing with 
apixaban or matching apixaban placebo will return to the study  site for final assessments in the 
double -blind dosing phase (Day 10-14visit, end of dosing [EOD ]), at which time a unilateral 
venograph y assessment of the operated leg will be performed within 24 hours of the last dose of 
apixaban or matching apixaban placebo. Further details regarding the venograph y are provided
in Section 9.2.1 , Assessments for DVT .
Unscheduled Visits
At the discretion of the investigator, subjects may return to the study  sitebetween scheduled 
visits. Subjects should return to the study  sitefor the assessment of any potential bleeding or 
efficacy  endpoint event s. Unscheduled PK and PDsamples (except D -dimer) should be collected 
as soon as practicall y possible for any subject that experiences symptomatic thrombotic or 
bleeding events.
Early Withdrawal
Subjects who do not receive the full infusion of JNJ-64179375 or prematurel y discontinue 
dosing with apixaban or matching apixaban placebo before the end of the double -blind dosing
phase will be instructed to return to the study  siteat the originally  scheduled Day 10-14 visit
(notearlier) to conduct assessment s, including the venograph yassessment of the operated leg. If 
a subject has a suspected symptomatic DVT prior to the Day 10-14 visit, an ultrasound will be 
performed. If the ultrasound confirms symptomatic proximal DVT, a subsequent venograph y 
assessment is not required . In addition, if the subject is diagnose dwith a PE as defined in 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
59
Approved , Date: 11 September 2017Section 9.2.2 , Assessments for PE, a venography  assessment is not required. Refer to 
Section 9.2, Efficacy  Evaluations for further details regarding anticoagulation treatment. If the 
ultrasound is negative or confirms a distal DVT ,the venograph y assessment should be conducted 
on the Day 10-14 visit.Subjects should complete the remaining visits through the 
Week 18assessments as indicated in the Time and Events Schedule. 
If a subject withdraws from the study  before the end of the follow -up phase and is unwilling or 
unable to return for follow -up visits in person or have follow -up contacts, the study  site should 
collect as much follow -up visit information as possible, including contacting the subject or the 
subject’s representative or health care professional by telephone or by mail to determine vital 
status and to collect medical information related to endpoint events, as agreed to by the subject 
during the initial informed consent process. For subjects who withdraw consent from study  
participation, the reasons for the withdrawal of consent should be document edin the source 
documents and entered in the eCRF. If applicable, vital status may be obtained by reviewing the 
subject’s medical or public records unless this contact is not permitted per local regulations .
Refer to Section 10.2, Discontinuation of Study  Drug /Withdrawal from the Study  for additi onal 
details.
9.1.4. Follow -UpPhase
The first follow -up visit will occur approximately 3weeks following the Day 10-14visit, with 
subsequent follow -up visits occurring until Week 18as described in the Time and Events 
Schedule . Reasonable attempts, as defined in Section 10.2, Discontinuation of Study  
Drug /Withdrawal from the Study should be made to conduct the follow -up visit(s)at the 
scheduled time points. Subjects will continue to be monitored for safety , including bleeding 
events and efficacy  events , according to the time points indicated in the Time and Events 
Schedule .
9.2. Efficacy Evaluations
Efficacy  evaluations, including the unilateral venograph yassessment of the operated leg and 
assessments of symptomatic DVT ,PE,death, or other thrombotic events (ie, MI, ischemic 
stroke, and peripheral arterial embolism) will be performed according to the time points in the 
Time and Events Schedule to assess the primary ,secondary , and exploratory efficacy  outcomes. 
All venogr aphy assessments , ultrasound evaluations for suspected symptomatic DVT, as 
applicable , and evaluatio ns for suspected PE or other thrombotic events will be performed and 
read locally  and sent for central adjudication by the independent CEC .The central adjudication 
evaluations will not be provided to the local sites. The CEC -adjudicated and 
investigator -reported results on efficacy  and safety  outcomes will be provided for theunblinded 
data reviews and theinterim analyses. The CEC -adjudicated events will beused in the final 
analysis. Refer toSection 11.11.4 , Clinical Events Committee for additional details on the 
composition of the CEC and their responsibilities.
If an event or condition requiring anticoagulant treatment occurs during the double -blind dosing
phase then the blinded apixaban or matching apixaban placebo should be discontinued. 
Antithrombotic therap y management for conditions requiring anticoagulation (eg, new onset 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
60
Approved , Date: 11 September 2017atrial fibrillation, symptomatic DVT, or symptomatic PE)will be at the discretion of the local 
investigator. It is recommended that the event betreated with either a DOAC only or LMWH 
with a transition to a DOAC .If knowledge of the likely  treatment group would change the 
planned event management strategy  then local laboratory  coagulation testing may also be 
considered, with a normal TTlikely  indicating the absence of JNJ-64179375. For asymptomatic 
distal DVT detected by venograph y, a possible management approach would be to use serial 
ultrasound to assess for any proximal progression and withhold anticoagulant therap y unless 
proximal progression is observed. If it is decided that treatment is to be given, the same approach 
as suggested for proximal DVT or PE is recommended.
In this study, all suspected symptomatic efficacy (thrombotic) events will also be captured as 
adverse events of special interest, which are defined in Section 9.7.2 , Adverse Events of Special 
Interest.
9.2.1. Assessments for DVT
Unilateral Venography
Venograph y assessments of the operated leg will be performed by injecting contrast agent into a 
foot vein and obtaining x-ray images of the proximal and distal leg veins consistent with the 
technique described byRabinov and Paulin .26Evaluable venograph y assessments require the 
visualization of all of the deep veins except for the muscular, anterior tibial, and deep femoral 
veins. A diagnosis of DVT will be made if a constant intraluminal filling defect is observed in at 
least 2images. An ultrasound will be performed in those subjects with suspected symptomatic
DVT prior tothe Day 10-14 visit. In these cases, if the ultrasound confirms symptomatic
proximal DVT , a subsequent venograph y assessment is not required. If the ultrasound is negative
or confirms a distal DVT , the venograph y assessment shoul d be conducted on the 
Day 10-14visit. Details regarding the timing of the venograph y assessment areprovided in 
Section 9.1.3 , Double- Blind Dosing Phase .
Study -specific venography  assessment training will be provided to each study  site. Each study 
site will be responsible for identify ing at least 1 primary  person to perform the venograph y 
assessments for subjects. Evaluability  of the venograph y assessment sbased on centrally 
adjudicated data will be monitored for each site on an ongoing basis. If venograph y assessment 
performance isconsidered not acceptable, then further randomization by the investigat or may be 
suspended until additional training or retraining is provided. Additional details regarding the 
venograph y procedure and study -specific training requirements will be provided in a venography 
manual, which will be provided separatel y to the study sites.
9.2.2. Assessments forPE
For all subjects with symptoms of PE, spiral computed tomography (CT) ,pulmonary 
angiograph y,or perfusion/ventilation lung scintigraph y combined with chest radiograph y will be 
performed. A diagnosis of PEwill be made only if thesubject has symptoms of PE (eg,sudden 
onset of dy spnea, chest pain, or fainting ), and 1 of the following criteria is met:
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
61
Approved , Date: 11 September 2017Positive spiral CT scan of the chest
Positive direct pulmonary arteriogram
High probability  ventilation/perfusion lung scan (defined as 1or more segmental or large 
[>75% of a segment] subsegmental perfusion defects associated with ventilation mismatch)
Intermediate probabilit y ventilation/perfusion lung scan and ultrasound or venographic 
evidence of DVT
Autopsy  confirmation
If a subje ct is diagnosed with a PE meeting the above definitions, a subsequent venograph y 
assessment of the operated leg is not required.
9.2.3. Assessments for Other Thrombotic Events
Other thrombotic events will include MI, ischemic stroke, and peripheral arterial embol ism. In 
addition, events that appear suggestive of study  endpoints (eg, transient ischemic attack [TIA], 
unstable angina) will be reported bythe investigator and reviewed by the CEC to ascertain if a 
thrombotic event has occurred. The investigator will use his/her medical judgment based upon 
the definitions below to determine if a thrombotic event has occurred.
Myocardial Infarction
The diagnosis of MI requires the combination of: 
Evidence of myocardial necrosis (either changes in cardiac biomarkers or postmortem
pathologic findings); and 
Supporting information derived from the clinical presentation, ECG changes, or myocardial 
or coronary  artery  imaging. 
Stroke
Stroke is defined as a new, sudden, focal neurologic deficit resulting from a presumed
cerebro vascular cause and not due to a readil y identifiable cause such as trauma, a tumor ,or 
seizure.
If an event matching this definition lasts less than 24 hours it will be considered a TIAunless 
imagin gconfirmation of infarction is obtained .Investigators will further classify  the strokes 
based upon imaging studies.
Primary  ischemic infarction –stroke without focal collections of intracranial blood
confirmed by imaging .The occurrence of hemorrhagic conversion of a primary  ischemic 
infarction will be record ed.
Primary  hemorrhagic –stroke with focal collections of intraparenchy mal blood .The
diagnosis of primary  hemorrhagic stroke can only be made with imaging studies. It may
include intraventricular hemorrhage.
Subarachnoid hemorrhage –the diagnosis requir es documentation by animaging stud y
Uncertain – no imaging or autopsy  available
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
62
Approved , Date: 11 September 2017Other events of intracranial bleeding such as subdural hematoma and epidural hematoma will not 
be considered to be a stroke as they  are usuall y traumatic in nature .
Peripheral Arterial Embolism
A peripheral arterial embolism is defined as an abrupt vascular insufficiency  associated with 
clinical or radiologic evidence of arterial occlusion in the absence of other likelymechanisms 
(eg,trauma, atherosclerosis, instrumentation) . In the presence of atherosclerotic peripheral 
vascular disease, diagnosis of embolism to the lower extremities should be made with caution 
and requires angiographic demonstration of abrupt arterial occlusion.
9.3. Pharmacokinetics and Immunogenicity
Plasma samples will be used to evaluate the PK of JNJ-64179375 , as well as the development of 
ADAs toJNJ-64179375 (immunogenicit y).
9.3.1. Evaluations
Sample sfor analysis of JNJ-64179375 plasma concentration will be collected for all subjects 
over time as specified in the Time and Events Schedule but will only be analy zed for subjects 
randomly  assigned to JNJ-64179375 . Dense PK sampling will be conducted at all sites for 
subjects at all visits in Part 1 until approximately up to the first 200subjects have been 
randomize d.Thereafter, the remaining subjects in Part 1 and all subjects in Part 2will have 
PKblood samples collected at a limited number of visits (ie, sparse PK sample collection ). The 
exact date and time of each PKblood sample collection will be recorded even if the time 
deviates slightl y from the scheduled time of collection . Subjects who experience a bleeding event 
or symptomatic thrombotic event should have PK sample scollected as soon as practically 
possible after the event occurs.
The timi ng of PK sampl es may  be changed to ensure thorough PK monitoring; however, the total 
number of samples and/or the volume of blood drawn will not exceed the amount stated in 
Section 9.1.1 , Overview without prior IEC/I RB and health authorit y approvals. Of note, 
additional blood samples may be collected for immediate safet y monitoring of a subject and do 
not require prior IEC/IRB and health authorit y approvals. 
Samples collected for analyses of JNJ-64179375 plasma concentration and antibodies to
JNJ-64179375 may additionally  be used to evaluate safet y or efficacy  aspects that address 
concerns arising during or after the study period, or for further characterization of 
immunogenicit y. Genetic analyses will not be performed on theseplasma samples. Subject 
confidentiality  will be maintained. Additional information about the collection, handling, and 
shipment of biological samples willbe provided in the laboratory  manual .
9.3.2. Analytical Procedures
Pharmacokinetics
Blood samples will be collected from all subjects according to the Time and Event sSchedule 
and analyzed to determine plasma concentrations of JNJ-64179375 in appropriate samples using 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
63
Approved , Date: 11 September 2017a validated, specific, and sensitive i mmunoassay method by or under the supervision of the 
sponsor.
Immunogenicity
The detection and characterization of antibodies to JNJ-64179375 w ill be performed using a 
validated assay  method by or under the supervision of the sponsor. All samples collected for 
detection of antibodies to JNJ-64179375 will also be evaluated for JNJ-64179375 plasma
concentration to enable interpretation of the antibody  data. The Day 1, 0 hours (predose) 
ADA sample may be used for baseline characterization for both the PK and immunogenicity 
assay s.
9.3.3. Pharmacokinetic Parameters
The PK parameters to be calculated following the single IV dose of JNJ-64179375 will include, 
but are not limited to, the following:
Cmax maximum concentration during a dosing interval
AUC inf area under the plasma concentration versus time curve from time 0 to infinity
t1/2 terminal half -life
CL total clearance of drug after IV administration
VZ apparent volume of distribution in the terminal phase
Additional PK parameters may  be determined, as appropriate.
Based on the individual plasma concentration- time data using the actual dose taken and the 
actual sampling times, PKparame ters and exposure information of JNJ-64179375 will be 
derived using population PKmodel ing. Baseline covariates (eg, body weight, age, sex, creatinine 
clearance , race) may be included in the model, if relevant. A separate population PK modeling 
plan will be developed befor e the first subject is consented and thepopulation PK modeling 
results will be reported separately , in a document other than the clinical study  report (CSR) .
9.3.4. Immunoge nicity  Assessments
Blood samples for antibodies toJNJ-64179375 will be collected from all subjects according to 
the Time and Events Schedule but will only be analyzedin plasma samples for subjects 
randomized to JNJ-64179375 . The exact date and time of each blood sample collection will be 
recorded. Additionally , samples should also be collected at the final visit from subjects who are 
discontinued from treatment or withdrawn from the study . These samples will be tested by the 
sponsor or sponsor's designee.
Plasma samples will be screened for antibodies binding toJNJ-64179375 and the titer of 
confirmed positive samples will be reported. Other analyses (eg, neutralization capacit y) may be 
performed to further characterize the immunogenicity  of JNJ-64179375 . 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
64
Approved , Date: 11 September 20179.4. Pharmacody namic /Biomarker Evaluations
All subjects will have plasma samples collected to assess PD markers as specified in the 
Time and Events Schedule. The assay  plan is designed to assess target engagement and the 
mechanism of action with a battery  of PD assessments. Pharmacod ynamic evaluations will 
include the coagulation assay s (ie, TT, ECT, PT, aPTT) and a D -dimer assessment. Subjects who 
experience a bleeding event or symptomatic thrombotic event should have PD samples (except 
D-dimer) collected as soon as practically possible after the event occurs. Samples on Day 1 will 
be obtained before the study  drug is administered and at 1hour after the start of the IV infusion 
and allassay s will be performed by a central specialty  laboratory . Additional information about 
the collection, processing, storage, and shipment of PD samples will be provided in a separate 
laboratory  manual. It is expected that apixaban would have no effect or minimal effects on all of 
the coagulation assay s and therefore, analy sis of the apixaban samples is not planned.
To maintain the blind of the study , the investigator should not measure coagulation assay s
locally unless considered necessary  for subject clinical care. In addition, the investigator will not 
receive the results of the PDparameters from the central specialty  laboratory  during the conduct 
of the study .
Thrombin Time
The thrombin clotting time (designated TT) is a simple test that measures the time for clot 
formation in citrated plasma after the addition of thrombin. Itreflects the effect of thrombin to 
cleave fibrinogen to form fibrin. Heparin and direct thrombin inhibitors such as hirudin, 
argatroban, and dabigatran are inhibitory , LMWH is partially  inhibitory , and apixaban is 
inactive. 
Ecarin C lotting Time
The ECT test is based on the cleavage of prothrombin by ecarin, a highl y purified 
metalloprotease isolated from the venom of the saw-scaled viper Echis carinatus. Ecarin 
generates meizothrombin from prothrombin, which is proteoly tically  active and can cleave
fibrinogen to form a fibrin clot. Meizothrombin ,like thrombin, is inactivated by hirudin and 
other direct thrombin inhibitors, but is unaffected by heparin (as the heparin -antithrombin 
complex cannot inhibit meizothrombin due to steric hindrance). JNJ-64179375 is able to block 
the binding of meizothrombin to fibrinogen and therefore inhibit clot formation . This assay  may 
offer potential advantages in sensitivity  and useful range over the TT test.
Prothrombin Time
Prothrombin time is a global clotting test that i s used for the assessment of the extrinsic pathway  
of the blood coagulation cascade. It is a 1-stage test based upon on the time required for a fibrin 
clot to form after the addition of Tissue Factor (historically  known as tissue thromboplastin), 
phospholi pid,and calcium to decalcified, platelet -poor plasma. The test is sensitive for 
deficiencies of Factors II, V, VII, and X, with sensitivity  being best for Factors V, VII, and X 
and less pronounced for Factor II. Prothrombin time and the normalized version, international 
normalized ratio, have been used to monitor warfarin therap y. It should be noted that currently , 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
65
Approved , Date: 11 September 20173types of PTreagents are used: recombinant thromboplastins, tissue thromboplastins (which are 
usually  from rabbit brain or human placenta), or combined thromboplastins 
(tissue thromboplastin diluted into fibrinogen). These reagents differ in factor sensitivity , heparin 
responsiveness, lot -to-lot consistency ,and absolute value of the clotting times.
Activated Partial Thromboplastin Time
Activat ed partial thromboplastin time is a measure of the intrinsic and final common pathway s of 
the coagulation cascade. Itrepresents the time, in seconds, for plasma to clot after addition of 
phospholipid, an intrinsic pathway  activator ,and calcium. The name 'Activated Partial 
Thromboplastin Time’ comes from the original form of the test in which only the phospholipid 
concentration of the test was controlled (as opposed to the phospholipid and the surface activator 
concentrations) and the name 'partial thromboplastin' was applied at the time to phospholipid 
preparations that accelerated clotting but did not correct the prolonged clotting times of 
hemophilic plasma. The term 'partial' means phospholipid is present but no tissue f actor. The 
normal and reference ranges vary depending on reagent and instrument combinations, 
particularl y with the phospholipid composition. I t is used to evaluate the coagulation Factors XII, 
XI, IX, VIII, X, V, II (prothrombin), and I (fibrinogen) as well as prekallikrein and high 
mole cular weight kininogen. Heparin and direct thrombin inhibitors, including hirudin, 
argatroban, and dabigatran have a neffect on the assay .
D-dimer
The various states of coagulation activation that occur in vivo lead to the production of thrombin 
and then, fibrin. What follows is a reactive fibrinoly sis, during which plasmin breaks down 
fibrin. The D-dimer is the ultimate degradation product of fibrin. The presence of D-dimer in 
plasma is an indirect marker of a coagulation activation followed by a reactive thrombol ysis. 
Increased levels can be found in patients with DVT , PE, disseminated intravascular coagulation, 
hemorrhages, surgery , cancers ,and severe infections. The D-dimer assay  is an enz yme 
immunoassay  procedure for the quantitative determination of D -dimer. 
9.5. Pharmacokinetic/Pharmacody namic Evaluations
The PD variables that will be evaluated for possible PK/PD relationships are TT, PT, and aPTT
(refer to Section 9.4, Pharmacod ynamic/Biomarker Evaluations fora description of the 
PDvariables) . The PK of JNJ-64179375 tobe used as predictor variables areCmaxand AUC inf
(butnot limited to) obtained by population PK analy sisas described in Section 9.3.3 , 
Pharmacoki netic Parameters. The relationship between TT, PT, and aPTT and plasma exposure 
metrics (Cmaxand AUC inf) will be evaluated using models that will further be detailed in a 
separate population PK model ingplan. 
9.6. Health Resource Utilization
Health resource utilization data, associated with medical encounters, will be collected in the 
eCRF by the investigator and study -site personnel for all subjects throughout the study . 
Protocol -mandated procedures, tests, and encounters are excluded. Key parameters of healt hcare 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
66
Approved , Date: 11 September 2017resource utilization will be collected for all subjects and compared between the treatment groups. 
The data collected will include the following :
Total length of initial hospitalization and length of stay for each specialized unit by level of 
care (eg,ward t ype, intensive care unit and cardiac care unit stays )
Rehospitalization for any reason through 18 weeks of follow up
Any scheduled and unscheduled visits to healthcare providers for study  outcomes, any other 
medical reasons, and diagnostic procedu res used in relati on to study  outcomes through 
18weeks of follow up
Discharge destination from the initial or subsequent hospitalization(s) (eg, home, 
rehabilitation)
Details related to the management of any  bleeding complications, (eg, procedures, extension 
of hospital stay , blood and/or plasma products)
Details regarding the management of subjects who develop s ymptomatic VTE
9.7. Safety  Evaluations
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provide d in the Time and Events Schedule :adverse events, including serious adverse 
events, adverse events of special interest (ie, bleeding events, infusion reactions, hypersensitivity  
reactions , and wound or joint complications ), clinical laboratory  tests (ie,hematology , clinical 
chemistry , urinaly sis), vital signs measurements (blood pressure, pulse/ HR, temperature) , and 
physical examinations. Safet y evaluations may also be performed at unscheduled time points, if 
deemed by the investigator or appropriate designee as necessary  to ensure the safety  of the 
subject.
Any clinicall y relevant changes occurring during the study  must be recorded on the adverse 
event section of the eCRF.
Any clinically  significant abnormalities persisting at the end of the study/earl y withdrawal will 
be followed b y the investigator until resolution or until a clinically  stable endpoint is reached.
9.7.1. Adverse Events
Adverse events, including serious adverse events, will be reported by the subject (or, when 
appropriate, by a caregiver, surro gate, or the subject's legall yacceptable representative) for the 
duration of the study . Adverse events will be followed by the investigator as specified in 
Section 12, Adverse Event Reporting.
All adverse event s, whether serious or nonserious, will be reported from the time a signed and 
dated ICF is obtained until the completion of the subject’s last study -related procedure. Refer to 
Section 12.3.1 , All Adverse Events for additional details.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
67
Approved , Date: 11 September 2017Any wound or joint complications occurring after the TKR surgery  will be specificall y evaluated
as described in Section 9.7.2.3 , Wound or Joint Complications . In addition, knee joint range of 
motion will be evaluated at Week 18as described in Section 9.7.6, Phy sical Examination .
9.7.2. Adverse Events of Special Interest
In this study , adverse events of special interest are:
Bleeding events (Section 9.7.2.1 , Bleeding Events)
Infusion orhypersensitivity  reactions (Section 9.7.2.2 , Infusion orHypersensitivity 
Reactions)
Wound or joint complications (Section 9.7.2.3 , Wound or Joint Complications)
As previousl y noted in Section 9.2, Efficacy  Evaluations, all suspected symptomatic efficacy
(thrombotic) events will also be capture d as adverse events of special interest.
9.7.2.1. Bleeding Events
9.7.2.1.1. Classification of Bleeding Events
All subjects will be observed for signs and symptoms of bleeding events throughout the study 
and at each study  visit as indicated in the Time and Events Schedule.
The investigator’s classification ofbleedi ng events according to the protocol classification will 
be collected in the eCRF (refer to Attachment 2).In addition, Guidelines for Reporting Bleeding 
Event Verbatim Terms will be provide d as noted inSection 15, Study -Specific Materials.
Additional information, including but not limited to the list below, will be collected for subjects 
with bleeding events and entered into the eCRF:
Location of the bleeding
Provocation of the bleeding
Association with anyprocedure
Action taken regarding the study  drug
Concomitant or additional treatment given for this bleeding event
Any associated h emoglobin (and/or hematocrit) levels
Any associated b lood tran sfusions and products
Hospitalization (or prolonged hospitalization) due to bleeding events
Outcome
All available information related to the classification of bleeding events will be collected and 
adjudicated by the independent CEC (refer to Section 11.11.4 , Clinical Events Committee for 
additional details).
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
68
Approved , Date: 11 September 20179.7.2.1.2. Approach to Subjects With a Bleeding Event
There is no antidote for either study  drug. If a subject has a bleeding event requiring intervention 
during the st udy, the following measures should be considered for both study  drugs :
Discontinue the study  drug (refer to Section 10.2, Discontinuation of Study  Drug /
Withdrawal from the Study )
Usual treatment measures for bleeding events, including local pressure, fluid replacement 
and hemod ynamic support, blood transfusion, and fresh frozen plasma, if physical 
examination and laboratory  testing suggest that benefit could be obtained
Other causes besides antithrombotic medica tion can be contributory  to the seriousness of the 
bleeding event (ie, rule out disseminated intravascular coagulation, thrombocy topenia, and 
other coagulopathies, kidney  and liver dysfunction, concomitant medications) and should be 
treated accordingl y
Depending on local availability , consultation with a coagulation expert should be considered
If bleeding cannot be controlled by  these measure s, consider administration of 1 of the following 
procoagulants according to the dosages and dosing schedules that arerecommended in their 
respective package inserts (Note: consultation with a coagulation expert is recommended before 
use):
PCC
Activated PCC
Factor VIIa
Of note, protamine sulfate and vitamin K are not expected to affect the anticoagulant activity  of 
eithe r study  drug. In a rat-tail transection bleeding model, Beriplex (4-factor PCC) and FEIBA 
(activated 4-factor PCC) returned bleeding times to control levels while TXA and activated 
Factor VIIa (NovoSeven) did not shorten the bleeding times after dosing with JNJ-64179375 at 
the doses studied. See Section 1.1.2.3 , Parts 2 and 3 for reversal of PD effects for JNJ -64179375. 
Reversal of thePD effects of apixaban , as demonstrated by changes in the thrombin generation 
assay , was evident at the end oftheinfusion and reached baseline values within 4 hours after the 
start of a 30-minute infusion of 4-factor PCC in healthy  subjects. However, there is little clinical 
experience with the use of 4-factor PCC products to reverse bleeding in individuals who have 
received apixaban . Currently ,there is no experience with the use of recombinant Factor VIIa in 
individuals receiving apixaban. 
Due to its high molecular weight, JNJ-64179375 is not expected to be dialy zable. Hemodial ysis
decreased the AUC of apixaban by 14% in subjects with end-stage renal disease when a single 
dose of apixaban 5 mg was administered orally. Therefore, hemodial ysis is unlikely  to be an 
effective means of managing anoverdose with apixaban or to manage bleeding with 
JNJ-64179375 .8
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
69
Approved , Date: 11 September 2017In those cases where approaches to reduce the blood levels of the study  drug are being 
considered:
In healthy  subjects, administration of activated charcoal 2 and 6 hours after ingest ion of a 
20-mg dose of apixaban reduced mean AUC of apixaban by 50% and 27%, respectivel y, and 
had no impact on Cmax.·The mean half-life of apixaban decreased from 13.4 hours when 
apixaban was administered alone to 5.3 hours and 4.9 hours, respectivel y, when activated 
charcoal was administered 2 and 6 hours after apixaban. Therefore , administration of 
activated charcoal may be useful in the management of an overdose with apixaban or 
accidental ingestion.8
JNJ-641 79375 has a plasma half-life of approximately  25 days as estimated from 
preliminary  PK data in healthy  subjects. Administration of IV immunoglob ulins would be 
expected to increase the clearance of JNJ-64179375 by saturation of neonatal Fcreceptors. 
A therapeutic plasma exchange to remove JNJ-64179375 could also be considered 
(estimated removal would be about 60% to 70% with 1 plasma volume exchange ).33
9.7.2.2. Infusion orHypersensitivity Reactions
Infusion reactions or hypersensitivity reactions (eg, anaphy laxis, u rticaria, dyspnea, hy potension) 
have been observed with the administration of monoclonal antibodies and may occur at any time 
during the administration of the IV study  drug or within the first few hours after administration. 
Serum sickness -like reactions (also known as delay ed hypersensitivity reactions) have been 
observed between 1 to 14 days after treatment. Sy mptoms associated with these reactions include 
fever, rash, headache, sore throat, myalgia, polyarthralgia, hand and facial edema, and/or 
dysphagia.
The IV study  drug must not be administered to individuals with known or suspected intolerance 
or hypersensitivity  to any biologic medication or known allergies or clinically  significant 
reactions to murine, chimeric, or human proteins, monoclonal antibodies or antibody  fragments, 
or to any of the excipients of the JNJ-64179375 formulation used in this study (refer to 
Section 4.2, Exclusion Criteria ).
A ph ysician mu st be immediately  available at the site at all times during the administration of the 
study  drug infusion as noted in Section 6, Dosage and Administration . All subjects will be 
carefully  observed for symptoms ofan infusion reaction during the infusion and for at least 
90minutes after the start of the IV infusion and for the development of any allergic reaction 
during the study . The investigator should use clinical judgment in assessing the intensity  of any 
infusion reactions. If an infusion reaction is observed, treatment such as oral 
paracetamol/acetaminophen and/or oral antihistamines may be administered. Details regarding 
the infusion reaction, including an y medications administered, should be captured in the eCRF.
The following precautions should be applied during a stud y infusion:
Before an infusion is started, the appropriate personnel, medications (eg, epinephrine , 
inhaled -agonists, antihistamines, and corticosteroids), and other requirements to treat 
allergic reactions, including anaphy laxis, must be readil y available .
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
70
Approved , Date: 11 September 2017If a subject has a moderate or severe infusion reaction, the infusion should be terminated 
immediately  and the subject should be treated appropriatel y according to institutional 
guidelines .
Subjects discontinuing the study  drug due to an infusion reaction will be asked to return for 
required assessments at all scheduled visits through the Week 18visit. Refer to Section 10.2, 
Discontinuation of Study Drug /Withdrawal from the Study  foradditional details regarding 
subject discontinuation.
9.7.2.3. Wound or Joint Complications
All subjects will be observed for signs and symptoms of wound or joint complications 
throughout the study  and at each study  visit as indicated in the Time and Events Schedule . The 
wound will be evaluated by the investigator for any abnormal bleeding, swelling, redness, 
drainage, or infection. Any joint complications such as bleeding/hematoma, infection, or 
prosthesis malfunction (eg,limited range of motion) will also be recorded as adverse events of 
special interest. Any medical or surgical treatments for wound or joint complications will be 
recorded as well .
9.7.3. Clinical Laboratory  Tests
Blood samples for serum chemistry and hematology  anda urine sample for urinal ysiswill be 
collected. The investigator or appropriate designee must review the laboratory  results, document 
this review, and record any clinically  relevant changes occurring during the study  in the adverse 
event section of the eCRF. The laboratory  reports must be filed with the source documents.
At screening, the investigator will need to determine that the subject is medically  appropriate for 
postoperative anticoagulant prophy laxis on the basis of clinical laboratory  tests perfo rmed as part 
of local standard -of-care as part of screening for elective TKR surgery and as part of standard
postoperative care following surger y.Hematology  and chemistry  laboratory  tests and a urine 
sample for urinal ysiswill be obtained before dosing (0 hour ) and performed by the central 
laboratory. The following tests will be performed by the central laboratory :
Hematology  Panel
-hemoglobin -platelet count
-hematocrit -mean corpuscular hemoglobin 
(MCH)
-red blood cell (RBC) count -mean corpuscular hemoglobin 
concentration (MCHC)
-WBC count with differential Mean corpuscular volume (MCV)
Note: A WBC evaluation may  include any  abnormal cells, which will then be reported by  
the laboratory . A RBC evaluation may  include abno rmalities in the RBC count, 
RBC parameters, or RBC morphology , which will then be reported by  the laboratory .
In addition, any  other abnormal cells in a blood smear will also be reported.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
71
Approved , Date: 11 September 2017Serum Chemistry  Panel
-sodium -alkaline phosphatase
-potassium -creatine kinase (CK) with myocardial band
fractionation, if elevated
-chloride -lactic acid deh ydrogenase (LDH)
-bicarbonate -uric acid
-blood urea nitrogen (BUN) -calcium
-creatinine -phosphate
-glucose -albumin
-aspartate aminotransferase (AST) -total protein
-alanine aminotran sferase (ALT) -cholesterol
-gamma -glutam yltransferase (GGT) - triglycerides
-total,direct andindirect bilirubin -magnesium
-globulin
Urinaly sis
Dipstick Sediment (if dipstick result is
-specific gravit y abnormal)
-pH -RBCs
-glucose -WBCs
-protei n -epithelial cells
-blood -crystals
-ketones -casts
-bilirubin -bacteria
-urobilinogen
-nitrite
-leukocy te esterase
If dipstick result is abnormal, flow cy tometry  will be used to measure sediment. I n case of 
discordance between the dipstick r esults and the flow cy tometric results, the sediment will 
be examined microscopically .
9.7.4. Electrocardiogram
A 12-lead ECG will be performed during screening . During the collection of ECGs, subjects 
should be in a quiet setting without distractions (eg, tele vision, cell phones). Subjects should rest 
in a supine position for at least 5minutes before ECG collection and should refrain from talking 
or moving arms or legs. If blood sampling or vital signsmeasurement sarescheduled for the 
same time point as ECG recording, it is recommended that the procedures be performed in the 
following order: ECG, vital signs, and blood draw.
9.7.5. Vital Signs ( temperature, heart rate, blood pressure)
Vital signs measurements will be obtained at the time points indicated in the Time and Events 
Schedule.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
72
Approved , Date: 11 September 2017Blood pressure and pulse/HR measurements will be assessed with subjects in the supine position
with a completel y automated device. Manual techniques will be used only  if an automated device 
is not available. Single measurements at eac h time point will be made. However , if any  clinically  
significant abnormal values are detected (systolic blood pressure >160 or <90 mmHg, diastolic 
blood pressure >100 mmHg, HR<40 or >100 beats per minute) then repeat measurements will 
be performed at the discretion of the investigator .
Blood pressure and HRmeasurements should be preceded by at least 5 minutes of rest in a quiet 
setting without distractions (eg, television, cell phones).
The subject’s temperature should also be obtained.
9.7.6. Physical Examina tion
The physical examination consists ofa routine medical examination that includes general 
appearance and a review of the following systems: neurologic , eyes/ears/nose/throat, thyroid, 
cardiovascular, respiratory , abdominal/gastrointestinal, hepatic, musculoskeletal, and 
dermatologic. Any bleeding observed during the exam ination (eg, skin, gingiva, nares) will be 
recorded as apotential bleeding event as described in Section 9.7.2.1.1 , Classification of 
Bleedi ng Events .Additional body  systems or further detailed physical examinations 
(eg,rectal examinations) should be performed if considered clinically  appropriate by the 
investigator. Physical examinations will be performed by the investigator or a designated health 
care professional who is licensed and/or certified in accordance with applicable local laws to 
perform ph ysical examinations.
Height and weight should be obtained at the screening visit, with weight only on Day -1or prior 
to dosing on Day 1 and t he final visit. Scales used should be calibrated according to the standard 
operating procedures at the study  site to assure weight is accurate.
The physical examination will be conducted at thetime points indicated in the Time and Events 
Schedule. An assessment of the wound will be made at all visits as part of the adverse event 
assessment and the final physical examination will assess the range of motion of the operated 
joint. Anynew, clinically  significant finding s(in the opinion of the investigator) that were not 
noted at the time of the screening visit must be captured as adverse events and will befollowed 
to resolution.
9.8. Sample Collection and Handling
The actual dates and times of sample collection must be recorded on thelaboratory  requisition 
form. If blood samples are collected via an indwelling cannula, an appropriate amount (1 mL) of 
serosanguineous fluid slightl y greater than the dead space volume of the lock will be removed 
from the cannula and discarded before each blood sample is taken. After blood sample 
collection, the cannula will be flushed with 0.9% sodium chloride, United States Pharmacopeia 
(USP) (orequivalent) and charged with a volume equal to the dead space volume of the lock. 
Blood samples for PK and PD assessments on Day 1  post dosing should be collected in the 
opposite arm as the infusion of JNJ- 64179375 or placebo.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
73
Approved , Date: 11 September 2017Refer to the Time and Events Schedule for the timing and frequency  of all sample collections.
Instructions for the collection, handling, storage, and shipment of all blood and urine samples are 
found in the separate laboratory  manual that will be provided. Collection, handling, storage, and 
shipment of samples must be under the specified, and where applicable, controlled temperature 
conditions as indicated in the labora tory manual.
10. SUBJECT COMPLETION/ DISCONTINUA TION OF STUDY DRUG / 
WITHDRA WALFROM THE STUDY
10.1. Completion
A subject will be considered to have completed the study  if he or she has completed the 
Week 18visit of the follow -upphase.
Subjects who prematurely discontinue the study  drug for any reason before completion of the 
double -blind dosing phase will be considered to have completed the study  if they  have completed 
the Week 18visit.A subject who dies will be considered to have completed the study .
10.2. Discontinua tion of Study Drug/Withdrawal from the Study
It is imperative for the integrit y of the study and results to have complete data. If a subject 
withdraws from the study  before the end of thefollow -up phase andis unwilling or unable to 
return for follow -up v isits in person, the study site should collect as much follow -up visit 
information as possible, bycontacting the subject by telephone or by mail. If applicable, vital 
status may  be obtained by  reviewing the subject’ s medical or public records unless this contact is 
not permitted per local regulations.
Study  drug assigned to a subject that discontinues study  drug or withdraws may not be assigned 
to another subject. Subjects who withdraw will not be replaced.
Discontinuation of Study Drug
A subject will not be automatically  withdrawn from the study  if he or shehasto discontinue the 
study  drug before the end of the double -blind dosing phase .
Subjects who discontinue the study  drug before the end of the double -blind dosing phase willbe 
instructed to return to the study  site, if possible, to conduct assessments, including venograph y 
assessments of the operated leg as described in Section 9.1.3 , Double -Blind Dosing Phase. If a 
subject withdraws from the study  before the end of the double -blind dosing phase, EOD and 
follow -up assessments should be obtained.
A subject's study drug must bediscontinue d for any  of the following reasons :
The investigator believes that for safet y reasons or tolerability  reasons (eg,adverse event) it 
is in the best interest of the subject to discontinue study drug
The subject requests to discontinue the study  drug permanentl y
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
74
Approved , Date: 11 September 2017Development of any condition that requires open -label treatment with an anticoagulant or 
other prohibited medication
Bleeding into a critical site, (eg, intracranial, intraspinal, intraocular, pericardial,
intra-articular, intramuscular with compartment sy ndrome, retroperitoneal )
Active uncontrolled hemorrhage
At the (exceptional) request of the sponsor
Withdrawal From t he Study
A subject will be withdrawn from the stud y for any of the following reasons:
Lost to follow up
Withdrawal of consent
Withdrawal of consent should be a very unusual occurrence in a clinical study . Subjects 
who elect to stop the study  drug are not automatically  considered to have withdrawn 
consent. The investigator should make every  effort to maintain a good relationship with 
subjects to avoid this occurrence. The recording of withdrawal of consent in the eCRF for 
this study will occur after a discus sion between the investigator and the appropriate sponsor 
representative has taken place.
At the time of signing the ICF, a subject will agree to be contacted to obtain poststudy  drug 
follow -up information should he or she decide to withdraw from the study . If a subject 
withdraws from the study before the end of the follow -up phase and is unwilling or unable to 
return for follow -up visits in person, he or she should be contacted and the study  site should 
collect as much follow -up information as possible. This includes contacting the subject or the 
subject’s alternative means of contact (eg, subject’s children, spouse, significant other, caretaker, 
legal representative or health care professional) , by telephone or mail to determine vital status 
and if an endp oint event has occurred, as agreed to by the subject during the initial informed 
consent process. If applicable, vital status may  be obtained by reviewing the subject’s medical or 
public records, unless this process is not allowed by local regulations.
For subjects who withdraw consent and are not agreeable to any follow -up contact, it is 
recommended that the subject withdraw consent in writing, and the subject will be asked to 
supplement the withdrawal of consent with a signed written statement documentin g refusal from 
all subsequent contact. If the subject refuses or is physically  unavailable, the study  site should 
document and sign the reason for the subject’s failure to withdraw consent in writing and 
maintain it with the subject’s source records.
When a subject withdraws consent before completing the study , it is not required for he/she to 
give a reason. If the reason for the withdrawal is known, it should be documented in the eCRF 
and in the source document.
If a subject is lost to follow up, every  reasonable effort must be made by  the study -site personnel 
to contact the subject and determine their status andthe reason for discontinuation/withdrawal , 
including the possible use of locator agencies to determine vital status, as local law permits. The 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
75
Approved , Date: 11 September 2017measures taken to follow up must be documented .A subject will be considered lost to follow up 
only after all means of all subsequent contact have been exhausted .
11. STATISTICA L METHODS
Statistical analy sis will be done by the sponsor or under the authority  of the sponsor. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in astatistical analy sis plan (SAP), which will be 
prepared for Part 1 before the first subject is consented forPart 1.For Part 2, a draft SAP will be 
prepared before the first subject is consented into Part 1 andanupdated Part 2 SAP based on the 
Part 1 data will be prepared before the first subject is consented in Part 2.
In Part 1, the intent is to escalate across the planned doses (0.3 to 0.6 to 1.2 mg/kg) of 
JNJ-64179375 based on the OC review of the totality  of the data but with a focus onbleeding 
events .Specific analy ses to be reviewed (eg, continual reassessment or escalation with overdose 
control methods) and dose-escalation decision guidel ines will be included in the OCcharter. 
After all subjects are expected to have completed the Day 10-14 visit forPart 1, an unblinded 
data review is planned and the selection of the dose range and doses for Part 2 will be based on 
the evaluation of the totality  of the data but with a focus onthe any bleeding and total VTE 
endpoints. Analy ses to aid in dose selection will be prespecified in the OC charter and the Part 1 
SAP. No formal hy pothesi s testing is planned for Part 1 due to the limited sample size. Historical 
apixaban bleeding and VTE event rates may  also be considered in making decisions. 
In Part 2, this study  will use an adaptive design intended to optimize data collection for 
dose-response modeling. In Part 2, the primary  goal is to assess the efficacy  (total VTE endpoint) 
dose-response relationship of JNJ-64179375. A hybrid methodology  that combines aspects of 
multiple testing with modeling techniques ( MCP -Mod) will be used for evalu ating dose -response 
trends and estimating the dose-response relationships for the efficacy and bleeding endpoints for 
JNJ-64179375 .2,3,25The sample size for Part 2 may be adjusted based on the observed bleeding 
and total VTE event rates in Part 1. Additional details are provided in Section 11.3, Efficacy  and 
Bleeding Analy ses.
If a sufficient number of JNJ-64179375 doses (ie,4 or more) are studied in Part 2 then dose-
response modeling using the MCP -Mod approach will be the primary  analysis strategy . If the 
number of JNJ-64179375 doses is not sufficient to support the MCP -Mod approach then linear 
dose-response modeling (if 3 doses are studied), or pairwise comparisons (if 2 doses are studied),
will be the primary analysis strategy . 
An unblinded data review is planned forPart 1 after all subjects are expected to have complete d
the Day 10-14 visit to determine the dose range and doses of JNJ-64179375 for Part2. Two 
planned, unblinded interim analy sesand 1 unblinded administrative interim anal ysisare intended
for Part 2 of this study . Refer to Section 11.10 , Interim Anal yses for further details.
11.1. Analysis Datasets
The2 elements that define an analy sis data set are: 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
76
Approved , Date: 11 September 2017The anal ysis population, which specifies those subjects who will be included in an anal ysis
The observation period, which specifies the time window within which data will be included 
in an anal ysis
Efficacy Analyses
Two populations will be used in the efficacy  anal yses:
Modified Intent to Treat (ITT): all randomized subjects with an evaluable venograph y 
assessment or a confi rmed sy mptomatic VTE event ,or any death.
Efficacy  Per Protocol: all randomized subjects with no major protocol deviations (to be 
defined in the SAP) and an evaluable venograph y assessment within 24hours after the last 
dose of the oral study  drug or with confirmed symptomatic VTE within 2 days of the last 
dose of oral study  drug,or any death within 2 days of the last dose of oral study  drug. 
Subjects without symptomatic VTE or death must also have received the single complete 
infusion of JNJ -64179375 or a t least 18 doses of oral apixaban.
The 2 observation periods to be used in the efficacy anal yses include the following:
Up to Day  10-14 visit (venograph yassessment )
Up to the Week 18 visit
The primary  efficacy  endpoint analy sis (total VTE) will use the modified ITT population up to 
the Day  14 observation period. Additional details will be provided in the SAP.
Bleeding Event Analyses
Two populations will be used in the bleeding event analy ses:
Safety : all randomized subjects who received at least 1 dose (partial or complete) of active 
study  drug
Safety  Per Protocol: all randomized subjects with no major protocol deviations who received 
the single complete infusion of JNJ -64179375 or at least 18doses of oral apixaban or with a 
bleeding event centrally  adjudi cated by the CEC within 2 days of the last dose of oral study  
drug
The 3 observation periods to be used in the bleeding event anal yses include the following:
Up to Day  10-14 visit (venograph yassessment )
Up to the Week 5 visit
Up to the Week 18 visit
The primary  bleeding event analy sis (any bleeding ) will use the safet y population up to the 
Day 10-14visit observation period.
11.2. Sample Size Determination
A total of 1,500 subjects are planned for this study , of which up to 300 subjects will be enrolled 
in Part 1and the remainder for the entire study  will be enrolled in Part 2.In Part 1, thesample 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
77
Approved , Date: 11 September 2017size is not based on hypothesis testing but rather on making a preliminary  assessment of the 
bleeding risk for the doses of JNJ-64179375 . The event rate of anybleed ing up to 14 daysfor 
apixaban 2.5 mg twice daily is expected to be between 5%and 10%. Figure 2shows the 
probability to flag a higher event rate compared to apixaban for anydose of JNJ-64179375 in 
Part 1, assuming that the trueunderl ying bleeding event ratein the apixaban group is 5%, 7.5%, 
or 10%. The figure presents the numbers of subjects in the JNJ-64179375 and apixaban 
treatment groups in rows and columns, respectivel y. The assumed event rate in the 
JNJ-64179375 group is presented as the relative risk to apixaban in the horizontal axis; the 
statistical comparison is based on the difference between event rates.
When the true underl ying event rate in the apixaban group is 7.5%, there is a 67% probability  for
a dose of JNJ-64179375 to have the lower bound of the 1-sided 90% CI for between- treatment 
difference exclude 0 ifthe true relative risk(or risk ratio) is 3(ie, the true underl ying event rate 
in the JNJ-64179375 group is 22.5%) ,with 40subjects in the JNJ-64179375 group (ie, any 
1planned cohort of JNJ-64179375 subjects) and 30 subjects in the apixaban group (ie, pooled 
apixaban subjects from 3planned cohorts) . The probability  will increase to 81% when the dose 
of JNJ-64179375 is repeated in another planned or optiona l cohort, where there will be 80 
subjects in the JNJ -64179375 treatment group and 40 subjects in the pooled apixaban group.
Figure 2: Probability to Flag a Higher Event Rate in the JNJ -64179375 Group Than in the Apixaban 
Group at a 1-Sided, 10% -Level
JNJ-9375=JNJ -64179375
In Part2,it is anticipated that 10% to 20% of subjects will either not have the venograph y 
assessment of the operated leg performed as scheduled or will not have an evaluable venograph y 
assessment for any DVT or proximal DVT. Assuming that 80% of venograph y assessments are 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
78
Approved , Date: 11 September 2017evaluable and the true underly ing total VTE event rates are 15%, 10%, 8%, and 6% at potential 
doses of JNJ-64179375 of 0.3, 0.6, 0.9, and 1.2mg/kg, respectivel y, with a total sample size of 
1,200 subjects, the study  is expected to have over 90% power to declare proof -of-efficacy , which 
is defined as either a statistically  significant dose-response trend or atotal VTE event rate lower 
than 30% in the pooled doses of JNJ-64179375 a t a 1-sided, 2.5% -level. The exact power will 
vary because of the nature of the adaptive study  design.
For comparison with apixaban in Part 2, if the true underl yingtotal VTE and any bleeding event 
rates are as specified in Table 7, a simulation study  demonstrates that there will be approximately 
90% probability  to identify  a dose within the dose range of 0.3to1.2mg/kg, of which both the 
model -predicted total VTE and any bleeding event rates met the prespecified noninferiority  (NI) 
criterion (the upper bound of the 1-sided 90% CI for the odds ratio [JNJ-64179375 to apixaban]
is equal to or lower than 1.5 for total VTE and any  bleeding events).
Table 7: Assu med Efficacy and Safety Event Rates by Treatm ent Group i n Sample Size Determination
for Part 2
JNJ-64179375 Apixaban
0.3 m g/kg 0.6 m g/kg 0.9 m g/kg 1.2 m g/kg 2.5 mg bid
Total VTE
(Efficacy) 15% 10% 8% 6% 15%
Any Bleeding
(Safety) 5% 6% 7% 8% 8%
bid=tw ice daily ; VTE=venous thromboembolism
11.3. Efficacy  and Bleed ing Analyses
A dose-response trend will be assessed with respect to the primary  efficacy (total VTE) and 
safet y (any bleeding) endpoints in Part 2. Depending on the number of doses studied, aset of up 
to 7candidate models (doses are in logarithm scale) will be used to cover a suitable range of 
possible efficacy  dose-response shapes (linear, E max, exponential, sigEmax1, sigEmax2, 
sigEmax3 , and sigEmax4) (see Figure 3). 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
79
Approved , Date: 11 September 2017Figure 3: Candidate Models for Total VTE (Efficacy)
sigEm ax 2 sigEm ax 3 sigEm ax 4Linear Emax Exponent ial sigEm ax 1
0.3 0.60.91.21.80.3 0.60.91.21.80.3 0.60.91.21.80.3 0.60.91.21.8510152025
510152025
Dose (mg/kg)Event Rate (%)
VTE=venous thromboembolism
Similarly , a set of up to 6 candidate models will be used to cover a suitable range of safety dose-
response shapes (linear, E max, exponential, sigEmax1, sigEmax2 , and sigEmax3 ) (seeFigure 4). 
The set of safet y candidate models used will be similarly  chosen as for the efficacy  candidate 
models, which is dependent on the number of doses studied in Part 2.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
80
Approved , Date: 11 September 2017Figure 4: Candidate Models for Any Bleeding (Safety)
sigEm ax 1 sigEm ax 2 sigEm ax 3Linear Emax Exponent ial
0.3 0.60.91.21.80.3 0.60.91.21.80.3 0.60.91.21.846810
46810
Dose (mg/kg)Event Rate (%)
Each of the dose-response shapes in the candidate set will be tested using the corresponding 
contrast t-test statistic, employ ing a critical value derived for the maximum of the t-test statistics 
(based on the associated multivariate t-distribution) to ensure appropriate multiplicity  correction 
that preserves the Type Ierror rate. A dose-response trend is established for anendpoint when 
the maximum of the t-test statistics for the corresponding endpoint exceeds the critical value .
Predicted event rates at a specific dose will be derived for each candidate model. The weighted 
average ofthese predicted event rates (weights are determined by the model goodness -of-fit), 
will then be used to estimate the target dose.4,16The minimum dose that meets the NIefficacy  
criterion (defined as the upper bound o f the 1-sided 90% CI for model -predicted 
JNJ-64179375/apixaban odds ratio less than 1.5) is considered as the minimum effective dose. 
The highest dose to be considered to proceed is the maximum dose that meets the NIsafety
criterion (defined as the upper bound of the 1-sided 90% CI for model -predicted 
JNJ-64179375/apixaban odds ratio less than 1.5). Any dose between the minimum effective dose 
and the highest dose to proceed is considered an eligible dose to befurther studied in a 
subsequent study(ies). The final dose selection will be based on the consideration of the total 
benefit -risk balance. 
The determination of the NI criterion above is based on 2 considerations: 1) distribution of the 
point estimate for the odds ratio for the given sample size when the NI criterion is met; and 
2)the balance between the false -positive rate (incorrectl y conclude an inferior dose to be 
compar able to apixaba n) and the false -negative rate (incorrectly  conclude an efficacious dose to 
be inferior to apixaban). With the given sample size and event rates as specified in Table 7, the 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
81
Approved , Date: 11 September 2017median corresponding odds ratio in 10,000 simulated studiesis approximately 1.0for total VTE 
and 0.94 for any  bleeding .With the same assumptions , these NI  criteria will yield approximately 
90% probability  to correctly  identify  an eligible dose for subsequent study (ies).
The details of the adaptive decision guidelines for adding and/or dropping treatment groups or 
changing the randomization ratio in Part 2 will be specified in the IDMC charter and the
Part2SAP.
Prespecified clinical variables of interest for the efficacy  subgroup analyses include region, age, 
sex, weight/body  mass index, renal function, surgery  duration, TXA use, tourniquet use, and 
mechanical VTE prophylaxis device use. The same variables will be used for safet y subgroup 
analyses with the addition of aspirin/NSAID use.
11.4. Pharmacokinetic A nalyses
Plasma concentrations of JNJ-64179375 will be listed for all subjects by time of collection and 
dose level. For each dose, descriptive statistics, including mean, median, standard deviation
(SD) , and coefficient of variation will be calculated for the plasma concentrations at each 
nominal sampling time.Plasma concentrations of JNJ-64179375 versus time profiles will be 
plotted for each subject based on actual sampling times, and mean concentration versus time 
profiles will be plotted for each dose level based on planned sampling times. 
Data will be listed for all subjects with available plasma concentrations per treatment group. 
Subjects will be excluded from the PK analy sis if their data do not allow for accurate assessment 
of the PK (eg, incomplete administration of the study  drug; missing information of dosing and 
sampling times; concentration data not sufficient for PK parameter calculation).
All plasma concentrations below the lowest quantifiable concentration or missing data will be 
labeled as such in the concentration database. Concentrations below the lower quantifiable 
concentration will be treated as zero in the summary  statistics. All subjects and samples excluded 
from the anal ysis will be clearl y documented in the study report.
In addition, a population PK model will be developed and the dependence of PK of 
JNJ-64179375 on population covariates (eg, demographics, laboratory  variables) will be 
evaluated. This will be performed using nonlinear mixed -effects modeling with the software 
package NONM EM. The mean (and variance) values for specific PK parameters (eg,CL and 
Vz)will be estimated and the statistical significance of the relationships between the covariates 
and PKparameters will be evaluated. The results of this population PK (PK paramet ers 
signify ing relationship between PK and various covariates) analysis will be reported separatel y, 
in a document other than the CSR.
11.5. Immunogenicity  Analyses
The incidence of antibodies to JNJ-64179375 will be summarized for all subjects who receive a 
dose of JNJ-64179375 and have at least 1 appropriate sample obtained after study  drug 
administration for the detection of antibodies to JNJ -64179375 .
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
82
Approved , Date: 11 September 2017Alisting of subjects who are positive for antibodies to JNJ-64179375 will be provided. The 
maximum t iters of antibodies to JNJ-64179375 will be summarized for subjects who are positive 
for antibodies to JNJ-64179375 .
Analy ses of the impact of immunogenicit yon PK, PD, PK/PD, efficacy , and safety endpoints
willbe performed to further characterize the immune res ponses that are generated.
11.6. Pharmacody namic /Biomarker Analyses
The PD parameters are TT, ECT, PT, aPTT, andD-dimer. Descriptive statistics including mean, 
median, SD, minimum, andmaximum will be provided for the PD parameters. The parameters of 
TT, PT, and aPTT may be statistically  analyzed using mixed models. The mixed model for the 
change from baseline PD parameters will include dose and visit as fixed effects and subjects as 
random effects. The least-squares means for change from baseline and associated 95% CIs will 
be provided. Other PD parameters may  be anal yzed similarly .
11.7. Pharmacokinetic/Pharmacody namic A nalyse s
The PK/PD relationship swill be investigated graphicall y and, if appropriate, may be further 
analyzed using suitable statistical methods.
Plasma PK exposures (Cmax,AUC inf, and/or time-matched concentration ) from the population 
PKmodel versus PD variables (eg, TT and aPTT) and safet y/efficacy  endpoints will be 
graphicall y examined. This can be accomplished by plotting relevant PD measures versus 
PKexposure parameters (quantiles/deciles) for preliminary  assessment and possible model 
identification. If the graphical representation of the relationship indicates possible correlation, 
then these data may be analyzed statistically  using a suitable m odel. For example, a 
mixed -effects linear model may be used to identify the possible relationship between PK and PD. 
Other models using time-matched concentrations with PD may also be used for exploring the 
relationship further, as appropriate. Other PD variable s(eg, ECT) may be analyzed in a similar 
fashion. The details of the analy ses plan will be presented in a population PK modeling plan that 
is separate from the SAP.
Preliminary  assessments of these relationships will be made available to the IDMC at both 
interim analy sesto support their evaluations.
11.8. Health Resource Utilization A nalyses
Health resource utilization will be descriptivel y summarized by treatment group.
11.9. Safety  Analyses
All safety  data will be fully listed. The reporting of the safet y data of all subjects receiving at 
least 1active dose of JNJ-64179375 or apixaban will include the incidence and type of adverse 
events , plus absolute values and changes in blood pressure (systolic and diastolic), HR, clinical 
laboratory  data, and phy sical exa minations from predose to the final postdose time point.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
83
Approved , Date: 11 September 2017Adverse Events
The verbatim terms used in the eCRF by investigators to identify  adverse events will be coded 
using the MedDRA. Treatment- emergent adverse events are adverse events with onset during t he 
treatment phase orthat are a consequence of a preexisting condition that hasworsened since 
baseline .All reported adverse events will be included in the analysis. For each adverse event , the
percentage of subjects who experience at least 1occurrence of the given event will be 
summarized by treatment group . In addition, comparisons between treatment groups will be 
provided if appropriate .
Summaries, listings, datasets, or subject narratives may be provided, as appropriate, for those 
subjects who die, w ho discontinue treatment due to an adverse event , or who experience a severe 
or a serious adverse event .
Based on the mechanism of action of JNJ-64179375 and given that it is a monoclonal antibody , 
adverse events of special interest will include bleeding events , infusion reactions,
hypersensitivity  reactions, and wound or joint complications as described in Section 9.7.2 , 
Adverse Events of Special Interest. Subjects with adverse events ofspecial interest may be 
counted or listed using MedDRA SMQs (eg,hemorrhage excluding laboratory  terms SMQ) .All 
suspected symptomatic efficacy  (thrombotic) events will also be captured as adverse events of 
special interest.
Clinical Laboratory Tests
Laboratory  data will be summa rized by type of laboratory  test. Reference ranges and markedl y 
abnormal results (specified in the Part 1 and Part 2 SAP) will be used in the summary  of 
laboratory  data. Descriptive statistics will be calculated for each laboratory  analyte at baseline 
and for observed values and changes from baseline at each scheduled time point. Frequency 
tabulatio ns of the changes from baseline will be presented in pre-versus posttr eatment 
cross -tabulations (with classes for below, within, and above normal ranges). Frequ ency 
tabulations of the abnormalities will be made. A listing of subjects with any laboratory  results 
outside the reference ranges will be provided. A listing of subjects with any markedl y abnormal 
laboratory  results will also be provided.
Vital Signs
Desc riptive statistics of temperature, HR, and blood pressure (systolic and diastolic) (supine)
values and changes from baseline will be summarized at each scheduled time point. The 
percentage of subjects with values bey ond clinically  important limits will be summarized.
Physical Examination
Descriptive statistics of changes from baseline will be summarized at each scheduled time point.
Physical examination findings will be summarized at each scheduled time point. Descriptive 
statistics will be calculated at ba seline and for observed values and changes from baseline at each 
scheduled time point. Frequency  tabulations of the abnormalities will be made.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
84
Approved , Date: 11 September 201711.10. Interim A nalyses
Two planned, unblinded interim analy ses will be conducted in Part 2 by the IDMC as part of the 
adaptive approach that will be used to guide decisions to drop and/or add doses of JNJ -64179375 
and adjust the randomization ratio based on available efficacy , safet y, PK, and PD data. The 
objectives of the interim anal yses are to :
Test futility
Test dose-response trend sto determine if the dose range being studied is appropriate for 
both efficacy  and safet y
Determine if a dose(s) should be added and/or dropped to optimize data collection for 
dose-response modeling
Determine how to allocate the remaining subjects optimally  (based on observed efficacy , 
safet y, or balanced efficacy/safet y results)
These 2 interim analy ses will be performed after approximately  400 and 800 subjects are 
enrolled and are expected to have completed the Day 10-14 visit. Depending oninterim analysis 
results, possible modification options to study  conduct are stopping the study  prematurel y for 
futility , adding/dropping a dose of JNJ-64179375 , and adjusting randomization ratio based on 
optimization of the dose -response model estimation.
Subject randomization will be balanced until the first interim analy sis. Adaptation guidelines, 
including futility , adding/dropping a dose, modification of the randomization ratio, will be 
specified in the IDMC charter and the Part 2 SAP.
Administrative Interim Analysis
An unblinded administrative interim analysisis planned to be conducted by the sponsor after all
subject sare expected tohave completed the Day 10-14 visit in Part 2 to facilitate additional 
study  planning . Details of this interim analy siswill be described in the Part 2 SAP. The conduct 
and integrity of the study will not be altered by  the results of this interim analy sis.
11.11. Committee s
11.11.1. Operations Committee
During Part 1 of the study, an OC consisting of members of the academic leadership of the study , 
including the SC and IDMC chairpersons, and clinical and biostatistics representatives from the 
sponsor (not directl y involved in study  monitoring) will review ongoing unblinded safety and 
efficacy data. The OC will be responsible for:
Reviewing ongoing safety  and efficacy  data by unblinded subject treatment assignments
approximately  every  1 to 3weeks
Determining the cohort sizes and number of cohorts for the up to approximately  300 unique 
subjects in Part 1
Making dose-escalation decisions in Part 1, including but not limited to deciding whether to 
proceed with optional cohorts and atwhat dose(s)
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
85
Approved , Date: 11 September 2017Reviewing the data forPart 1
The detail sof the OC function and composition, as well as dose-escalation decision guidelines 
will be described in the OC charter.
After all the subjects to be enrolled in Part 1 are expected to have completed the Day  10-14 visit , 
an unblinded review of available preliminary  safety , tolerability , efficacy , PK, and PD data will 
be conducted to determine the dose range and number of dose groups (maximum of 4 for 
JNJ-641793 75 and 1 for apixaban) for Part2. This Part 1 data review will be conducted by the 
OC, SC, IDMC,and the sponsor .
11.11.2. Independent Data Monitoring Committee
An unblinded IDMC will be established to monitor ongo ing safet y data in Part 2. The 
IDMC activities will include participation in the unblinded data review after all subjects in Part 1 
are expected to have completed the Day 10-14 visit to determine the dose range and doses of 
JNJ-64179375 for Part 2andtoconduct the2 planned interim analy ses,apply ingthe adaptive 
design rules forthe study as described in Section 11.10 , Interim Analy ses. The IDMC will 
consist of individuals who are not partici pating in the cond uct of the study  and will include at 
least one medical expert in the relevant therapeutic area and at least one statistician. Following 
the interim analy ses, the IDMC will be responsible for providing their recommendations for 
study  modifications to the SCand sponsor . The IDMC responsibilities, authorities, and 
procedures will be documented in a separate charter.
11.11.3. Steering Committee
A SCwith expertise in thrombosis, thromboprophy laxis , hematology , orthopedic surgery , and 
clinical studies will be commission ed to provide scientific leadership for both Parts 1 and 2 of 
the study . The SCwill be responsible for providing advice to the sponsor in an effort to ensure 
the scientific validity  and integrit y of the study  and for the publication of results. In Part 2, the 
SCwill receive recommendations from the IDMC regarding suggested modifications to the study  
based on thereview of the unblinded data by the IDMC . The sponsor, in collaboration with the 
SC, will ultimately  decide whether to accept the recommendations and will oversee the 
implementation of any  modifications, if applicable . Details regarding the composition, roles, and 
responsibilities of the SCwill be documented in a separate charter.
11.11.4. Clinical Events Committee
A CEC will be established to review, adjudicate, and classify  endpoint events in Parts 1 and 2 of 
the study  as they become available in a blinded, consistent, and unbiased manner according to 
the definitions provided in the CEC charter. Committee members will not have direct operational 
responsibilities for the conduct of the study , nor will they directly  enroll subjects or be involved 
in study  monitoring. Further details regarding the composition, roles, and responsibilities of the 
CEC will be documented in a separate charter.
The CEC will have responsibility  for reviewing, adjudicating, and classify ing the following
assessments and study  endpoint events or events that appear suggestive of a study  endpoint 
event :
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
86
Approved , Date: 11 September 2017Venograph y assessment of the operated leg
Suspected s ymptomatic DVT
Suspected s ymptom atic PE
Suspected bleeding events
Suspected MI
Suspected stroke 
Suspected peripheral arterial embolism
Death
The CEC will verify  all components of the bleeding and efficacy  endpoint events. The CEC will 
centrall y adjudicate all clinical events based on the endpoint definitions. All necessary  source 
documents will be sent to the CEC in a blinded fashion to enable adjudication and verification of 
events. The CEC -adjudicated and investigator -reported results on efficacy  and safet y outcomes 
will be provided fo r both of the interim analy ses. The CEC- adjudicated events will be used in the 
final anal ysis.
12. ADVERSE EVENT REPORT ING
Timely, accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subje cts, investigators, and the sponsor, and are mandated by 
regulatory  agencies worldwide. The sponsor has established standard operating procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
Adverse events of special interest have been identified for this study and are described in 
Section 9.7.2 , Adverse Events of Special Interest .
Method of Detecting Adverse Events and Serious Adverse Events
Care will be taken not to introduce bias when detecting adverse events or serious adverse events. 
Open -ended and nonleading verbal questioning ofthe subject is the preferred method to inquire 
about adverse event occurrence . For some studies, subjects are not alway s able to provide valid 
verbal responses to open -ended questions. In these circumstances, events will be solicited. I n this 
study , subje cts will be queried directl y to solicit potential bleeding events using general 
questions about any bleeding and specific questions about common minor bleeding events that 
could be overlooked b y the subject (eg, bruising, gingival bleeding, epistaxis).
Solicited Adverse Events
Solicited adverse events are predefined local and systemic events for which the subject is 
specificall y questioned. Inthis study , bleeding events will be solicited.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
87
Approved , Date: 11 September 2017Unsolicited Adverse Events
Unsolicited adverse events are all advers e events for which the subject is specifically  not 
questioned.
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study  subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavorable 
and unintended sign (including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (investigational or non-investigational) product, whether or not 
related to that medicinal (investigational or non-investigational) product. (Definition per 
International Conference on Harmonisation [I CH])
This includes any occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
A laboratory  test abnormality  that is considered by the investiga tor to beclinically  relevant
(eg,causing the subject to discontinue the study  drug, requiring treatment, or causing apparent 
clinical manifestations ) should be reported as an adverse event .
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Secti on12.3.1 , All Adverse Events, for time of last adverse event recording).
Serious Adverse Event
A serious adverse event based on I CH and E uropean U nion Guidelines on Pharmacovigilan ce for 
Medicinal Products for Human Use is an y untoward medical occurrence that at any dose:
Results in death
Is life threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious a gent via a medicinal product
Is Medicall y Important*
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
88
Approved , Date: 11 September 2017*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately  life threatening or result in death or hospitalization but may jeopardize the subject 
or may require intervention to prevent one of the other outcomes listed in the definition above. 
These should usually  be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study  drug and the event (eg, death from anaph ylaxis), the event must 
be reported as a serious and unexpected suspected adverse reaction even if it is a component of 
the study endpoint (eg, all -cause mortalit y).
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity  is not consistent with the 
applicable product reference safet y information. For JNJ-64179375 , the expectedness of an 
adverse event will be determined b y whether or not it is listed in the I nvestigator's Brochure.
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or v ery likel yby the definitions listed in Sec tion12.1.2 , Attribution Definitions .
12.1.2. Attribution Definitions
Not Related
An adverse event that is not related to the use of the d rug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An adverse event that might be due tothe use of the drug. An alternative explanation, 
eg,concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg,confirmed by dechallenge). An alternative explanation is less likely, eg,concomitant 
drug(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explained 
by an alternative explanation, eg,concomitant drug(s), concomitant disease(s). The relationship 
in time is very  suggestive (eg, it is confirmed b y dechallenge and rechallenge).
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
89
Approved , Date: 11 September 201712.1.3. Severity Criteria
An assessment of severity grade will be made using the following general categorical 
descriptors:
Mild : Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate : Sufficient discomfort is present to cause interference with normal activity .
Severe : Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events not direc tly 
experienced b y the subject (eg, laboratory  abnormalities).
12.2. Special Reporting Situations
Safety  events of interest on a sponsor study  drugthat may require expedited reporting or safet y 
evaluation include, but are not limited to:
Overdose of a sponsor study drug . Overdose is defined as any  occasion when the subject has 
taken or received (accidentally  orintentionally or unspecified) any single dose OR a 
cumulative daily  dose that is higher than the maximal target single dose ORa cumulative 
daily  dose as defined in the study  protocol. For apixaban, this is defined as more than 10 mg 
per day or more than 15 days of treatment. For JNJ-64179375, this is defined as more than 
the planned single -dose amount or more than 1 dose.
Suspected abuse/misuse of a sponsor study  drug
Accidental or occupational exposure to a sponsor study  drug
Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study  drug , eg, name confusion)
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the eCRF.
12.3. Procedures
12.3.1. All Adverse Events
All adverse events and special reporting situations, whether serious or nonserious, will be 
reported from the time a signed and dated ICFis obtained until completion of the subject's last 
study -related procedure ,which may include contact for follow up of safety . Serious adverse 
events, including those spontaneously  reported to the investigator through the Week 18visit, 
must be reported using the Serious Adverse Event Form. The sponsor will evaluate any safety 
information that is spontaneously reported by an investigator beyond the time frame specified in 
the protocol .
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
90
Approved , Date: 11 September 2017All events that meet the definition of a serious adverse event will be reported as serious adverse 
events, regardless of whether they  are protocol -specific assessments.
All adverse events, regardless of seriousness, severity , or presumed relationship tostudy  drug, 
must be recorded using medical terminology  in the source document and the eCRF. Whenever 
possible, diagnoses should be given when signs and symptoms are due to a common etiology 
(eg,cough, runny nose, sneezing, sore throat, and head congestio n should bereported as 
"upper respiratory  infection"). Investigators must record in the eCRF their opinion concerning 
the relationship of the adverse event to study  therap y. All measures required for adverse event 
management must be recorded in the source document and reported according to sponsor 
instructions.
The sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory  
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (SUSARs) . The 
investigator (or sponsor where required) must report SUSARs to the appropriate IEC/IRB that 
approved the protocol unless otherwise required and documented by  the IEC/I RB.A SUSAR will 
be reported to regulatory  authorities unblinded. Participating investigators and IEC/I RB will 
receive a blinded SUSAR summary , unless otherwise specified.
The subject must be provided with a "wallet (study )card" and instructed to carry this card with 
them for the duration of the study  indicating the following:
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name and 24-hour contact telephone number
Local sponsor's nam e and 24 -hour contact telephone number (for medical staf f onl y)
Site number
Subject number
Any other information that is required to do an emergency  breaking of the blind
12.3.2. Serious A dverse Events
All serious adverse events occurring during thestudymust be reported to the appropriate sponsor 
contact person b ystudy -site personnel within 24 hours of their knowledge of the event.
Information regarding serious adverse events will be transmitted to the sponsor using the Serious 
Adverse Event Form and Safety  Report Form of the eCRF, which must be completed and 
reviewed by a physician from the study  site, and transmitted to the sponsor within 24 hours. The 
initial and follow -up reports of a serious adverse event should be transmitted electronicall y or by 
facsimile (fax).
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
91
Approved , Date: 11 September 2017All serious adverse events that have not resolved by the end of the study , or that have not 
resolved upon discontinuation of the subject's participation in the study , must be followed until 
any of the following occurs:
The event resolves
The event s tabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow up after demonstration 
of due diligence with follow- up efforts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospitalization (or prolongation of hospitalization) 
that occurs during the course of a subject's participation in a study  must be reported as a serious 
adverse event , except hospitalizations for the following:
Hospitaliz ations not intended to treat an acute illness or adverse event (eg, social reasons 
such as pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the 
eCRF ). Note: Hospitalizations that were planned before the signing of the ICF, and where 
the underl ying condition for which the hospitalization was planned has not worsened ,will 
not be considered serious adverse events. Any  adverse event that results in a prolongation of 
the originall y planned hospitalization is to be reported as a new serious adverse event.
The cause of death of a subject in a study  through the Week 18, whether or not the event is 
expected or associated with the study  drug , is considered a serious adverse event.
12.3.3. Pregnancy
All initial reports of pregnancy  in partners of male subjects must be reported to the sponsor by 
the study -site personnel within 24 hours of their knowledge of the event using the appropriate 
pregnancy  notification form. Abnormal pregnancy  outcomes (eg, sp ontaneous abortion, fetal 
death, stillbirth, congenital anomal ies, ectopic pregnancy ) are considered serious adverse events 
and must be reported using the Serious Adverse Event Form.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required .
12.4. Contacting Sponsor Regarding Safety
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safet y issues or questions regarding the study  are listed in the Contac t Information 
page(s), which will be provided as a separate document.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
92
Approved , Date: 11 September 201713. PRODUCT QUA LITY COMP LAINT HA NDLING
A product qualit y complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfa ction relative to the identity , quality , 
durability , or reliabilit y of a product, including its labeling or package integrity . A PQC may  have 
an impact on the safet y and ef ficacy  of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the sponsor , and are mandated by regulatory  agencies worldwide. The sponsor has 
established procedures in conformity  with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by the sponsor or its affiliates 
will be conducted in accordance with those procedures.
13.1. Procedures
All initial PQCs must be reported to the sponsor by  the study -site personnel within 24 hours af ter 
being made aware of the event .
If the defect is combined with a serious adverse event, the study -site personnel must report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2 , Serious Adverse Events). A sample of the suspected product should be 
maintained for further investigation if requested by the sponsor .
13.2. Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality  issues are listed in the Contact Information page(s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drugs
JNJ-64179375 or JNJ -64179375 Placebo
The JNJ-64179375 supplied for this study  is a sterile, preservative -free liquid with a 
concentration of 50 mg/mL of monoclonal antibody  in a solution composed of 10 mM sodium 
phosphate, 8.5% (w/v) sucrose, 0.04% (w/v) poly sorbate 20, and 10 g/mL  EDTA at a pH of 7.1.
JNJ-64179375 will be provided frozen in a glass vial with an approximately  3-mL fill volume.
JNJ-64179375 has a molecular mass of 149,139 Dalton for the G0F/G0F glycoform and 
isoelectric points, ranging from 6.1 to 6.4. The absorptivity  constant for JNJ -64179375 at 2 80 nm 
was determined to be 1.37 (mg/mL)-1cm-1.It will be manufactured and provided under the 
responsibility of the sponsor .
Placebo infusions will be 0.9% normal saline.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
93
Approved , Date: 11 September 2017Apixaban or Matching Apixaban Placebo
Apixaban will besupplied for this study  as over-encapsulated 2.5-mg tablets in a red-colored, 
hard, gelatin capsule. The over-encapsulated tablet will be backfilled with microcry stalline 
cellulose to prevent the tablet from rattling in the capsule shell.
Matching apixaba nplacebo capsules will consist of microcry stalline cellulose within a red -colored, 
hard, gelatin capsule.
14.2. Packaging
JNJ-64179375 will be packaged in individual kits. Each kit will consist of 1 vial of 
JNJ-64179375 frozen liquid in a carton . JNJ-64179375 will not be dispensed in child- resistant 
packaging. It will be stored in a locked pharmacy  and onl y dispensed after preparation for an 
IVinfusion.
Apixaban or matching apixaban placebo will be packaged in bottles containing 30 capsules . The 
bottles will b e child resistant.
14.3. Labeling
Study  drug labels will contain information to meet the applicable regulatory requirements.
14.4. Preparation, Handling, and Storage
JNJ-64179375 must be stored at -40°C ± 10°C (-30°C to -50°C) or -70°C ± 20°C (-50°C to 
-90°C), and protected from light. Before use, the drug product should be diluted to the required 
dose strength using 0.9% normal saline . Diluted drug product for IV administration must be 
administered with in- line filtration.
Apixaban and matching apixaban placebo must be stored at controlled temperatures, as indicated 
on the product- specific labeling.
Refer to the pharmacy  manual/ IPPI for additional guidance on study  drug preparation ,handling , 
and storage .
14.5. Drug A ccountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study . For the single IV dose of JNJ-64179375 t he study  drug 
vial(s) used to prepare the dose that will be administered to the subject must be documented in 
the IWRS.For oral apixaban or matching apixaban placebo, the dispensing of study  drug to the 
subject, and the return of study  drug from the subject (if applicable), must be documented in the 
IWRS . Subjects must be instructed to return all original containers, whet her empty  or containing 
study  drug. All study  drug will be stored and disposed of according to the sponsor's instructions. 
Study-site personnel must not combine contents of the study  drug containers.
Study  drug must be handled in strict accordance with theprotocol and the container label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
94
Approved , Date: 11 September 2017environmental conditions. Unused study  drug, and study  drug returned by the subject, must be 
available for verification by the sponsor's study  site monitor during on -site monitoring visits. The 
return to the sponsor of unused study  drug, or used returned study  drug for destruction, will be 
documented in the IWRS. When the study  site is an authorized destruction unit and study drug 
supplies are destro yed on-site, this must also be documented in the I WRS .
Potentially  hazardous materials such as used ampules, needles, syringes ,vials containing 
hazardous liquids (this does not include the used vials of study  drug),and used infusion supplies
should be disposed of immediately  in a safe manner and therefore will not be retained for drug 
accountability  purposes.
Study  drug should be dispensed under the supervision of the investigator or a qualified member 
of the study -site perso nnel, or by a hospital/clinic pharmacist. Study  drug will be supplied only 
to subjects participating in the study . Study  drug may not be relabeled or reassigned for use by 
other subjects. The investigator agrees neither to dispense the study  drug from, norstore it at, 
any site other than the study  sites agreed upon with the sponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provided with the following supplies:
Investigator 'sBrochure for JNJ -64179375
Laboratory  manual s
IWRS manual
Venograph y manual
eCRF manual
Sample I CF
IPPI
Guidelines for Reporting Bleeding Event Verbatim Terms 
Subject contact card s(wallet card)
Contact information page
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
Potential subjects will be fully informed of the risks and requirements of the study  and during the 
study , subjects will be given any new information that may affect their decision to continue 
participation. They  will be told that their consent to participate in the study  is voluntary  and may  be 
withdrawn at any time with no reason given and without penalt y or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and 
potential adverse events of the study , and provide their consent volunta rily will be enrolled.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
95
Approved , Date: 11 September 2017JNJ-64179375 is an investigational drug that is being developed for multiple thrombosis -mediated 
conditions. The nonclinical and clinical data obtained to date with JNJ-64179375 support 
administration of single doses in a well-contro lled clinical research study . The present study  is 
needed to support further clinical development of JNJ-64179375, and the study  design is based on 
sound scientific rationale, as described in this protocol. Thorough scientific evaluation of any 
promising treatment before marketing authorization is an ethical requirement. In the continuing 
search for medications with improved efficacy and safety profiles, it is necessary  to fully 
investigate and understand new products.
The primary  ethical concern is thatthe safety  and efficacy  profile of JNJ-64179375 hasnot been 
well established as it has only been studied in a limited number of healthy  male subjects . Subjects 
in this study  who are at risk for VTE following TKR surgery  are being asked to take a new 
treatme nt for the prevention of VTE. Based on the nonclinical and Phase 1 clinical study , a range 
of doses of JNJ-64179375 has been selected for further evaluation in Part 1of this study . The 
starting dose of 0.3 mg/kg is expected to provide efficacy  and be well tolerated. Subsequent dose 
escalation will be based on the evaluation of the observed efficacy  and safety data on a regular 
basis (ie, every  1to3weeks) by the OC, which willconsist ofindividuals with both clinical and 
statistical expertise. Women will be exposed to JNJ-64179375 for the first time. The nonclinical 
studies did not show any difference between males and females for blood levels or tolerabilit y of 
JNJ-64179375. Based on the Part 1 results, doses that areexpected to provide efficacy  and tobe 
well tolerated will be selected for evaluation in Part 2.In Part 2, the IDMC will review VTE and 
bleeding events to closely monitor the safety  of subjects participating in the study . Subjects in both 
parts will be monitored for 18weeks after the sing le IV administration of JNJ -64179375.
The primary  risk with any anticoagulant drug is the potential for bleeding events, and because 
JNJ-64179375 is a monoclonal antibody , infusion and hypersensitivit y reactions could also be 
potentiall y observed. Based onthe nonclinical evaluations of JNJ-64179375, the risk for these 
events is anticipated to be low (ie, all planned doses are below those shown to statisticall y 
significantl y increase bleeding risk)and no cytokine release or allergic reactions have been 
observed in animals. In addition, subjects in the first-in-human SAD study  did not experience any 
infusion or hypersensitivity  reactions. A bleeding signal was detected at the 2.125- and 
2.5-mg/kgdosesin healthy  male subjects . This signal consisted primaril y of increased local 
bruising at the venipuncture and infusion sites in subjects who received JNJ-64179375 compared 
with placebo. The starting dose of 0.3 mg/kg in Part 1 is approximatel y one-seventh of this dose 
and was well tolerated in the SAD study . The highest planned dose (1.2 mg/kg) in Part 1 of this 
study  is approximatel y 50% of the 2.125 -mg/kgdose and will only be studied if lower doses are 
tolerated. Subjects in this study  will be carefull y observed for both bleeding events and infusion or 
hypersensitivit y reactions throughout the duration of the study  and management strategies for each 
type of event are outlined in the protocol (see Section 9.7.2.1.2 , Approach to Subjects With a 
Bleeding Event and Sect ion 9.7.2.2 , Infusion orHypersensitivit y Reactions, respectivel y).
Venography assessments will be used to evaluate for the presence of DVT. The x-ray used in the 
imaging exposes the body  to a small dose of ionizing radiation. The risks of radiation exposure 
may be tied to the number of x-rays and x-ray treatments a person has had over their lifetime. 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
96
Approved , Date: 11 September 2017Given that all of the subjects in this study  will be 50 years of age, the incremental risk of this 
radiation exposure is considered small. X-rays are the oldest and most frequentl y used form of 
medical imaging. Other risks associated with venography  assessments include pain, infection, 
and/or bleeding at the site of venous access and the risks from contrast medium administration 
(ie,allergy , nephrotoxicity , and/or possible irritation of the venous system leading to the 
development of DVT). In previous studies, venography  assessments have been well tolerated and 
do provide clinicall y useful information about the presence or absence of DVT following 
surgery .26
There are risks associated with venipuncture and multiple blood sample collection, including 
prolonged bleeding due to the anticoagulant effects of JNJ -64179375. The t otal blood volume to be 
collected for safety, PK, and PD laboratory  testsis approximatel y95.4 mL for subjects with dense 
PK sampling and approximatel y 80.4 mL for subjects with sparse PK sampling . This is well below 
the standard blood donation volume forhealthy  donors as set forth by the World Health 
Organization (standard donation of 450 mL every 79 days)and is therefore considered to be 
acceptable for subjects following TKR surgery .34
16.2. Regulatory  Ethics Comp liance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance tha t the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki ,and that the study  data are credible.
16.2.2. Independent Ethics Committee or Institutional Review  Board
Before thestart of the study , the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copies of the following documents (as required by local 
regulations) :
Final protocol and, if applicable, amendments
Sponsor -approved ICF(and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
97
Approved , Date: 11 September 2017Information regarding funding, name of the sponsor, institutional affiliations, other potentia l 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/I RB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct , unless required locall y), the ICF, applicable 
recruiting materials, and subject compensation programs, and the sponsor has received a copy of 
this approval. This approval letter must be dated and must clearl y identify the IEC/IRB and the 
documents being approved.
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approv al, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data ,or study  conduct)
Revision(s) to ICFand any  other written materials to be provided to subjects
If applicable, new or re vised subject recruiting materials approved by  the sponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator's Brochure and amendments/addenda
Summar ies of the status of the study at intervals stipulated in guidelines of the IEC/I RB
(atleast annually )
Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study  drug
New information that may adversel y affect the safety of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the stud y at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduc t), the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/I RB for review and approval before implementation of 
the change(s).
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where 
required.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
98
Approved , Date: 11 September 2017Atthe end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion (if applicable, the notification will be submitted through the head of 
investigational institution) .
16.2.3. Informed Consent
Each subject must give written consent according to local requirements after the nature of the 
study  has been fully  explained. The ICF(s) must be signed before performance of any study -
related activity . The ICF(s) that is/areused must be approved by both the sponsor and bythe 
reviewing IEC/I RB and be in a language that the subject can read and understand. The informed 
consent should be in accordance with principles that originated in the Declaration of Helsinki, 
current ICH and GCP guidelines, applicable regulatory  require ments, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study ,and any discomfort participation in the study  may entail. 
Subjects will be informed that their participation is voluntary  and that they may withdraw 
consent to participate at any time. They  will be informed that choosing not to participate will not 
affect the care the subject will receive for their surgery or postoperative care. Subjects will be 
told that alternative treatments are available if they refuse to take part and that such refusal will 
not prejudice future treatment. Finally , they will be told that theinvestigator will maintain a 
subject identification register for the purposes of long-term follow up if needed and that their 
records may be accessed by health authorities and authorized sponsor personnel without 
violating the confidentiality  of the subje ct, to the extent permitted by the applicable law(s) or 
regulations. By  signing the ICFthe subject is authorizing such access , which includ espermission 
to obtain information about his or her survival status.
The subject will be given sufficient time to read the ICF and the opportunity  to ask questions. 
After this explanation and before entry  into the study , consent should be appropriatel y recorded 
by means of the subject's personall y dated signature. After having obtained the consent, a copy  of 
the ICF must be given to the subject.
If the subject is unable to read or write, an impartial witness should be present for the entire 
informed consent process ,(which includes reading and explaining all written information) and 
should personally  date and sign the ICF after the oral consent of the subject is obtained.
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary  to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
99
Approved , Date: 11 September 2017put in place. Sponsor personnel whose responsibilities require access to personal data agree to 
keep the identit y of subjects confidential.
The informed consent obtained from the subject includes explicit consent for the processing of 
personal data and for the investigator /institution to allow direct access to his or her original 
medical records (source data/documents) for study -related monitorin g, audit, IEC/IRB review, 
and regulatory  inspection. This consent also addresses the transfer of the data to other entities 
and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
Exploratory  PK,immunogenicity , and PD biomarker research is not conducted under standards 
appropriate for the return of data to subjects. In addition, the sponsor cannot make decisions as to 
the significance of any findings resulting from exploratory  research. Therefore, exploratory  
research data will not be returned to subjects or investigators, unless required by lawor local 
regulations . Privacy  and confidentiality  of data generated in the future on stored samples will be 
protected b y the same standar ds applicable to all other clinical data.
16.2.5. Long -Term Retention of Samples for Additional Future Research
Samples collected in this study  may be stored for up to 15 years (or according to local 
regulations) for additional research. Samples will only be used to understand JNJ-64179375 , to 
understand thrombosis , to understand differential drug responders, and to develop tests/assay s 
related to JNJ-64179375 ,and VTE proph ylaxis. The research may begin at any time during the 
study  or the post study storage period.
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers.
16.2.6. Country Selection
This study  will only be conducted in those countries where the intent is to launch or otherwise 
help ensure access to the developed product if the need for the product persists , unless explicitly  
addressed as a specific ethical consideration in Section 16.1, Study -Specific Design 
Considerations.
17. ADMINISTRA TIVE REQU IREMENTS
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment 
by the sponsor. All protocol amendments must be issued by  the sponsor, and signed and dated by 
the investigator. Protocol amendments must not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
100
Approved , Date: 11 September 2017amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  the investigator and IEC/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study , the 
IEC/IRB ( whererequired) only needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor 
representative listed in theContact Information page (s), which will beprovided as a separate
document . Except in emergency  situations, this contact should be made before implementing any 
departure from the protocol. In all cases, contact with the sponsor must be made as soon as 
possi ble to discuss the situation and agree on an appropriate course of action. The data recorded 
in the eCRF and source documents will reflect any departure from the protocol, and the source 
documents will describe this departure and the circumstances requirin g it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulator y 
requirements are met.
17.2.2. Required Prestudy  Document ation
The following documents must be provided to the sponsor before shipment of study  drug to the 
study site:
Protocol and amendment(s), if an y, signed and dated by the principal investigator
A copy of thedated and signed (or sealed, where appropriate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by title and number and must be signed (or sealed, where appropriate per local 
regulations) by the chairman or authorized designee.
Name and address of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a stateme nt that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. If an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opinion of the study .
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
Documentation of investigator qualifications (eg, curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
101
Approved , Date: 11 September 2017Signed and dated clinical trial agreement, which includes the financial agreement
Any other documentation required by  local regulations
The following documents must be provided to the sponsor before enrollment of the first subject:
Completed investigator financial disclos ure forms from all subinvestigators
Documentation of subinvestigator qualifications (eg, curriculum vitae)
Name and address of any local laboratory  conducting tests for the study , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollme nt log to permit easy 
identification of each subject during and after the study . This document will be reviewed by the 
sponsor study -site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed by 
the investigator in the study  file. To ensure subject confidentiality , no copy  will be made. All 
reports and communications relating to the study  will identify  subjects by subject identification
and date of birth (as allowed by local regulations) . In cases where the subject is not randomized 
into the study , the date seen and date of birth (as allowed by  local regulations) will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determin e eligibility  for inclusion in the study .
17.4. Source Documentation
At a minimum, source document s consistent in the type and level of detail with that commonly  
recorded at the study  site as a basis for standard medical care must be available for the following:
subject identification, eligibility , and study  identification; study  discussion and date of signed 
informed consent; dates of visits; results of safety and efficacy  parameters as required by the 
protocol; record of all adverse events and follow up of adve rse events; concomitant medication; 
drug receipt/dispensing/return records; study  drugadministration information ; and date of study 
completion and reason for early discontinuation of study  drug or withdrawal from the study , if 
applicable.
The author of a n entry  in the source documents should be identifiable.
Specific details required as source data for the study  and source data collection methods will be 
reviewed with the investigator before the stud y.
An electronic source system may be utilized, which contains data traditionally  maintained in a 
hospital or clinic record to document medical care (eg, electronic source documents) as well as 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
102
Approved , Date: 11 September 2017the clinical study -specific data fields as determined by the protocol. This data is electronicall y 
extracted for use by the sponsor. If the electronic source system is utilized, references made to 
the eCRF in the protocol include the electronic source system but information collected through 
the electronic source system may not be limited to that found in the eCRF. Data in this system 
may be considered source documentation.
17.5. Case Report Form Completion
Case report forms are prepared and provided by  the sponsor for each subject in electronic format.
All CRF entries, corrections, and alterations must be made by the investigat or or authorized 
study -site personnel. The investigator must verify  that all data entries in the CRF are accurate 
and correct.
The study  data will be transcribed by study-sitepersonnel from the source documents onto an 
electronic CRF, if applicable. Study -specific data will be transmitted in a secure manner to the 
sponsor.
Worksheets may be used for the capture of some data to facilitate completion of the CRF. Any 
such worksheets will become part of the subject's source document s. Data must be entered into
eCRF in English . The eCRF must be completed as soon as possible after a subject visit and the 
forms should be available for review at the next scheduled monitoring visit.
If necessary , queries will be generated in the electronic data capture (eDC)tool. If corrections to 
a CRF are needed after the initial entry  into the eCRF, this can be done in either of the following
ways:
Investigator and study-site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  the eDC tool) .
Sponsor or sponsor delegate can generate a query  for resolution by the investigator and 
study -site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -sitepersonnel before the study , and periodic monitoring visits by the sponsor, and direct 
transmission of IWRS data, adjudicatio n data from the CEC ,and laboratory  data from a central 
laboratory  into the sponsor's data base. Written instructions will be provided for collection, 
handling, storage, and shipment of samples.
Guidelines for eCRF completion will be provided and reviewed with study -sitepersonnel before 
the start of the stud y.
The sponsor will review eCRF for accuracy  and completeness during on-site monitoring visits 
and after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designe e, as appropriate. In addition, data will be reviewed centrally  as described in 
Section 17.8, Monitoring. After upload of the data into the study database selected data will be 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
103
Approved , Date: 11 September 2017verified for accuracy  and consiste ncy with the data sources (refer to Section 17.8, Monitoring for 
further details).
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by the applicable regulatory  require ment(s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by the applicable regulatory  requirements or by an 
agreement with the sponsor. It is the responsibility  of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keeping the study  records, custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name and address of the 
new custodian. Under no circumstance shall the investigator relocate or dispose of any study  
documents before having obtained written approval from the sponsor .
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such 
reports.
17.8. Monitoring
The sponsor will use a combination of monitoring techniques (central, remote, or on-site 
monitoring )to monitor this study .
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study -site visit log that will be kept at the study  site. The first 
post-initiation visit will be made as soon as possible after enrollment has begun. At these visits, 
the monitor will compare data entered into the CRF with the source documents
(eg,hospital/clinic/phy sician’s office medical records) ; a sample may be reviewed. The nature 
and location of all source documents will be identified to ensure that all sources of original data 
required to complete the CRF are known to the sponsor and study -site personnel and are 
accessible for verification by the sponsor study -site contact. If electronic records are maintained 
at the study site, the m ethod of verification must be discussed with the study -site personnel .
Direct access to source document s(medical records) must be allowed for the purpose of 
verify ing that the recorded data are consistent with the original source data. Findings from this
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
104
Approved , Date: 11 September 2017review will be discussed with the study -site personnel . The sponsor expects that, during 
monitoring visits, the relevant study -site personnel will be available, the source document swill 
be accessible, and a suitable environment will be provided for revie w of study -related 
documents. The monitor will meet with the investigator on a regular basis during the study to 
provide feedback on the study conduct.
In addition to on-site monitoring visits, remote contacts can occur. It is expected that during 
these re mote contacts, study -site personnel will be available to provide an update on the progress 
of the study  at the site.
Central monitoring will take place for data identified by  the sponsor as requiring central review.
17.9. Study Completion/Termination
17.9.1. Study Comp letion /End of Study
The study  is considered completed with the last visit for the last subject participating in the 
study . The final data from the study site will be sent to the sponsor (or designee) after completion 
of the final subject assessment at thatstudy  site, in the time frame specified in the clinical trial 
agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor .Study sites will be closed upon study  completion. A
study site is considered closed when all required documents and study  supplies have been 
collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of astudy site by the sponsor or investigator may include but are 
not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  the investigator
Discontinuation of further study  drug development
17.10. On-Site A udits
Representatives of thesponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection. Subject privacy  must, however, be 
respected. The investigator and study -site personnel are responsible for being present and 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
105
Approved , Date: 11 September 2017available for consultation during routinely  scheduled study -site audit visits conducted by the 
sponsor or its designees.
Similar auditing procedures may also be conducted by agents of any regulatory  body, either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify  the sponsor if he or shehas
been contacted b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regard ing JNJ-64179375 or the 
sponsor's operations (eg,patent application, formulas, manufacturing processes, basic scientific 
data, prior clinical data, formulation information) supplied by the sponsor to the investigator and 
not previously  published, and any data, including biomarker research data, generated as a result 
of this study , areconsidered confidential and remain the sole propert y of the sponsor. The 
investigator agrees to maintain this information in confidence and use this information only to 
accom plish this study , and will not use it for other purposes without the sponsor's prior written 
consent.
The investigator understands that the information developed in the study will be used by the 
sponsor in connection with the continued development of JNJ-641793 75and thus may be 
disclosed as required to other clinical investigators or regulatory  agencies. To permit the 
information derived from the clinical studies to be used, the investigator is obligated to provide 
the sponsor with all data obtained in the study .
The results of the study  will be reported in a CSR generated by the sponsor and will contain data 
from all study  sites that participated in the study as per protocol . Recruitment performance or 
specific expertise related to the nature and the key assessment parameters of the study  will be 
used to determine a coordinating investigator for the study . Results of PK, PD, and cost
effectiveness analyses performed will be reported in separate reports and will not require a 
revision of the CSR. Study  subje ct identifiers will not be used in publication o f results. An y work 
created in connection with performance of the study  and contained in the data that can benefit 
from copyright protection (except any publication by the investigator as provided for below) 
shall be the propert y of the sponsor as author and owner of cop yright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary  (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
study  site-specific data after the primary  data are published. If an investigator wishes to publish 
information from the study ,a copy of the manuscript must be provided to the sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in 
writing, the investigator will withhold such publication for up to an additional 60days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulatory  compliance, the sponsor will review these issues with the investigator. The sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
106
Approved , Date: 11 September 2017information. Formulticenter study  designs and substudy  approaches, secondary  results generall y 
should not be published before the primary endpoints of a study  have been published. Similarly , 
investigators will recognize the integrity  of a multicenter study by not submitting for publication 
data derived from the individual study  site until the combined results from the completed study
have been submitted for publication, within 18months of the availability  of the final data
(tables, listings, graphs), or the sponsor confirms there will be no multicenter study  publication. 
Authorship of publications resulting from this study  will be based on the guidelines on 
authorship, such as those described in the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, which state that the named authors must have made a significant 
contribution to the design of the study  or analy sis and inte rpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as 
required b y law.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
107
Approved , Date: 11 September 2017REFERENCES
1. Baglin TP, Langdown J, Frasson R, Huntington JA. Discovery and characterization of an antibody directed 
against exosite I of thrombin. J Thromb Haemost. 2016;14:137 -142.
2. Bornkamp B, Pinheiro J, Bretz F. Planning and ana lyzing dose finding experiments. 
http://www.cran.r -project.org/web/packages/dosefinding .Updated July 26, 2016. Accessed January 24, 2017.
3. Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose- response 
studies. Bio metrics. 2005;61:738 -748.
4. Buckland ST, Burnham K, Augustin NH. Model selection: an integral part of inference. Biometrics. 
1997;53:603 -618.
5. Büller HR, Bethune C, Bhanot S, et al; FXI -ASO TKA Investigators. Factor XI antisense oligonucleotide for 
prevention of venous thrombosis. N Engl J Med. 2015;372(3):232 -240.
6. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE 
events and associated morbidity and mortality. Thromb Haemost. 2007;98:756 -764.
7. Dahl OE, Borris LC, Bergqvist D, et al. International Surgical Thrombosis Forum. Major joint replacement. A 
model for antithrombotic drug development: from proof -of-concept to clinical use. Int Angiol. 2008;27(1):
60-67.
8. Eliquis [Summary of Product Characteristics]. Uxbridge , Middlesex, United Kingdom: Bristol -Myers Squibb/
Pfizer EEIG; 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002148/
human_med_001449.jsp&mid=WC0b01ac058001d124 . Accessed February 9, 2017.
9. Eriksson BI, Dahl OE, Rosenche r N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the 
prevention of venous thromboembolism after total knee replacement: t he RE -MODEL randomized trial. 
JThromb Haemost 5(11):2178 -2185.
10. Falck -Ytter Y, Francis CW, Johanson NA, et al; Ame rican College of Chest Physicians. Prevention of VTE in 
orthopedic s urgery patients: antithrombotic therapy and p revention of throm bosis, 9th ed: American College of 
Chest Physicians evidence -based clinical practice guidelines. Chest. 2012;141(2_suppl):
e278S-e325S.
11. Francis CW, Davidson BL, Berkow itz SD, et al. Ximelagatran versus warfarin for the prevention of venous 
thromboembolism after total knee arthroplasty. A randomized, double -blind trial. Ann Intern Med. 
2002;137(8):648 -655.
12. Fuji T, Fujita S, Tachi bana S, Kaw ai Y. A dose -ranging study evaluating the oral factor Xa inhibitor edoxaban 
for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb 
Haem ost. 2010;8(11):2458 -2468.
13. Fuji T, Wang CJ, Fujita S, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin 
for thromboprophylaxis after total knee arthroplasty: the STARS E -3 trial. Thromb Res. 2014;134(6):
1198 -1204.
14. Geerts WH (2004), Pineo GF, Heit JA, et al. Prevention of venous th romboem bolism: the Seventh ACCP 
Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:338S -400S.
15. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate versus North 
American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. 
JArthroplasty 24(1):1 -9.
16. Hjort NL, Claeskens G. Frequentist model average estimators. J Am Stat Assoc. 2003;98:879 -899.
17. Investigator’s Brochure: JNJ -64179375 ,Edition 1. Janssen Research & Develo pment, LLC 
(29September 2016).
18. Investigator’s Brochure. Addendum 1.0 to Investigator’s Brochure, Edition 1.0. Janssen Research & 
Development, LLC (02 June 2017).
19. JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary 
thromboembolism and deep vein thrombosis (JCS 2009). Circ J. 2011;75(5):1258 -1281.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
108
Approved , Date: 11 September 201720. Kearon C. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice 
Guidelines Initiative. Ann Intern Med. 1998;128:663 -677.
21. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an 
oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb 
Haem ost. 2007;5:2368 -2375.
22. Lassen MR, Fisher W, Mouret P, e t al; SAVE Investigators. Semuloparin for prevention of venous 
thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE -HIP1, 
SAVE -HIP2 and SAVE -KNEE. J Thromb Haemost. 2012;10(5):822 -832.
23. Lassen MR, Raskob GE, Ga llus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for 
thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594 -604.
24. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee 
replacement (A DVANCE -2): a randomised double- blind trial. Lancet. 2010;375:807 -815.
25. Pinheiro JC, Bornkamp B, Glimm E, Bretz F. Model -based dose findings under model uncertainty using 
general parametric models. Statistics Med. 2014;33:1646 -1661.
26. Rabinov K, Paulin S. Roen tgen diagnosis of venous thrombosis in the leg. Arch Surg. 1972;4:134 -144.
27. Schellong SM, Beyer J, Kakkar AK, et al. Ultrasound screening for asymptomatic deep vein thrombosis after 
major orthopaedic surgery: the VENUS study. J Thromb Haemost. 2007;5(7):143 1-1437.
28. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Subcommittee on Control of 
Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis 
and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products 
in surgical patients. J Thromb Haemost. 2010;8(1):202 -204.
29. Segers AE, Prins MH, Lensing AW, Buller HR. Is contrast venography a valid surrogate outcome measure in 
venous thromboembolism prevention studies? J Thromb Haemost. 2005;3:1099 -1102.
30. Turpie AG, Lassen MR, Davidson BL, et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for 
thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 
2009;373(9676):167 3-1680.
31. Verhamme P, Tangelder M, Verhaeghe R, et al; TB -402 Study Group. Single intravenous administration of 
TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose- escalating, 
randomized, controlled trial. J Thromb Haemo st. 2011;9(4):664 -671.
32. Warw ick D. Prevention of venous thromboembolism in total knee and hip replacement. Circ. 2012;125:
2151 -2155.
33. Winters JL. Plasma exchange: concepts, mechanisms, and an overvie w of the American Society for Apheresis 
guidelines. Hemato l Am Soc Hematol Education Program. 2012;2012:7 -12.
34. World Health Organization. Blood donor selection guidelines on assessing donor suitability for blood donation. 
Geneva: World Health Organization; 2012. http://www.ncbi.nlm.nih.go v/books/NBK138212/. 
Access ed22Sep 2016 .
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
109
Approved , Date: 11 September 2017Attachment 1:Sample Bleeding Risk History
Family History:
1. Family history of bleeding disorder (at least one parent, grandparent, sibling 
or child)Yes ⃝ No ⃝
If yes, what was the diagnosis? ___________ ___________________________
Personal Lifetime History:
2. Any blood vessel aneurysms (eg, intracranial) or arteriovenous 
malformations? Yes ⃝ No ⃝
If yes, specify diagnosis and date : ___________________________________
3. Any history of any anemia? Yes ⃝ No ⃝
If yes, specify diagnosis and date: ___________________________________
4. Any history of any gastrointestinal ulcer disease? Yes ⃝ No ⃝
If yes, specify diagnosis and date : __________________________________
5. Any history of any g astrointestinal polyps? Yes ⃝ No ⃝
If yes, specify diagnosis and date : __________________________________
6. Any invasive procedures (eg, surgery, biopsy, dental extraction)? Yes ⃝ No ⃝
If yes, number _____ type of procedure ___________________ 
Any abnormal bleeding with any of the procedures? Yes ⃝ No ⃝
If yes, describe and include date. ____________________________________
7. Any intracranial bleeding Yes ⃝ No ⃝
If yes specify site:   ⃝ Subdural ⃝ SAH ⃝ Parenchymal Date: ___________
8. Any blood in urine Yes ⃝ No ⃝
If yes specify:   ⃝ Hematuria (Visible)   ⃝ Microscopic only   Date: ________
9. Any muscle or joint bleeding Yes ⃝ No ⃝
If yes specify:  ⃝ Muscle ⃝ Joint    Date: ______________
10. Any lung bleeding Yes ⃝ No ⃝
If yes specify:  ⃝ Blood in sputum  ⃝ Other, specify____________   
Date: __________
11. Any upper gastrointestinal tract bleeding Yes ⃝ No ⃝
If yes specify:   ⃝ Hematemesis ⃝ Coﬀ ee-ground emesis ⃝ Melena  
Date: ______
12. FEMALES ONLY: Chil dbirth?
If yes, specify if any bleeding complications? Yes ⃝ No ⃝
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
110
Approved , Date: 11 September 2017Personal History in the past 6 months:
Personal history  of bleeding events in the past 6 months not involving invasive procedures 
(review below categories):
Gastrointestinal 
Bleed ing-lower No ⃝ Yes ⃝ → # episodes in last 6 months: ⃝ 1 ⃝ 2 -5 ⃝ 6 -12 ⃝ >12
Duration of average episode: ⃝ <1 min ⃝ 1 -5 min ⃝ >5 min
Type: ⃝ Hemorrhoids
⃝ Other, specify ________________________
Onset: ⃝ Spontaneous ⃝ A  er bowel movement
Nosebleeds No ⃝ Yes ⃝ → # episodes in last 6 months: ⃝ 1 ⃝ 2 -5 ⃝ 6 -12 ⃝ >12
Duration of average episode: ⃝ <1 min ⃝ 1 -5 min ⃝ >5 min
Onset: ⃝ spontaneous ⃝ secondary trauma (eg, blowing nose)
Resolution: ⃝ Usually resolved spontaneously
⃝ Required medical a  en on
Bruising No ⃝ Yes ⃝ → # episodes in last 6 months: ⃝ 1 ⃝ 2 -5 ⃝ 6 -12 ⃝ >12
Onset: ⃝ With minimal or no trauma ⃝ With trauma
Average size: ⃝ <1 cm ⃝ 1 -5 cm ⃝ >5 cm
Oral cavity bleeding No ⃝ Yes ⃝ → # episodes in last 6 months: ⃝ 1 ⃝ 2 -5 ⃝ 6 -12 ⃝ >12
Type: ⃝Gums, spontaneous
⃝ Gums, a er brushing or ﬂossing
⃝ Other, specify ______________
Bleeding from minor 
woundsNo ⃝ Yes ⃝ → # episodes in last 6 months: ⃝ 1 ⃝ 2 -5 ⃝ 6 -12 ⃝ >12
Duration of average episode: ⃝ <1 min ⃝ 1 -5 min ⃝ >5 min
Resolution: ⃝ Usually resolved spontaneously
⃝ Required medical a  en on
FEMALES ONLY:
Dysfunctional 
uterine bleedingNo ⃝ Yes ⃝ → # episodes in last 6 months: ⃝ 1 ⃝ 2 -5 ⃝ 6 -12 ⃝ >12
Duration of average episode: ⃝ <1 day ⃝ 1 -5 days ⃝ >5 days
Resolut ion: ⃝ Usually resolved spontaneously
⃝ Required medical a  en on
Any Other Bleeding Site(s) not mentioned under lifetime or past 6 month history 
sections: Yes ⃝ No ⃝
If yes  →   specify siteand date 
Note: The final questions will be part o f the eCRF. Responses to these questions will be obtained 
by the investigator through an interview with the subject. These responses should be reviewed 
and any condition for which the use of apixaban is not recommended should be considered by  
the investiga tor when determining eligibility  for the study .
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
111
Approved , Date: 11 September 2017Attachment 2:Definitions of Bleeding Events
1. Major Bleeding in Surgical Setting28
1.Fatal bleeding, and/or
2.Bleeding that is symptomatic and occurs in a critical area or organ, such as intracranial, 
intraspinal, intraocular, retroperitoneal, peric ardial, in a non-operated joint, or intramuscular 
with compartment syndrome, assessed in consultation with the surgeon, and/or
3.Extrasurgical sitebleeding causing a fall in hemoglobin level of 20 g L)-1(1.24 mmol L-1) or 
more, or leading to transfusion of 2or more units of whole blood or red cells, with temporal 
association with in 24 to 48 hours to the bleeding, and/or
4.Surgical site bleeding thatrequires a second intervention open, arthroscopic, endovascular ,
or a hemarthrosis of sufficient size as to interfere with rehabilitation by delaying 
mobilization or delayed wound healing, resulting in prolonged hospitalization or a deep 
wound infection, and/or 
5.Surgical site bleeding that is unexpected and prolonged and/or sufficiently large to cause 
hemodynamic instability, as assessed by the surgeon. There should be an associate fall in 
hemoglobin level of at least 20 g L-1) (1.24 mmol L-1), or transfus ion, indicated by the 
bleeding, of at least 2units of whole blood or red cells, with temporal association within 
24 hours to the bleeding.
2. Clinically Relevant Non major Bleeding23,24
Clinically relevant nonmajor bleeding is defined as a ny bleeding event that is :
 Acute clinically overt bleeding
 Does not satisfy additional criteria required for the bleeding event to be defined as a major 
bleeding event and meets at least 1 of the following criteria:
o Epistaxis (nose bleed):
 Subject seeks medical attention from a physician
 Subject visits an emergency room
 Bleeding requires an intervention (eg, nasal pack)
 Single bleeding episode persists for 5 minutes or more
o Gastrointestinal bleed:
 Vomit containing frank blood or coffee -ground material, which tests positive for 
blood
 Endoscopically confirmed bleeding
 Frank blood per rectum or melenic stools
o Hematuria
 Overt, spontaneous bleeding
 Bleeding (bloody urine) persists for 24 hours or more after instrumentation
o Bruising/ecchymosis :
 Any bruise that is assessed as “unusual” (eg, greater than expected following surgery)
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
112
Approved , Date: 11 September 2017o Hemoptysis:
 Expectoration of blood or blood -stained sputum
o Hematoma:
 Overt blood collection with the surgical wound
 Presence of a hematoma is demonstrated radiographically (eg, ultrasound, CT, 
magnetic resonance imaging) and a drop of hemogl obin is present with no external 
evidence of bleeding
Note: Any bleeding event not meeting major or clinically relevant nonmajor criteria will be recorded as 
minimal bleeding.
[STUDY_ID_REMOVED]
JNJ-64179375      
Clinical Protocol 64179375THR2001 Amendment 1
113
Approved , Date: 11 September 2017INVESTIGA TOR AGREEME NT
[STUDY_ID_REMOVED]